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ABSTRACT 
The vast majority of studies on attention-deficit/hyperactivity disorder (ADHD) are based 
on samples with inherent age, sex, and referral biases. Therefore, the current study used 
population-based data to 1) estimate the prevalence of adult ADHD (ADHD screening 
status as well as previous diagnosis and medication use using an ADHD screener) and co-
occurring psychiatric distress and substance use in Ontario 2) examine the sex differences 
in ADHD screening status and co-occurring psychiatric distress and substance use and 3) 
model ADHD screening status as a risk factor for psychiatric distress using the 2011 
cycle of the Centre for Addiction and Mental Health Monitor. A positive ADHD screen 
was significantly associated with psychiatric distress and substance use; however the 
majority of those with a positive ADHD screen did not exhibit these issues. Symptom 
overlap and lack of diagnosis and treatment may have contributed to the findings in this 
sample. Importantly, the effect of age must also be accounted for in future studies where 
sample size permits. 
Keywords: ADHD, Adult, Ontario, CAMH Monitor, Prevalence, Sex,  Psychiatric 
distress, Antidepressants, Anti-anxiety medications, and Substance use 
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Chapter 1: ADHD Prevalence, Aetiology and Concurrent Disorders 
 
1.1 What is ADHD? 
  
Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurobiological disease 
characterized by difficulties with attention, motor activity, and impulse control 
(American Psychiatric Association, 1994). The diagnostic criteria for ADHD in North 
America are outlined in the Diagnostic and Statistical Manual of Mental Disorders IV 
(DSM-IV). This diagnosis of ADHD requires that six or more of the symptoms of 
inattention, hyperactivity, or impulsivity cause considerable impairment in two or more 
settings and have persisted for the last six months to an extent that is maladaptive and 
inconsistent with developmental level (APA, 1994). Furthermore, these symptoms must 
have occurred before the age of seven to warrant a diagnosis (APA, 1994). The clinical 
heterogeneity of ADHD is recognized in the DSM-IV by three subtype classifications 
based on primary symptom category endorsement. These subtypes include the 
predominantly inattentive subtype (ADHD-I), the predominantly hyperactive-impulsive 
subtype (ADHD-H) and a combined subtype (ADHD-C) (APA, 1994).  
ADHD is a controversial disorder in part due to its aetiological complexity, but 
also because conceptualizations of the disorder have varied drastically since its inception 
(Toplak, Connors, Shuster, Knezevic, & Parks, 2008). Gomez and colleagues (1999) 
posit that no other disorder has been subject to as much renaming and reconceptualization 
within different versions of the DSM. Since its clinical emergence in 1902 (Still, 1902), 
ADHD has been designated by a myriad of terms including: minimal brain damage, 
hyperkinetic syndrome, hyperactivity and attention-deficit disorder (ADD) among others. 
The most notable shift in the conceptualization of ADHD occurred in the 1970s, when 
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attention dysfunction was presented as the defining feature of the disorder (Douglas, 
1972). Although based on a progressively larger empirical foundation, the evolution of 
the nomenclature for the disorder from DSM-III to DSM-IV has broadened the case 
definition so that more individuals are diagnosed with ADHD. Furthermore, these 
changes reflect an adaptation from earlier definitions that stressed a more narrow focus 
on motor activity, to the current conceptualization which emphasizes difficulty with 
sustained attention and deficits in the regulation of cognitive functioning (Faraone et al., 
2000).  
1.2 Aetiology 
The aetiology of ADHD is unknown; recent findings suggest that a strong genetic 
link and environmental factors interact in the genesis of the disorder.  
Compelling evidence of the heritability of ADHD is derived from family, adoption, and 
twin studies, as well as from neurophysiological and molecular genetics research. 
The rate of ADHD in the biological relatives of individuals with ADHD is 
significantly higher in comparison to the rates of ADHD in families of children without 
ADHD (e.g., Faraone, Biederman, & Friedman, 2000). Specifically, 30-35% of the 
siblings of ADHD-diagnosed individuals also met criteria for ADHD, with a relative risk 
for ADHD that was approximately five times that of the estimated population prevalence 
of the disorder. Furthermore, when analyses were restricted to those with ADHD 
persisting into adolescence or young adulthood, the risk increased several fold (reviewed 
in Faraone et al., 2000). Although the heritability estimates for ADHD are not as high as 
those proposed for autism, they are however substantially higher than those estimated for 
3 
 
 
other highly heritable disorders such as bipolar affective disorder and schizophrenia 
(NIMH Genetics Workgroup, 1997).   
Results from adoption studies showed that the biological siblings and parents of 
non-adopted children with ADHD exhibited significantly higher rates of ADHD and 
associated attention problems, whereas adoptive parents of individuals with ADHD were 
not significantly different from parents of comparison children without ADHD (reviewed 
in Willcut, 2005).  
Further evidence of the biological underpinnings of the disorder come from 
studies of monozygotic and dyzygotic twins. ADHD twin studies have found that the 
concordance rate was significantly higher among monozygotic pairs (58% - 82%) than 
same-sex dizygotic pairs (31% - 38%) (Levy, Hay, McStephen, Wood, & Waldman, 
1997; Levy, McStephen, & Hay, 2001; Sherman, McGue, & Iacono, 1997; Willcutt, 
Pennington, & DeFries, 2000). In addition, Willicut (2005) found that the mean 
heritability across a number of large-scale population-based twin studies was 73%, 
demonstrating that individual differences in ADHD symptoms are largely attributable to 
genetic influences. 
Neurophysiological research indicates that the prefrontal cortex (specifically the 
dorsolateral prefrontal cortex and the orbital frontal cortex), the basal ganglia (striatum), 
the caudate nucleus, and the cerebellum play a significant role in ADHD because of their 
involvement in complex processes that regulate behaviour (Castellanos, 1997; Seidman, 
Valera & Makris, 2005).  
The primary deficits in ADHD typically involve executive function. Executive 
function refers to a variety of cognitive processes that are implicated in managing other 
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cognitive functions (Elliot, 2003). Executive function includes planning, working 
memory, attention, problem-solving, inhibition, and task switching (Monsell, 2003). 
Therefore, areas primarily responsible for these functions have been implicated in the 
disorder (Seidman et al., 2005). Specifically, under-activation in the dorsolateral 
prefrontal cortex and the orbital frontal cortex has been found to be responsible for 
inattention, disinhibition, and hyperactivity in ADHD (Giedd, Blumenthal, Molloy & 
Castellanos, 2006). Functional neuroimaging studies of ADHD support this theory, as 
these studies suggest hypoactivation in prefrontal neural processing in individuals with 
ADHD (Silberstein, Farrow, Levy, Pipingas, Hay & Jarman, 1998).  
Another hypothesis regarding the aetiology of ADHD suggests that prenatal and 
perinatal damage to the striatum, an area within the basal ganglia, is responsible for 
deficits in executive function as the circuitry within the basal ganglia is essential for 
executive processes (Lou, 1996; Seidman et al., 2005). The striatum has been found to be 
particularly vulnerable to complications during pregnancy and delivery, premature birth, 
and low birth weight which have been found to occur at higher than normal rates in 
ADHD (Sprich-Buckminster, Biederman, Milberger, Faraone & Krifcher Lehman, 1993). 
Furthermore, animal studies of experimentally-induced striatal lesions have demonstrated 
that insult to this area produces hyperactivity and poor performance on working memory 
and response inhibition tasks akin to that seen in ADHD (Alexander, DeLong & Strick, 
1986). Lastly, stimulant medications used to treat ADHD have been found to affect the 
striatum, possibly via the rich source of dopaminergic synapses in this area (Dougherty, 
Bonab, Spencer, Rauch, Madras & Fischman, 1999; Volkow, Fowler, Wang, Ding & 
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Gatley, 2002). Taken together, these results implicate striatal anomalies in the 
pathophysiology of ADHD. 
The cerebellum was originally thought to be primarily involved with motor 
control; however findings over the past 20 years indicate that the cerebellum is also 
involved in cognitive and affective processes. Interestingly, Middleton and Strick (2001) 
have shown cerebellar-cortical connections that provide an anatomic substrate for a 
cerebellar-prefrontal circuit in the pathophysiology of ADHD. In addition, reduced 
cerebellar volume has also been found in studies of ADHD children and cerebellar 
volume has been shown to be significantly and negatively correlated with attention 
problems (Seidman et al., 2005). Therefore, anomalies in the cerebellum are also thought 
to be characteristic of the pathophysiology of ADHD.  
Dysregulation in catecholamine neurotransmission is implicated in the 
pathophysiology of ADHD (Faraone & Biederman 2002). Converging evidence from 
animal studies of behaviour and biochemistry (Gainetdinov, Wetsel, Jones, Levin, Jaber 
& Caron, 1999; Giros, Jaber, Jones, Wightman & Caron, 1996; Jaber et al., 1999), 
neuropharmacological studies of the effectiveness of methylphenidate in reducing 
symptoms of hyperactivity and inattention, and neuroimaging studies demonstrating the 
association of ADHD with executive functions and the fronto-striatal pathways 
dependent upon dopamine transmission (Dougherty et al. 1999; Krause, Dresel, Krause, 
Kung & Tatsch, 2000), have made the dopaminergic pathways and their candidate genes 
areas of intense study in ADHD (Banaschewski, Becker, Scherag, Franke & Coghill, 
2010).  
6 
 
 
Molecular genetics research has found limited but suggestive evidence of a causal 
relationship between DNA variants in serotonin and dopamine transporter genes 
SLC6A3, DRD4, DRD5, HTR1B, SLC6A4 and SNAP25 and ADHD (Banaschewski et 
al., 2010). As such, although family, adoption, and twin studies implicate a genetic 
component in the aetiology of ADHD, no specific DNA variants have been identified as 
sufficient risk factors for the development of the disorder.  
Recent studies have examined the existence of rare Copy Number Variants 
(CNVs) in individuals with ADHD. CNVs are rare genetic duplications or deletions that 
are likely to directly affect gene function. A study by Williams and colleagues (2010) 
demonstrated that individuals with ADHD had a significantly higher burden of rare 
CNVs than controls. Although several rare variants have been found, a confirmed 
common variant for ADHD has yet to be discovered. Therefore at present, it can be 
concluded that a substantial number of DNA variants may be implicated in the disorder. 
The genetic findings to date underscore the biological basis of the disorder, however 
future research using large sample sizes akin to those used in studies of schizophrenia and 
bipolar disorder are necessary to establish genome-wide significance as hard evidence of 
genetic causation in ADHD. 
  Genetics alone are not sufficient to produce ADHD and several environmental 
factors have also been proposed as possibly contributing to the aetiology of the disorder. 
Risk factors such as diet (Feingold, 1976), ineffective parenting (Willis & Lovaas, 1977), 
and television exposure (Christakis et al., 2004) were proposed; however, these 
hypotheses have since been disproven by later studies (Kavale & Forness, 1983; Obel 
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Henriksen, Dalsgaard, Linnet, Skajaa, & Thomsen, 2004; Stevens & Mulsow, 2006; 
Wolraich, Wilson & White, 1995).  
Environmental factors that have demonstrated sufficient evidence of a temporal 
association and/or suggestive evidence of a causal relationship with ADHD include 
cerebral hemorrhage and traumatic brain injury (Max et al., 2002; Herskovits, 
Megalooikonomou, Davatzikos, Chen, Bryan & Gerring, 1999), low birth weight 
(Breslau et al., 1996), maternal smoking and alcohol use during pregnancy (Mick, 
Biederman, Faraone, Sayer, & Kleinman, 2002; Milberger, Biederman, Faraone, Guite & 
Tsuang, 1997), exposure to toxins (reviewed in Banerjee, Middleton & Faraone, 2007), 
maltreatment and emotional trauma (Famularo, Kinscherff & Fenton , 1992), and family 
psychosocial adversity (Milberger et al., 1997 ). However, these factors may interact with 
parental genotype as parents who have ADHD may be more likely to smoke, give birth 
prematurely, use other substances, neglect their children, and face psychosocial adversity.  
Because ADHD is a complex disorder, its aetiology most likely involves the 
heritability of specific genes and DNA variants, environmental exposures and the critical 
timing of such exposures. Importantly, aetiological mechanisms include not only biology 
and the environment, but synergistic interactions between these factors which are much 
more challenging to identify. Biederman and Faraone (2005) suggested that the 
developmental pathophysiology of ADHD can best be conceptualized as consisting of a 
genetic predisposition to the disorder and early environmental insults which lead to 
fronto-subcortical catecholamine dysfunction and ADHD in childhood. ADHD in turn 
may lead to later environmental exposures such as substance use and psychosocial 
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adversity which lend to the secondary effects of the disorder such as low-self-esteem, 
school failure, social disability and ultimately in unremitting cases, adult ADHD. 
1.3 ADHD Prevalence 
   
ADHD often emerges in childhood and is usually apparent during the first few 
years of grade school (Goldman, Genel, Bezman & Slanetz, 1998) with the majority of 
ADHD diagnoses being made between 4 to 12 years of age (Biederman & Faraone, 
2005). ADHD had been deemed, “the most common neurobehavioral disorder of 
childhood” (American Academy of Pediatrics, 2000) as children with ADHD comprise 
up to 50% of some child psychiatric populations (Cantwell, 1996). The DSM-IV states 
that the prevalence of ADHD is about 3 to 5% among school-age children (APA, 1994). 
This estimate, although frequently cited, is poorly documented. For example, three 
reviews of ADHD in pediatric clinical settings reported prevalence estimates ranging 
from 1.7% to 17.8%, 3% to 6% and 4% to 12%, respectively (Brown et al., 2001; Elia, 
Ambrosini & Rapoport, 1999; Goldman et al., 1998). Furthermore, epidemiological 
studies that applied the DSM-IV criteria to school populations have yielded prevalence 
estimates as high as 11% to 16% (Cantwell, 1996). In their meta-analysis of the 
epidemiology of ADHD, Polanczyk and Rhode (2007) found that the worldwide 
prevalence of ADHD is around 5.29% for children and adolescents and 4.4% in adults. 
Prevalence estimates of adult ADHD worldwide range from 1.0% to 7.3% 
(Almeida Montes, Hernandez Garcıa & Ricardo-Garcell, 2007;  Barbaresi et al., 2004; 
Bitter, Simon Balint, Meszaros & Czobor, 2012; DuPaul et al., 2001; Faraone & 
Biederman, 2005; Fayaad et al., 2007; Gadow, Sprafkin, Schneider, Nolan, Schwartz & 
Weiss, 2007; Heiligenstein, Conyers, Berns & Miller, 1998; Kooij, Buitelaar, van den 
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Oord, Furer, Rijnders & Hodiamont, 2005; Medina-Mora et al., 2005; Murphy & 
Barkley, 1996; Weyandt, Linterman & Rice, 1995) and from approximately 4 to 5% in 
the United States (Faraone & Biederman, 2005). Yet due to the use of convenience 
samples with low mean ages and gender biases, results from many of these studies cannot 
accurately be extrapolated to the general population. Higher prevalence rates have also 
been documented among urban compared to rural communities (Offord, Boyle & 
Szatmari, 1987), although it is uncertain whether these findings indicate greater access to 
mental health and medical care in urban populations. Nonetheless, the substantial 
variation in ADHD prevalence rates appears to be largely affected by the methodological 
characteristics of these studies. Furthermore, Anderson (1996) states that standardized 
diagnostic criteria and methodology can reduce the variability in reported prevalence, 
even in studies of highly diverse populations such as the United States, China, and 
Kenya. 
1.4 ADHD in Adults 
Because ADHD was originally conceptualized as a disorder of childhood, debate 
exists around the legitimacy of the disorder in adults. However growing evidence 
supports the persistence of symptoms into adulthood. Longitudinal studies of individuals 
diagnosed with ADHD in childhood demonstrate that ADHD persists into adulthood in a 
substantial proportion of cases (Barkley, Fischer, Smallish, & Fletcher, 2004; Mannuzza, 
Klein, & Moulton, 2003; Weiss & Hechtman, 1993). Follow-up studies of children with 
ADHD estimate that 10 to 66% of individuals experience symptoms of the disorder 
throughout adolescence and into adulthood (Gittelman et al. 1985; Manuzza et al. 1993; 
Weiss, 1985; Weiss et al. 1985; Weiss & Hechtman, 1992). Furthermore, approximately 
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30-60% of children with ADHD will continue to meet full criteria for the disorder as 
adults (Biederman, 1998; Biederman, Mick & Faraone, 2000; Manuzza et al. 1993; 
Weiss, 1985; Weiss & Hechtman, 1992). Moreover, a meta-analysis of these studies 
revealed that as many as 65% of children with ADHD will show symptoms of sufficient 
severity to impair functioning in adulthood (Faraone, Biederman, & Mick, 2006).  
Corroborating evidence of the legitimacy of the disorder in adulthood comes from 
findings from neurobiology and genetics that mirror results seen in children (Faraone, 
2004). Specifically, ADHD adults show evidence of structural and functional brain 
anomalies akin to those found in ADHD children (Paloyelis, 2007; Valera, Faraone, 
Murray & Seidman, 2007). ADHD adults share similar neuropsychologic deficits, 
executive dysfunction and familial transmission as ADHD youth (Barkley, Murphy & 
Fischer, 2008; Manuzza et al., 1993; Faraone, Doyle, Lasky-Su, Sklar, D'Angelo, 
Gonzalez-Heydrich, Kratochvil, et al., 2008). ADHD adults also present similar clinical 
features as ADHD children and have been found to respond to the same pharmacological 
interventions used with younger populations (Faraone & Glatt, 2010). Finally, ADHD 
adults also exhibit psychiatric difficulties analogous to those found among their younger 
counterparts (Barkley, Murphy & Fischer, 2008).  
Diagnosis of adult ADHD is particularly challenging. A developmental shift in 
the disorder in adulthood has been suggested, whereby overt hyperactivity is reduced but 
inattention and disorganization persist (Bierderman, Mick & Faraone, 2000; Faraone, 
Bierderman, Spender, Wilens, Seidman, Mick & Doyle, 2000). As such, the DSM-IV 
criteria for ADHD may not be applicable to adults because the type and number of 
11 
 
 
symptoms listed in the current edition (DSM-IV) may not accurately reflect adult 
behaviours (Ingram, Hetchman & Morgenstern, 1999).  
Furthermore, a diagnosis of ADHD requires that symptoms be present before the 
age of seven (APA, 1994). Therefore, in order to be diagnosed as an adult, individuals 
must provide corroborating evidence from childhood either via parents, siblings, 
pediatricians or childhood teachers or they must retrospectively report experiencing 
symptoms during childhood. However, numerous studies have revealed discrepancies in 
self-reports of ADHD symptoms relative to other informants (Barkley, Fischer, Smallish, 
& Fletcher, 2002). These discrepancies may result from deficient self-awareness or a 
positive illusory bias- the tendency toward positive self-perception (Knouse, Bagwell, 
Barkley, & Murphy, 2005) often seen among ADHD children (Owens, Goldfine, 
Evangelista, Hoza, & Kaiser, 2007). Nonetheless, self-report measures are a commonly 
used method for diagnosing ADHD in adults. 
As previously mentioned, prevalence rates for adult ADHD vary considerably 
between studies due to the characteristics of the sample and study methodology. Despite 
the fact that interest in adult ADHD has increased in recent years, it remains relatively 
under-investigated in Canada. Consequently, the prevalence of adult ADHD in Canada is 
currently unknown. 
1.5 Sex and ADHD 
Most of what we know about ADHD at present is based on studies of boys 
(Gershon, 2002). Much less is known about adult manifestations of this disorder, and 
even less is known about how symptoms and outcomes may be differentially expressed 
by sex in adulthood. Clinical diagnostic studies in children indicate that a considerable 
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discrepancy exists in the diagnosis of ADHD in childhood. The gender ratio comparing 
males to females has ranged anywhere from 2:1 to 9:1 (Biederman, Faraone, Keenan, 
Knee & Tsuang, 1990; Gittelman, Mannuzza, Shenker & Bonagura, 1985; Weiss, 
Hechtman, Milroy & Perlman, 1985). More recent prevalence estimates come from a 
nation-wide telephone survey conducted in 2003-2004 that indicated the prevalence of 
ADHD was 14% in 10-year-old boys and 6% in 10-year-old girls, with stimulant 
medication use rates of 9% and 4%, respectively (Swanson et al., 2007).  
However, other recent epidemiological evidence suggests that prevalence may be 
similar in both sexes. Diagnosis of ADHD in a representative national US survey of 
adults found an odds ratio of 1.6 between men and women, reflecting 5.4% of men and 
3.2% of women (Kessler et al., 2006), indicating an equalization of the sex distribution of 
the disorder in adulthood (Kessler et al., 2005; McGough et al., 2005). A representative 
student survey conducted in Atlantic Canada included an ADHD screening and found a 
non-significant difference between girls and boys, with a prevalence of 6.2% and 5.9%, 
respectively (Poulin, 2007).  
The vast majority of the research on sex and ADHD was conducted with 
clinically-referred samples. Therefore, the preponderance of males versus females 
possibly reflects the higher number of referrals for males with ADHD, due to their 
greater propensity towards disobedience in educational settings (Gershon, 2002). Females 
with ADHD however tend to display inattentive and therefore less disruptive behaviour 
than males with ADHD. Since disruptive behaviour is likely to be a motivating force 
behind clinic referrals, girls are more liable to be overlooked, resulting in an 
underrepresentation of females in clinical samples (Gaub & Carlson, 1997). Thus, 
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clinically-referred girls likely display particularly disruptive behaviour, but may not 
accurately represent the majority of women with ADHD (Gershon, 2002). As Miller and 
Leger (2003) state, “recent scholarship regards the association of males with ADHD as 
largely mythic, proposing that the clinical imbalance derives from under-diagnosis 
among girls and a similar failure to identify ADHD in older women”. 
Thus, the research suggests contradictory findings: some studies found higher 
prevalence of ADHD males to females, while other studies found no sex differences in 
prevalence of ADHD. Only one Canadian non-clinical study, a high school survey, was 
found which indicated a non-significant difference favouring girls over boys.  
1.6 ADHD and Concurrent Disorders 
Whether ADHD stands alone as a distinct disorder is unclear, as ADHD 
symptoms have been found to converge with other forms of psychopathology (Furman, 
2005). The difficulty distinguishing ADHD from other pathology indicates that ADHD 
may not be a distinct neurological or psychological disease entity and mayrepresent a 
common behavioural pathway for a plethora of emotional, psychological and/or learning 
difficulties (Furman, 2005). In young people, ADHD has been found to co-occur with 
anxiety disorders in 25-35% of cases, mood disorders in 20% of cases, and oppositional 
defiant disorder (ODD) and conduct disorder (CD) in 25-50% of cases (Steele, Jensen & 
Quinn, 2006). ADHD therefore, often co-occurs with other psychiatric disorders in child 
populations. 
Interestingly, high levels of psychiatric difficulties in ADHD adults parallel 
findings from ADHD children. Studies consistently show that adult ADHD frequently co-
occurs with mood, anxiety, substance use and antisocial personality disorders (Biederman 
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et al., 1991a; Downey, Stelson, Pomerleau, & Giordani, 1997). Shekim and colleagues 
(1990) studied a group of 56 adults who met the DSM-III-R criteria for ADHD. Of this 
sample, only 14% met criteria solely for ADHD; 20% had one comorbid diagnosis, 29% 
met criteria for  two other diagnoses, 11% met criteria for three additional diagnoses, and 
as many as 33% suffered from four other diagnoses. As such, converging results indicate 
that ADHD commonly co-occurs with other mental disorders among both children and 
adults. 
1.7 Internalizing Disorders: Mood and Anxiety Disorders 
1.7.1 ADHD and Depression in Children. Depression is a mental state 
characterized by feelings of sadness, low mood and anhedonia, accompanied by reduced 
energy (APA, 1994).The association between ADHD and depression in children has been 
demonstrated across a number of studies (reviewed in Angold, Costello, & Erkanli, 1999) 
with up to 47% of clinical ADHD children cases having this comorbidity (Wilens et al., 
2002). Moreover, a substantial overlap between ADHD and major depressive disorder 
(MDD) has been reported from both population (Anderson, Williams, McGee & Silva, 
1987; Bird et al., 1988) and clinical studies (Biederman, Faraone, Keenan, Knee & 
Tsuang, 1990; Jensen et al., 1988; Woolston, Rosenthal, Riddle, Sparrow, Cicchetti & 
Zimmerman, 1989). Reviews of the literature have concluded that the two disorders co-
occur more frequently than expected by chance alone and that their relationship is bi-
directional as relatively high rates of ADHD and depression have been reported in studies 
of both mood disorders and ADHD (Angold & Costello, 1993; Biederman et al., 1992; 
Angold, Costello & Erkanli, 1999; Bird, Gould, & Staghezza, 1993; Butler, Arrendondo, 
& McCloskey, 1995; MTA Cooperative Group, 1999). 
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The association between ADHD and depression has been demonstrated in studies 
of clinically referred children and adolescents as well as in community samples. For 
example, results from a study by LeBlanc and Morin (2004) indicated that children 7-12 
years of age with ADHD reported significantly higher scores on a self-report measure of 
depressive symptoms (n = 68). A study by Nolan and colleagues (1999) used parent and 
teacher checklists based on DSM-IV diagnostic criteria to obtain information about 
depressive symptoms in 222 clinic-referred children between the ages of three and 18 
years of age. Results from this study showed that ADHD was significantly associated 
with MDD according to both parent and teacher reports (Nolan, Volpe, Gadow & 
Sprafkin, 1999). Souza, Pinheiro, Denardin, Mattos and Rohde (2004) examined ADHD 
and comorbid depression in two clinical samples consisting of three to 17 year olds and 
found that prevalence rates were 10.3% and 11.4% respectively. As such, studies 
examining clinical samples demonstrate high rates of ADHD and comorbid depression.  
The association between ADHD and depression has also been demonstrated in 
community samples. Romano and colleagues (2005) studied a community sample of 
adolescents (n = 1,201) and found that 2.9% met diagnostic criteria for both ADHD and 
MDD. Also, based on parent reports in a community sample of 7,231 children attending 
grades one to four, Blackman, Ostrander and Herman (2005) found that 10% of 
participants with ADHD also had depression; hence having a diagnosis of ADHD 
increased the risk of having depression. Furthermore, in their study comparing children 
and youth with ADHD from both clinic (n = 763) and community (n = 1,896) samples, 
Bauermeister and colleagues (2007) found that the rates of depression were 9.27% and 
22.73% in the community and clinic samples, respectively. Therefore, the concurrence of 
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ADHD and depression, although higher among clinical samples, is also apparent in 
community samples.  
1.7.2 ADHD and Depression in Adults. ADHD has also been found to be 
associated with clinical depression in adults. Similar to studies of ADHD children, 
studies of ADHD adults have reported high levels of depression with a correspondingly 
wide range of prevalence rates in both clinic and epidemiological samples. A prospective 
follow-up study comparing individuals referred for clinical assessment in childhood (n = 
147) to community controls (n = 71), found that adults with ADHD were at a greater risk 
for developing MDD, with a prevalence rate of 26% versus 12% in community controls 
(Fischer, Barkley, Smallish & Fletcher, 2002). A study conducted by Sobanski and 
colleagues (2007) compared clinic-referred adults with ADHD (n = 70) to age and sex 
matched controls (n = 70) to ascertain the difference in prevalence rates for Axis-I 
disorders. Results showed that the prevalence of depression was 55% in adults with 
ADHD versus 25.3% in controls (Sobanski et al., 2007). Cumyn, French and Hechtman 
(2009) also compared ADHD to non-ADHD adults (n = 477) and found that the ADHD 
group had significantly higher rates of MDD with a prevalence of 19.2%. 
Furthermore, using a nationally representative survey of adults (n = 9282), 
findings from the National Comorbidity Survey Replication demonstrated that 38.3% of 
ADHD adults had a concurrent mood disorder (Kessler et al. 2006). Concurrent ADHD 
and depression is related to poor long-term prognosis and psychiatric impairment 
(Biederman, Faraone, Keenan, & Tsuang, 1991b; Biederman, Faraone, Milberger, Guite, 
Mick & Chen, 1996; Ollendick & King, 1994) including higher rates of suicide 
(Biederman et al., 1991; Lewinsohn, Rohde, & Seeley, 1994).  
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As indicated by the above studies, prevalence rates for comorbid ADHD and 
depression range extensively with higher rates found in clinical samples (Biederman et 
al., 1992; Biederman, Faraone, et al., 1991b; Biederman et al., 1987; Butler, Arrendondo 
& McCloskey, 1995). Yet it is likely that clinical cases are more symptomatic and more 
impaired than the general population, resulting in a referral bias for more troubled 
individuals. Another reason for the considerable discrepancy in prevalence rates is the 
use of various measures and cut off scores for determining the presence of ADHD and 
depression. Some studies use third party reports in the form of checklists and 
questionnaires, whereas others use standardized interviews with the individual, parent, or 
teacher, and still others use self-report questionnaires or combinations of these measures. 
Therefore, prevalence rates show substantial variability across studies not only due to 
differing study populations, but also due to the lack of consistent measures and varying 
disease thresholds. 
1.7.3 ADHD and Anxiety Disorders in Children.  
In addition to mood disorders, anxiety disorders are also particularly prevalent 
among individuals with ADHD. Anxiety disorders refer to those disorders for which 
severe anxiety is a salient and ongoing symptom (APA, 1994). Pediatric studies of 
clinical and community samples from the United States have documented a concurrence 
between anxiety disorders and ADHD. Results from a review of the literature prior to 
1998 showed that 15% to 35% of children with ADHD also exhibit considerable anxiety 
(Pliszka, Carlson & Swanson, 1999).  
Several prevalence rates have been documented in referred pediatric samples.  
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Based on parental reports of children clinically referred for ADHD, the Multimodal 
Treatment Study of Children with ADHD Cooperative Group (1999b) found that, 33.5% 
of children with ADHD had comorbid anxiety disorders. A study by Karustis and 
colleagues (2000) examined the prevalence of comorbid anxiety using parent, teacher and 
child self-reports in a clinical sample of children aged 7-12 years (n = 125). Results from 
this study showed that the prevalence of comorbid anxiety was approximately 17% 
(Karustis, Power, Rescorla, Eiraldi & Gallagher 2000).  
Similar rates of comorbid ADHD and anxiety have also been found among 
adolescent samples. Biederman and colleagues (1991c) assessed a sample of clinically-
referred patients aged 6-17 years using structural diagnostic interviews with parents. 
Thirty percent of this sample met diagnostic criteria for ADHD and one or more 
comorbid anxiety disorders (Biederman et al., 1991c).  Another study compared the 
prevalence of ADHD and comorbid psychopathology in preschool children and school-
aged youth and found similar degrees of ADHD and comorbid anxiety in both cohorts, 
with prevalence rates around 30% (Wilens et al., 2002).   
1.7.4 ADHD and Anxiety Disorders in Adults. An elevated prevalence of 
anxiety disorders is also present in adult ADHD. In the National Comorbidity Survey 
replication, Kessler and colleagues (2006) found a 47% prevalence rate of anxiety 
disorders among adults with ADHD. Adults with ADHD also had significantly higher 
odds of anxiety compared to the general population (OR = 3.7). Also, Biederman and 
colleagues (1993) reported on a large sample of clinic-referred adults with ADHD 
identified during a family study of children with ADHD, and a control group of adults 
without ADHD obtained through the same study. The results indicated a high incidence 
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of lifetime diagnoses of anxiety disorders (43% to 52%). Shekim and colleagues (1990) 
examined 56 clinically-referred adults who met DSM-III-R criteria for ADHD (n = 56), 
53% of whom also met criteria for generalized anxiety disorder (Shekim, 1990). A 
clinical study conducted by Murphy and Barkley (1996) (n = 202) found the prevalence 
of anxiety in adult ADHD to be approximately 32% (Murphy & Barkley, 1996). 
Furthermore, the co-occurrence of ADHD and generalized anxiety appears to be robust, 
also existing in international populations (Souza, Pinheiro, Denardin, Mattos, & Rohde, 
2004). 
The vast majority of prevalence estimates for concurrent ADHD and anxiety 
disorders in children, adolescents, and adults are derived from clinically-referred samples 
and studies examining the co-occurrence of these disorders using representative samples 
of the general population are sparse. Therefore research on adult ADHD and concurrent 
disorders in the context of the general population in Canada is necessary not only to 
address the scarcity of population studies in the ADHD-anxiety literature, but also to 
investigate adult ADHD and internalizing disorders in a Canadian context.  
1.8 ADHD and Externalizing Disorders 
1.8.1 ADHD, Oppositional Defiant Disorder and Conduct Disorder. Along 
with ADHD, oppositional defiant disorder (ODD) and conduct disorder (CD) are the 
most frequently studied psychiatric conditions of childhood (Althoff et al., 2003). The 
defining feature of ODD is a persistent pattern of hostile and defiant behaviour towards 
authority figures causing considerable impairment, whereas CD is described as a 
continuous pattern of aggressive behaviour that consistently violates both the rights of 
others and age-appropriate social norms (APA,1994). The prevalence of ODD ranges 
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from 2-15% and the prevalence of CD ranges from 1.5-3.4%, with some estimates as 
high as 16% contingent upon the type of sample under study (Althoff et al., 2003). Also, 
there is a higher prevalence of ODD and CD among boys than girls. 
ADHD frequently co-occurs with ODD (35%) and CD (50%) (Althoff et al., 
2003). Comorbid disruptive disorders are so pervasive that may not be separable, with 
some authors suggesting that ADHD subtypes with ODD and CD should be considered 
(Jensen, Martin & Cantwell, 1997). Conversely, evidence also exists suggesting that 
ODD and CD are distinct disorders from each other and from ADHD (Loeber, Burke, 
Lahey, Winters & Zera, 2000).  
 Although the disruptive disorders (ADHD, ODD and CD) are among those most 
commonly seen by pediatricians, family practitioners, psychologists, and psychiatrists, 
they often remain underdiagnosed, misdiagnosed or untreated (Althoff et al., 2003).  The 
paucity of treatment of these disorders is concerning, since ODD and CD have been 
found to be associated with negative psychosocial outcomes such as substance abuse and 
criminality (Robins & Price, 1991; Walters & Knight, 2010).  CD has been found to be a 
strong predictor of antisocial personality disorder (ASPD) in adulthood (Robins & Price, 
1991) as several studies of clinic and population-based samples have shown that 
childhood conduct problems predict serious adult antisocial behaviour (Hill, 2003; 
Kratzer & Hodgins, 1997; Robins, 1978). 
1.8.2 ADHD and Antisocial Personality Disorder. Antisocial personality 
disorder (ASPD) is a term used to designate a pattern of behaviours which include the 
failure to conform to social norms and the law, a reckless disregard for the safety of 
others and consistent irresponsibility among those 18 years or older (APA, 1994). A 
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diagnosis of antisocial personality also warrants the diagnosis of its childhood precursor 
conduct disorder (APA, 1994). ADHD has been found to be significantly associated with 
ASPD in adulthood, as longitudinal studies of ADHD children have revealed high rates 
of ASPD in later life (Barkley, Fischer, Smallish, & Fletcher, 2004; Mannuzza, Klein, 
Bessler, Malloy, & LaPadula, 1998; Satterfield & Schell, 1997; Weiss, Hechtman, Milroy 
& Perlman, 1985). In their 15-year prospective follow-up study of 61 hyperactive boys 
and 41 controls, Weiss and colleagues (1985) found that the only DSM-III diagnosis that 
was significantly more prevalent in the probands than the comparison subjects was ASPD 
(23% versus 2%) (χ2 = 8.22, df = 1, p < .01). Another prospective follow-up study of 
clinically-referred boys (n = 104) showed that approximately 20% of children with 
ADHD enter adulthood with ASPD (Manuzza et al., 1998). In an earlier study by the 
same authors, 27% of the probands and only 8% of the comparison subjects had ongoing 
ASPD (χ2 = 12.50, df = 1, p < .0001) (Manuzza et al., 1993). These findings were also 
replicated in yet another study conducted by the same authors with an independent cohort 
of 104 boys. Here, 32% of the probands and 8% of the comparison subjects had ongoing 
ASPD (χ2 = 15.11, df = 1, p < .0001) (Manuzza et al., 1991). These studies provide 
evidence for an association between ADHD in childhood and ASPD in adulthood.  
Magnetic resonance imaging (MRI) studies of the brains of persons with ASPD 
suggest that these individuals also exhibit frontal cortical deficits (Raine, Lencz, Bihrle, 
LaCasse & Colletti, 2000). Studies using both positron emission tomography (PET) 
(Goyer et al., 1994; Volkow et al., 1995; Raine, Meloy, Bihrle, Stoddard, Lacasse & 
Buchsbaumm, 1998) and single-photon emission computed tomography (SPECT) 
(Amen, Stubblefield, Carmicheal & Thisted, 1996; Kuruoglu, Arikan, Vural, Karatas, 
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Arac & Isik, 1996) have shown that poor prefrontal processing is exhibited in violent, 
antisocial persons, a deficit that is also a cardinal feature of ADHD. Therefore, similar 
abnormalities in areas that are critical in modulating emotion, arousal, and attention are 
characteristic of both ADHD and ASPD.  
In addition to common neural deficits, both ADHD and ASPD individuals are low 
on the personality trait known as effortful control (Frick & Morris, 2004; Nigg, 2006). 
Effortful control refers to the ability to focus attention resources and to inhibit 
behavioural responses and is critical to emotion regulation (Frick & Morris, 2004). There 
is robust evidence that a temperamental vulnerability termed ‘low effortful control’ is a 
risk factor for the development of oppositional/noncompliant antisocial behaviour (Frick 
& Morris, 2004; Nigg, 2006).  
ADHD has been shown to increase the risk for ODD and CD, thus consequently 
increasing the risk for the development of antisocial behaviour, as explained by 
developmental pathway theories that argue that antisocial behaviour evolves in a largely 
predictable manner (Frick & Marsee, 2006; Loeber, Green, & Lahey, 2003;Waschbusch, 
2002). Therefore, it is not surprising that ASPD has been found to be significantly 
associated with ADHD due to corresponding features present in both disorders.  
1.9 ADHD and Substance Use Disorders 
Substance use refers to the ingestion of drugs of abuse, inhalants, or medications 
for the purpose of intoxication (APA, 1994). As outlined in the DSM-IV, the substance 
use disorders (SUDs) are divided into substance abuse disorder and substance 
dependence disorder. The necessary feature of substance abuse disorder is a recurrent 
pattern of substance use despite negative consequences related to the use of the substance 
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(APA, 1994). An example of substance abuse would be binging on alcohol or drugs. 
Substance dependence disorder on the other hand, is a collection of cognitive, 
behavioural and physiological symptoms demonstrating that the individual continues 
substance use despite substance-related problems including the development of tolerance 
and withdrawal symptoms, hence being ‘dependent’ on a particular substance or 
substances (APA, 1994). Of the SUDs, substance dependence disorder is more severe 
than substance abuse disorder.  
Concurrent SUDs are of particular concern in the treatment of ADHD because 
habit-forming stimulant medication is currently the gold standard in treatment of the 
disorder. Given the need to identify antecedent risk factors to initiate early intervention in 
SUD, in addition to the clinical implications of concurrent ADHD and SUD, several 
authors have investigated the relationship between ADHD and SUD and have even 
proposed ADHD as a possible causal mechanism for the development of subsequent 
SUD.  
In their meta-analysis of longitudinal studies that prospectively followed children 
with and without ADHD, Lee, Humphreys, Flory, Lui and Glass (2011) found that 
children with ADHD were significantly more likely to have ever used drugs, but not 
alcohol. In addition, children with ADHD are also more likely to develop disorders of 
abuse/dependence for alcohol, marijuana, cocaine, and other substances (i.e., unspecified) 
(Lee et al., 2011). The authors’ concluded that individuals with ADHD are significantly 
more likely to develop SUDs than those without ADHD and that this increased risk was 
evident despite demographic and methodological differences that varied across studies.  
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The relation between ADHD and SUDs is bidirectional in nature in that the 
prevalence of ADHD is approximately 1-5% in the general adult population, yet it affects 
between 11 and 35% of adults with SUD (Kalbag & Levin, 2005) and between 25 and 
50% of adolescents with SUD (Wilens & Biederman, 2006). Furthermore, several studies 
involving adults with alcohol and drug use disorders show that from 15 to 25% referred 
for SUD also have ADHD (Carroll & Rounsaville, 1993; Levin, Evans & Kleber, 1998; 
Schubiner et al., 2000; Wilens, 2004a).  
A sex difference in ADHD and the risk for SUDs has also been documented. 
Research using both community and clinical samples suggests that compared to boys, 
ADHD girls have a higher risk for substance use by early adolescence (Biederman et al., 
1999; Disney, Elkins, McGue & Iacono, 1999). For example, as part of the Minnesota 
Twin project, Disney and colleagues (1999) reported trends towards higher rates of SUD 
within the past month in 17 year old ADHD girls compared to ADHD boys of the same 
age (any substance use: 73% versus 44%; SUD: 29% versus 14%, respectively). 
Similarly, studies by Biederman and colleagues (1991, 1999) demonstrate a greater age-
corrected risk for SUD in ADHD girls relative to boys. As such, ADHD girls appear to be 
at greater risk for SUD than ADHD boys, yet ADHD alone nonetheless acts as a risk 
factor for SUD regardless of gender. 
Studies suggest that compared to their non-ADHD peers, ADHD individuals 
appear to preferentially use drugs instead of alcohol (Biederman et al., 1995; Biederman 
et al., 1997; Molina & Pelham, 2003). However, the choice of a specific drug of abuse 
(e.g. cocaine over marijuana) or drug type (stimulant or depressant) has not been shown 
for persons with ADHD and concurrent SUD (Biederman et al., 1995; Biederman et al., 
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1997). Pharmacological treatment of ADHD has been found to attenuate the risk of 
subsequent SUD in some studies. For instance, a meta-analysis of the literature revealed 
that ADHD youth who were treated with stimulant medication had twice the reduction in 
risk for SUD compared to those not receiving pharmacotherapy for ADHD (Wilens et al., 
2003). However, other studies have found no evidence that stimulant medication 
increases or decreases risk for subsequent SUD (Biederman, Monuteaux, Spence, Wilens, 
MacPherson & Faraone, 2008). Regardless of the various reasons for use, adult ADHD 
has an especially negative impact on the development and course of SUD. Individuals 
with ADHD have been found to show an earlier onset of SUD, a more rapid progression 
of SUD, a greater severity of SUD, and a prolonged course of SUD (Wilens & Morrison, 
2011).  
 As shown in the above literature review, studies of the prevalence of ADHD and 
concurrent disorders show a substantial variability in estimates. This, in part, may be due 
to an inconsistency of measures used to ascertain these estimates. In addition, the 
selection of cut points to determine the presence or absence of a given disorder may 
differ, resulting in variable figures. Moreover, some studies employed measures whose 
psychometric properties were wanting.  
The observed variability in the prevalence of ADHD and concurrent disorders can 
be attributed to the clinical nature of the samples. Specifically, ADHD studies are largely 
based on clinical pediatric samples exhibiting significant gender discrepancies resulting 
in biased results that cannot be generalized to populations that do not conform to the 
specified characteristics of these samples. Furthermore, most ADHD studies to date have 
been conducted in the United States and therefore, may not be comparable to Canadian 
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findings. There is a marked deficit of Canadian epidemiological evidence regarding 
ADHD mental health correlates. As such, studies using population-based data from 
Canadian adults are necessary not only to address age differences, but also referral bias 
concerns and gender bias in order to better describe ADHD prevalence, mental health 
correlates and substance use in Canada. 
1.10 Study Objectives 
The current study used population-based data from Ontario adults to 1) estimate 
the prevalence of adult ADHD (using an ADHD screener), previous diagnosis and 
stimulant medication use correlated mental health issues and substance use in Ontario; 2) 
examine the sex differences in the prevalence of ADHD screener status, psychiatric 
distress and substance use in ADHD and 3) model ADHD screener status as a risk factor 
for psychiatric distress. The above aims were achieved using data gathered from the 2011 
cycle of the Centre for Addiction and Mental Health (CAMH) Monitor, a cross sectional 
telephone survey of Ontarians 18 years of age and older. 
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Chapter 2: Methods 
 
2.1 Study Design 
 
This study was a secondary data analysis conducted using cross-sectional data 
from the Centre for Addiction and Mental Health (CAMH) Monitor, a large ongoing 
population-based survey of Ontario adults aged 18 and over collected in 2010-2011 
(Ialomiteanu & Adlaf, 2012). 
2.2 CAMH Monitor 
 
2.2.1 Survey Design. Data were collected using the CAMH Monitor, an ongoing 
cross-sectional telephone survey of Ontario adults aged 18 and over. The survey was 
designed to monitor addictions and mental health issues in Ontario, including alcohol and 
drug consumption, public opinion on these topics, and mental health status. The 2011 
CAMH Monitor was an aggregation of 12 independent monthly surveys (January to 
December).  
2.2.2 Sampling Strategy. The target population of the current study was non-
institutionalized adults 18 years of age and older residing in Ontario households during 
the year 2011. The sampling frame was based on adult telephone subscribers residing in 
Ontario who were capable of completing the interview in English. Participants were 
contacted via random-digit dialing and were selected from a sampling frame of all active 
area codes and exchanges in Ontario provided each month by the American Telephone 
and Telegraph (ATT) Long Lines Tape.  
Since 2000, the CAMH Monitor sampling frame has consisted of listed 10-digit 
telephone numbers in Ontario. The numbers that are listed and selected, along with 
telephone numbers between or on either side of that number, are included in the sampling 
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frame. For example, if the selected number 416-651-8513 is published in a directory, then 
all numbers from 416-651-8510 to 416-651-8519 are included in the sampling frame 
even if they are cell phone numbers or unlisted numbers. Numbers are only excluded if 
they are identified “not-in-service” numbers. A computer is then used to generate a 
random sample of telephone numbers from this frame from which each quarterly sample 
is drawn. Because unlisted numbers, cell phone numbers, and newly published numbers 
are interspersed among published numbers in the sampling frame, this strategy provides a 
much more robust sample than one restricted to listed landline numbers alone 
(Ialomiteanu & Adlaf, 2012). Moreover, studies using exclusively landlines have been 
shown to underestimate several health behaviours such as binge drinking and smoking 
(Blumberg, Luke, & Cynamon, 2006).  
The sampling design employed a stratified two-stage probability selection 
procedure occurring each quarter. For the purpose of this survey, the province is divided 
into six geographical regions: Toronto, Central West, Central East, West, East, and 
North. In the first stage of selection, a random sample of telephone numbers was selected 
from within each of the six regional strata. In stage two, one respondent aged 18 or older 
who was able to complete the interview in English was selected without replacement 
based on the most recent birthday of all household members (Ialomiteanu & Adlaf, 
2012).  According to O’Rourke and Blair (1983), the most recent birthday technique is a 
relatively non-intrusive method for producing an unbiased sample. Unanswered numbers 
were called back a minimum of 12 times and households that initially refused to 
participate were re-contacted to ensure maximum participation (Ialomiteanu & Adlaf, 
2012).   
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Two-stage probability sampling differs in subtle ways from simple random 
sampling (SRS). The selection of respondents from household by most recent birthday 
creates a design effect (DEFF). Design effects are the ways departures of the sampling 
frame from simple random sampling impact statistical estimates from the sample. The 
DEFF is basically the ratio of the actual variance under the sampling method used, to the 
variance computed under the assumption of simple random sampling (Henry, 1990). The 
implication of using SRS formulas on estimates from complex sampling designs is the 
underestimation of the error and the construction of narrower confidence intervals than 
truly exist, resulting in false positive findings of statistical significance (Henry, 1990). As 
such, a greater number of type I errors (false positive statistically significant differences) 
are more likely.  
A DEFF of 1.0 indicates that the variance of a given sample design is equivalent 
to the variance of a SRS and most complex survey designs tend to have DEFFs larger 
than one (Ialomiteanu & Adlaf, 2012). However, random-digit dialing telephone surveys 
typically have smaller DEFFs relative to multistage, clustered area samples (Ialomiteanu 
& Adlaf, 2012).  DEFFs in the current study ranged from 1 to 2 (Ialomiteanu & Adlaf, 
2012). Therefore, most of the statistically significant differences generated from standard 
statistical software would be correct, yet some may not be, especially those involving 
small sample sizes. 
2.3 Study Population, Inclusion Criteria and Exclusion Criteria 
The current study included respondents from the 2011 cycle of the CAMH 
Monitor (n = 3039). This cycle was the first to include questions regarding adult ADHD, 
previous ADHD diagnosis, and previous ADHD medication use. Furthermore, the 2011 
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cycle was also the first cycle to include questions on antisocial personality disorder. 
Excluded by design are Ontario households that are phoneless, which represent 1% of 
Ontario residents (Statistics Canada, 2011). Also excluded are those too ill or aged to be 
interviewed and those unable to communicate on the telephone or in English. Therefore, 
the CAMH Monitor is representative of non-institutionalized English-speaking Ontarians 
age 18 and older who are sufficiently healthy to answer a telephone (n = 9,118,084 from 
2001 Ontario Census) (Ialomiteanu & Adlaf, 2012).   
2.4 Data Collection 
Data were collected from January 3rd through December 20th 2011. All interviews 
were conducted by trained staff from the Institute for Social Research (ISR) at York 
University. On average, the 2011 interviews lasted 23 minutes (range 6-71 minutes; 
median 22 minutes) with 90% of interviews completed within 30 minutes (Ialomiteanu & 
Adlaf, 2012). The interviews used computer-assisted telephone interviewing (CATI) 
which consists of telephone, video monitor and computer keyboard to ask questions and 
record participants’ responses (Bondy, 1994). The computer program associated with the 
questionnaire controlled the presentation of items on the video monitor during the 
interview. The CATI system followed a programmed skip pattern and customized the 
wording of some items to make the interview flow smoothly and ensure consistency 
between interviewers. Interviews were conducted by 60 ISR interviewers, many of whom 
had considerable CATI experience and had completed interviews on prior CAMH 
surveys (Ialomiteanu & Adlaf, 2012). 
 CATI technology allowed for the blind supervision of interviewers while 
simultaneously storing participant responses in computer data files. CATI systems are 
31 
 
 
preferred over the more traditional paper and pencil questionnaires as they produce fewer 
errors and missing data (Cattlin & Ingram, 1988). One advantage of the CATI system 
over paper and pencil questionnaires is that the computer program notifies the interviewer 
of out of range values and interviews cannot proceed until the value error is rectified.  
A matrix interview design was used in order to reduce respondent burden and 
maximize questionnaire content and flexibility. Here, random subsets of respondents 
within each panel are asked one set of questions, whereas other subsets of respondents 
are asked a different set of questions. The majority of the interview consists of core items 
which were asked of all respondents. Two interview schedules were employed for the 
remaining questions on the survey. Panel A represents interviews with 1,040 respondents, 
and Panel B represents interviews with 1,999 respondents. Only panel B was analyzed in 
this study as it comprised all questions pertaining to ADHD.  
2.5 Response Rates 
Of the 8,277 telephone numbers selected over the four quarters of 2011, 5,677 
were estimated to be eligible and 3,039 respondents participated, representing an 
effective response rate of 51% (quarterly response rates varied from 50% to 52%). This 
response rate was lower than previous years (57% in 2009, 55% in 2008, 53% in 2007, 
and 60% in 2006) (Ialomiteanu & Adlaf, 2010). Unit response rates for the 20 surveys 
conducted between 1991 and 2010 were found to vary from 51% to 69% with an average 
of 62% (Ialomiteanu & Adlaf, 2010). 
These response rates are similar to those achieved by other high quality surveys in 
the past decade. For example, the Canadian Alcohol and Drug Use Monitoring Survey, 
conducted in 2010, obtained an overall response rate of 44% (Health Canada, 2010). 
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Also, the Behavioural Risk Factor Surveillance System, the largest health risk survey 
conducted in the United States by the Centers for Disease Control and Prevention, 
obtained an overall response rate of 41% in 2004 (Centers for Disease Control and 
Prevention, 2004). Further, the University of Michigan’s Survey of Consumer Attitudes 
found a decline in response rates from 60% in 1996 to 48% in 2003 (Curtin, Presser, & 
Singer, 2005).  
2.6 Survey Instrument 
The CAMH Monitor was written for use with the CATI interviewing system. The 
corresponding telephone interview averages 25 minutes in duration (Ialomiteanu & 
Adlaf, 2010). There are over 300 items, but no respondents were administered all items 
due to panel divisions and logical skip patterns designed into the survey. For example, if 
a respondent was asked if they consumed any alcoholic beverages in the past year and 
responded no, any questions regarding alcohol consumption in the last seven days would 
be skipped. 
2.7 Measures 
2.7.1 Adult ADHD Self-Report Scale (ASRS-v1.1). Developed by the World 
Health Organization, the Adult ADHD Self-Report Scale (ASRS- v1.1) Screener is a six-
item checklist used to assess ADHD symptoms based on DSM-IV criteria for ADHD. The 
ASRS-v1.1 Screener was designed to effectively capture the three primary symptom 
domains of ADHD: hyperactivity, impulsivity and inattention. The ASRS-v1.1 Screener 
questions were selected using stepwise logistic regression analysis. This method selects 
the least redundant set of symptoms in an effort to maximize prediction of an external 
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criterion, in this case, the DSM-IV diagnosis of ADHD (Kessler, Adler, Gruber, Sarawate, 
Spencer & Van Brunt, 2007). 
The wording of questions in the ASRS-v1.1 Screener differs slightly from the 
wording in other ADHD rating scales. Unlike the items in previous ADHD scales, the 
questions in the ASRS-v1.1 Screener are designed to suit adult, rather than child 
respondents. The language in the ASRS also provides a context for symptoms to which 
adults can relate, to better capture adult ADHD symptom manifestations. To this end, 
references to such things as play and schoolwork were deleted. Therefore by using 
language and context specific to adults, the ASRS-v1.1 Screener addresses the issue of 
variability in ADHD symptom expression between children and adults, which was a 
concern raised by Biederman et al. (2000) and Faraone et al. (2000) in regards to other 
ADHD scales. 
The ASRS-v1.1 Screener measures the frequency of ADHD symptoms. The 
developers of the instrument employed frequency-based ratings in order to allow 
respondents to focus on symptom occurrence, rather than on symptom severity. The 
ASRS-v1.1 Screener has an expanded rating scale of zero to four, which allows more 
accurate discrimination of symptom frequency. For example, the previously combined 
‘never or rarely’ response option from other ADHD rating scales, was separated into: 0 
‘never’, 1 ‘rarely’, 2 ‘sometimes’, 3 ‘often’, and 4 ‘very often’ on the ASRS Screener. 
The optimal scoring approach for the ASRS-v1.1 Screener involves summing the items’ 
numeric response options (0-4). This method yields a summary score with a theoretical 
range of 0-24 (as opposed to the 0-6 scoring approach which was found to be less 
discriminative) (Kessler et al., 2007). 
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Using the 0-24 scoring approach with a cutoff score of 14, the ASRS-v1.1 
Screener demonstrated high concurrent validity, as the Screener was found to have a 
strong concordance with clinician diagnosis with an area under the receiver operating 
characteristic curve (AUC) of 0.90 (Kessler et al., 2007). The ASRS-v1.1 Screener has a 
sensitivity of 0.65 (SE = 0.23), specificity of 0.94 (SE = 0.3), a positive predictive value 
(PPV) of .50, and a negative predictive value (NPV) of .97 (Kessler et al., 2007). Overall, 
the ASRS-v1.1 Screener had a total classification accuracy of 0.92 (SE = 0.38) (Kessler 
et al., 2007). These findings show that the ASRS-v1.1 is better at ruling in adult ADHD 
than ruling it out. However, a more recent study by Hines and colleagues (2012) 
compared the ASRS-v1.1 Screener and the Conner’s Adult ADHD Self Report Scale Self 
Report-Short Version (CAARS-S: S) in a primary care setting. These authors found that 
the ASRS showed a sensitivity of1.0, a specificity of 0.71, a PPV of 0.52, and a NPV of 
1.0 (Hines, King & Curry, 2012). The high sensitivity suggests that cases of adult ADHD 
are rarely missed by the ASRS-v1.1. Furthermore, the moderately high specificity and 
NPV of 0.99 suggest that the ASRS-v1.1 Screener does not identify someone as having 
adult ADHD in they in fact do not. Therefore, these values show that the ASRS-
v1.1Screener would rarely miss someone with adult ADHD and would also be successful 
at discounting non-cases.  
In order to assess the test-retest reliability of the ASRS-v1.1 Screener, Kessler and 
colleagues (2007) administered the Screener at baseline, again six months to one year 
after initial screening, and once more one to three months after the second screening.  
This allowed the authors to calculate the correlations between times one, two and three. 
The ASRS-v1.1 Screener was found to have test-retest reliabilities ranging from .58- .77 
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(Kessler et al., 2007). The ASRS-v1.1 Screener was found to have internal consistency 
reliabilities (Cronbach’s alphas) ranging from .63- .72, demonstrating acceptable 
intercorrelations between items on the Screener (Kessler et al., 2007). The authors note 
however that very high Cronbach’s alphas would not be expected because the ASRS 
Screener questions were selected by stepwise logistic regression analysis, a method 
which optimizes inconsistency among items in a way that would be reflected in low 
estimates of internal consistency (Kessler et al., 2007). In addition to its applicability in 
assessing adult ADHD, the sound psychometric properties of the six-question ASRS-v1.1 
Screener make it a useful screening tool for epidemiological research.  
Variables adh1-adh6 represented the six ASRS Screener items. The ASRS 
Screener items are presented in Appendix A.  
Response options to variables adh1 to adh6 were 1 ‘never’, 2 ‘rarely’, 3 
‘sometimes’, 4 ‘often’ and 5 ‘very often’ in the Monitor. These variables were recoded to 
correspond to the Kessler and colleagues (2007) response options, 0 ‘never’, 1 ‘rarely’, 2 
‘sometimes’, 3 ‘often’, and 4 ‘very often’ mentioned above. Reponses to each question 
were then summed, yielding summary scores with a theoretical range of 0-24. A derived 
variable delineating positive from negative ADHD screens was created using a summary 
score threshold of 13/14, as it corresponds to the optimal cutoff score for case-finding 
using the 0-24 scoring approach recommended by Kessler and colleagues (2007).    
Kessler and colleagues (2007) also recommended that the 0-24 summary scores 
be classified according to four strata denoting high negative to high positive Screener 
scores. A derived variable was created with four values: 1 ‘high negative, 2 ‘low 
negative, 3 ‘low positive and 4 ‘high positive’ (strata). The high negative stratum 
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represented participants with ASRS Screener scores 0-9; the low negative, scores 10-13; 
the low positive, scores 14-17; and the high positive, scores greater than or equal to18.   
2.7.2 Previous ADHD diagnosis and medication use. Previous ADHD diagnosis 
was assessed by the item ‘have you ever been diagnosed with Attention Deficit Disorder 
(ADD) or Attention Deficit Hyperactivity Disorder (ADHD) by a doctor or health care 
professional?’ (adh11).  
Drawn from the Ontario Student Drug Use and Health Survey (Paglia-Boak et al., 
2012), the item ‘have you ever been treated with MEDICATION for ADHD or ADD by a 
doctor or health care professional?’ (adh12) assessed previous ADHD medication use.  
2.7.3. General Health Questionnaire (GHQ-12). The GHQ-12 is a self-report 
screening instrument that measures current mental health status while focusing on two 
areas: the inability to execute normal ‘healthy’ functions and the appearance of novel and 
distressing experiences. The questionnaire asks respondents about their recent experience 
of particular psychological symptoms and probes whether these symptoms are worse than 
usual. The GHQ-12 is intended for adults 16 and over and consists of 12 questions 
balanced in agreement sets. That is, half of the items are worded positively and the other 
half is worded negatively. Responses are categorized along a four point Likert scale with 
response options 0 ‘not at all’, 1 ‘no more than usual’, 2 ‘rather more than usual’, and 3 
‘much more than usual’. Items gq1 through gq12 in the CAMH Monitor correspond to 
the GHQ-12 items. 
Lewis and Wessely (1990) found that the convergent validity between the GHQ-12 
and the Hospital Anxiety and Depression Scale was 0.74. Furthermore, Goldberg and 
colleagues (1997) studied the validity of the GHQ-12 in 15 countries and found no 
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significant differences in the validity of results by age, sex and education or between 
developed and developing countries. 
In a comprehensive review of the GHQ-12, Vieweg and Hedlund (1983) found 
that Cronbach’s alpha coefficients ranged from .82 to .90 (Vieweg & Hedlund, 1983; 
Goldberg et al., 1997). Clinical assessments of psychiatric illness have been found to be 
directly proportional to the number of symptoms reported on the GHQ-12, demonstrating 
good external consistency (Goldberg & Huxley, 1980). The median sensitivity and 
specificity drawn from 17 studies was 83.7% and 79.0% respectively (Goldberg et al., 
1997).  
There are three scoring approaches for the GHQ-12, a binary method (ex. 0-0-1-
1), a Likert method (ex. 0-1-2-3) and the C-GHQ method. The standard method of 
scoring the GHQ is the binary method where symptomatic responses to each item are 
scored ‘1’ and summed over the items, resulting in a score ranging from 0-12 (Goldberg 
et al., 1997). The Likert scoring method involves assigning response scores of 0-3 to each 
item. These scores are then summed across items, giving an overall score ranging from 0 
to 36 (Goldberg et al., 1997). Another scoring method, the C-GHQ method, scores 
positive items in the binary method and negative items are scored 0-1-1-1, thus assuming 
that the ‘no more than usual’ response to negative questions indicates the presence of a 
chronic problem rather than good health (Goldberg et al., 1997). In all three scoring 
methods, higher scores indicate an increased likelihood of psychiatric distress. 
 Goldberg and colleagues (1997) found that the Likert and C-GHQ scoring 
methods offer no advantage over the simpler binary scoring method for the GHQ-12. The 
same study found 1/2 to be the optimal threshold with an ROC of 0.88, 83.5% sensitivity 
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and 75.1% specificity (Goldberg et al., 1997). However, in their study using the CAMH 
Monitor to determine optimal GHQ-12 threshold values for the Ontario population, Mann 
and colleagues (2011) identified 4 as the value at which both sensitivity and specificity 
are maximized. This cut-off provided estimates of prevalence of probable anxiety and 
mood disorder (psychiatric distress) in the Ontario population nearly identical to those 
found in the Canadian adult population with the CIDI (Rush et al., 2008). 
Therefore, after summing GHQ-12 responses using the binary scoring method, a 
cut-off score of 4 was used to delineate cases of psychiatric distress from non-cases.  
2.7.4 Psychotropic medication use. Two items addressed psychotropic 
medication use. One item corresponded to antidepressant medication use, ‘in the past 12 
months have you taken any prescription medication to treat depression?’(ps11) and the 
other to anxiolytic medication use, ‘in the past 12 months have you taken any 
prescription medication to reduce anxiety or panic attacks?’ (ps16). Both items had 
binary response options ‘yes’ and ‘no’.  
2.7.5 The Antisocial Personality Disorder Scale from the Mini-International 
Neuropsychiatric Interview (MINI-APD). The Mini-International Neuropsychiatric 
Interview (MINI) is a screening tool used to identify individuals in need of further mental 
health assessment (Sheehan et al., 1998). The MINI consists of a structured diagnostic 
interview comprised of 120 questions, and assesses the presence of the 19 most common 
DSM-IV and International Statistical Classification of Diseases and Related Health 
Problems, 10th Revision (ICD-10) disorders, 17 Axis I disorders, one Axis II disorder 
(antisocial personality disorder) and suicidal ideation/attempts. Items are answered 
dichotomously as either ‘yes’ or ‘no’.  
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The current study was concerned solely with the antisocial personality disorder 
module from the MINI. The MINI-APD module consists of 12 behavioural questions 
largely drawn directly from the diagnostic criteria for ASPD and from the diagnostic 
criteria for conduct disorder prior to age 15 (a necessary requirement for diagnosis of 
ASPD). The ASPD section involves two areas of interest. In the first section, subjects are 
asked about six specific problematic childhood misbehaviours; if two or more questions 
are endorsed, subjects are subsequently asked about six antisocial behaviours since age 
15. Three or more of these behaviours are required for a diagnosis of ASPD.  
The MINI was found to have acceptably high validity, inter-rater and test-retest 
reliability scores for most disorders when compared with both the Structured Clinical 
Interview for DSM-III-R (SCID) and the CIDI (Pinninti, Madison, Musser & Rissmiller, 
2003; Lecrubier, Sheehan, Hergueta, & Weiller, 1997; Sheehan et al., 1997). Sheehan 
and colleagues (1998) found kappas over 0.70 for most of the psychiatric diagnoses and 
only a single kappa value (current drug dependence) being under 0.50.  Sensitivity was 
0.70 for all disorders except dysthymia, obsessive-compulsive disorder, and current drug 
dependence. PPVs were above .75 for major depression, lifetime mania, current and/or 
lifetime panic disorder, lifetime agoraphobia, lifetime psychotic disorder, anorexia, and 
posttraumatic stress disorder. However, none of these studies assessed the antisocial 
personality disorder module of the MINI. As such, information regarding the validity and 
reliability of the ASPD module is lacking.  
For the present study, the MINI-APD module was shortened by one item to 11 
items in total. The first section consists of only 5 items instead of 6 (items apd1 through 
apd5). For ethical reasons, item six from the MINI ASPD module, ‘before you were 15 
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years old did you force someone to have sex with you?’ was excluded from the CAMH 
Monitor and therefore from the current study. Scoring the first five items was 
programmed directly into the CATI interviewing system and differed from the 
aforementioned scoring. In order to be asked the next set of ASPD questions, participants 
must have endorsed greater than three questions out of the initial five (instead of two out 
of six). Similar to the original scoring developed by Sheehan and colleagues (1998), 
antisocial personality disorder was identified as present if a participant scored three or 
higher on the latter six questions (apd6 through apd11). A dichotomous variable 
delineating those who screened positive from those who screened negative for ASPD was 
created using a scoring threshold of 5/6.   
2.7.6 Alcohol Use Disorders Identification Test (AUDIT). 
The Alcohol Use Disorders Identifications Test (AUDIT) was developed by the 
World Health Organization, Department of Mental Health and Substance Dependence to 
identify the presence or absence of an alcohol use disorder. The AUDIT contains 10 
items and 4 subscales and takes about two minutes to administer (Babor, Biddle-Higgins, 
Saunders & Monteiro, 2001). Response options range from zero to four, however the 
phrases associated with the numeric response options vary depending on the item. A 
score of eight or more denotes hazardous alcohol use (Babor, Biddle-Higgins, Saunders 
& Monteiro, 2001).  
The AUDIT has demonstrated a high degree of internal consistency across a 
broad range of studies. In their review of studies prior to the year 2001, Shields and 
Caruso (2003) calculated a median reliability of .81, with a range of .59 to .91. In a 
review of 18 studies published since 2002, Reinert and Allan (2007) found a comparable 
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median reliability coefficient of .83, with a range of .75 to .97. Using the standard cut-
point of eight, three studies were conducted with general population samples and reported 
test-retest reliability kappas of .70, .86, and .89 respectively (Dybek, Bischof, Grothues, 
Reinhardt, Meyer, Hapke, et al., 2006; Rubin, Migneault, Marks, Goldstein, Ludena & 
Friedman, 2006; Selin, 2003).   
Interclass correlations have also confirmed the stability of the test-retest reliability 
of the AUDIT in general population samples. Rubin and colleagues (2006) derived an 
interclass correlation coefficient of .87 among 102 participants from the general U.S. 
population who were screened by telephone with a seven day interval between 
screenings. In their study of 61 participants from the general Swedish population, 
Bergman and Kallmen (2002) reported an interclass correlation of .93 between initial 
screening and three to four week follow-up. Moreover, Dybek and colleagues (2006) 
screened 99 German general practice patients and found an interclass correlation of .95 
between the initial in-person screening and a one month follow-up by telephone. The 
AUDIT has therefore repeatedly been shown to have good test-retest reliability.  
Regarding the construct validity of the AUDIT, the stability of a two factor 
structure has been demonstrated across numerous studies. These studies support a 
‘consumption’ factor (items one to three) and an ‘adverse consequences of drinking’ 
factor (items four to ten). Bergman and Kallmen (2002) found a Cronbach’s alpha 
reliability coefficient of .69 and a test–retest reliability of .98 for the consumption factor 
items. Shields, Guttmannova and Caruso (2004) found Cronbach’s alphas of .74 and .81 
for the scores on the same consumption factor in a clinical and a college student sample.  
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Measures of the criterion validity of the AUDIT have varied across studies. 
Studies examining the concurrent and  the predictive validity of the AUDIT using the 
DSM-IV criteria for alcohol abuse or dependence reported  that the sensitivity of the 
AUDIT ranged from .67 to 1.00 and the specificity from .65 to .97 (Cherpitel, 1997; 
Cherpitel, 1998; Cherpitel, 2001; Clements, 1998; Cook, Chung, Kelly & Clark, 2005; 
Dawe, Seinen & Kavanagh, 2000; Hearne, Connolly & Sheehan, 2002; Kelly, Donovan, 
Chung, Cook & Delbridge, 2004; Maisto, Carey, Carey, Bordon & Gleason, 2000; 
McCann, Simpson, Ries & Roy-Byrne, 2000). These same studies reported positive 
predictive values (PPVs) and negative predictive values (NPVs) ranging from .32 to .87 
and .88 to .98 respectively.   
The AUDIT is scored as follows. The first response for each question (e.g. 
‘never’) is scored zero. The second response option (e.g. ‘less than monthly’) is scored 
one, the third (e.g. ‘monthly’) is scored two, the fourth (e.g. ‘weekly’) is scored three and 
the last response (e.g. ‘daily or almost daily’) is scored four. Questions nine (aud9t) and 
10 (aud10t) have three response options and these are scored zero, two, and four 
respectively. Scores are then summed to obtain a total score ranging from 0-40 (audit). A 
total score of eight or more denotes hazardous alcohol use. The variable audit8 delineates 
those who screened positive for hazardous alcohol use from those who screened negative 
for hazardous alcohol use.  
2.7.7 Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). 
The Alcohol and Substance Involvement Screening Test (ASSIST) was developed for the 
World Health Organization by an international collaborative of substance abuse 
researchers to screen primary care patients for psychoactive substance use and related 
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problems (WHO ASSIST Working Group, 2002). The ASSIST is a self-report measure 
consisting of eight questions, the first of which asks the respondent about any lifetime use 
of tobacco, alcohol, cannabis, cocaine, stimulants, inhalants, sedatives/hypnotics, 
hallucinogens, opioids and ‘other drugs’. If the respondent answers no, the screen is 
complete. If the respondent answers yes however, the next seven items are administered. 
These items probe areas such as health, social, financial or legal problems, inability to 
manage routine responsibilities, expression of concern by friends or family, prior 
attempts to control use associated with each drug that was positively endorsed in the first 
question. The final question asks about intravenous drug use. Questions are rated on a 
five-point Likert scale. The ASSIST takes less than five minutes to administer and is 
designed to ascertain both lifetime and current substance use (WHO ASSIST Working 
Group, 2002).  
In their study examining the feasibility and reliability of the ASSIST with a group 
of 236 participants, the WHO ASSIST Working Group (2002) found test-retest reliability 
coefficients ranging from .58 to .90 with retest interviews occurring one to three days 
after the initial screening. In general, reliabilities showed substantial agreement. The 
same study evaluated the internal consistency reliability of the ASSIST and found that 
the correlations were high for most items across all substance classes with Cronbach’s 
alphas ranging from .73 to .92 (WHO ASSIST Working Group, 2002).   
The concurrent, construct and discriminative validity of the ASSIST was 
examined in a multi-site international study consisting of 1047 participants (Humeniuk et 
al., 2008). This study utilized a stratified sampling procedure to ensure balanced 
recruitment in regards to sex and age groups (18-25) (26-35) and (36-45) years 
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(Humeniuk et al., 2008). Concurrent validity of the ASSIST was assessed by comparison 
of scores with the Addiction Severity Index-Lite (ASI-Lite), the MINI-plus, the Severity 
of Dependence Scale (SDS), the Revised Fagerstrom Tolerance Questionnaire (RTQ) and 
the AUDIT. The authors found significant positive correlations between the ASSIST and 
the ASI-Lite (r = .76- .88; p < .001), the MINI-Plus (r = .76, p < .001), the SDS (r = .59, 
p = .001), the RTQ (r = .78, p < .001) and the AUDIT (r = .82, p < .001) (Humeniuk et 
al., 2008) demonstrating the concurrent validity of this instrument. 
The ASSIST also showed good internal consistency with Cronbach’s alpha 
calculations displaying good inter-item correlations for the total substance involvement 
score (.89) as well as for the specific substance involvement scores (.86 for cannabis) 
(Humeniuk et al., 2008). Cannabis abuse and dependence thresholds were taken from the 
Technical Report of Phase II Findings of the WHO ASSIST Project (Humeniuk & Ali, 
2006). The authors investigated the discriminative validity of the ASSIST by comparing 
ASSIST scores grouped by known standards of dependence, abuse and non-problematic 
use. The dependent group consisted of individuals who were recruited from drug and 
alcohol treatment centres and met independent clinical evaluation criteria for current 
dependence of specific substances. The subjects recruited from primary health care 
settings were classified as abusers or non-problematic users according to the presence of 
a diagnosis for current abuse on the MINI Plus. ASSIST Scores for Global continuum of 
substance use risk, and Specific Substance ASSIST scores for alcohol, cannabis, cocaine, 
amphetamines, sedatives and opioids were compared for all three groups using ANOVA 
and ROC curves. Results showed that the optimal ASSIST cut-off score for cannabis (the 
specific substance of interest in the current study) use and abuse was 0.96 with 91% 
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sensitivity, 90% specificity and an ANOVA Scheffe’s differences between groups of 8.1, 
p < .001 (Humeniuk & Ali, 2006). An ASSIST cut-off score of 10.5 differentiated 
cannabis abuse from cannabis dependence with an AUC of .62, 57% sensitivity, 61% 
specificity and an ANOVA Scheffe’s differences between groups of 2.2, p < .001 
(Humeniuk & Ali, 2006). Hence the ASSIST can better discriminate use from abuse than 
abuse from dependence (Humeniuk & Ali, 2006).  
The ASSIST was added to the CAMH Monitor in 2004 and was only employed 
for the assessment of cannabis use. The first item asks about lifetime use of cannabis 
(cn1). If the participant answers yes to lifetime cannabis use, subsequent items probe 
areas such as compulsion to use, problems and failure to function as expected and others 
expressing concern about use and attempts to control use are administered. The last 
question pertaining to intravenous drug use was excluded from the CAMH Monitor 
because of its irrelevance to cannabis use. Therefore, the version of the ASSIST used in 
this study consisted of seven rather than eight questions. 
Scoring the ASSIST for specific substance involvement consists of summing 
participants’ responses to questions two through six. Each question is rated along a five-
point Likert scale. The scores associated with each response option vary depending on the 
question. Question two has response options: 0 ‘never’, 2 ‘once or twice’, 3 ‘monthly’,  4 
‘weekly’, and  6 ‘daily or almost daily’. Question three has the same response options but 
the numbers associated with each option range instead from 0 to 3, 4, 5 and 6. Similarly 
for question 4, yet the numbers are 0, 4, 5, 6 and 7 and likewise for question 5 however 
numeric scores are 0, 5, 6, 7 and 8. Question 5 and 6 differ in that the response options 
are 0 ‘no, never’, 6 ‘yes, in the past 3 months’ and 3 ‘yes, but not in the past 3 months’. 
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Questions two though seven of the ASSIST originally corresponded to Monitor 
items ascan1, ascan2, ascan3, ascan4, ascan5 and ascan6 with response options 0-4 (0 
‘never’, 1 ‘once or twice’, 2 ‘monthly’, 3 ‘weekly’, 4 ‘daily’). These items were recoded 
according to the ASSIST scoring guidelines mentioned above and made into new 
variables ascan1 to ascan6. Items ascan1 through ascan6 were then summed to obtain a 
cannabis involvement summary score ranging from 0 to 39. A cut-off score of 1.5 for 
abuse was used to create the cannabis abuse variable.   
2.7.8 Standard questions for alcohol, cannabis and cocaine use. Standard 
quantity and frequency questions pertaining to alcohol, cannabis, and cocaine 
consumption identical to those used in previous studies by the Addiction Research 
Foundation and the Centre for Addiction and Mental Health were included in the 
Monitor.  
2.7.9 Socio-demographic information. Socio-demographic information relating 
to age, sex, level of education, employment status, marital status, annual household 
income, and household location were also collected. Age was originally recorded as a 
continuous variable and was later divided into four categories according to the 2006 
census: 18-24, 25-44, 45-64, and 65+ (agecen4).  Male or female sex was recorded (sex). 
Level of education was coded as less than high school, completed high school, some 
post-secondary education, and university degree (educat4). Employment status was 
divided into employed, unemployed, and other (empcat8). Marital status was coded into 
three categories: married/living with a partner; previously married (divorced, widowed or 
separated); and never married (marstat3) because this was a common method used in the 
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literature. Annual household income was divided into 5 categories (hinccat5). Household 
location was divided into two categories: rural or urban (rur_urb). 
2.8 Secondary Data source 
 
A secondary data source was used for this study. Secondary data are defined as 
data that have not been collected for the purpose of this study (Sorenson, Sebroe & 
Olsen, 1996). Secondary data sources have numerous advantages as they cost less, save 
time, and are usually more representative of the population as they often consist of large 
samples. In addition, they have a reduced chance of bias due to the effect of the 
diagnostic process or attention caused by the research question (Sorenson et al., 1996).  
One of the major disadvantages of secondary data sources is that the researchers do not 
control data collection, choice of questions and data quality.  
2.9 Data Analysis 
All analyses were conducted using Statistical Package for Social Sciences (SPSS) 20. 
Variables of interest were selected from the information collected during the interviews 
for the 2011 cycle of the CAMH Monitor. All analyses were conducted using appropriate 
sampling weights to ensure estimates are representative of the Ontario general 
population. All significance (alpha) levels were set at .05. 
Use of the Bonferroni correction is still under debate (e.g. Bender & Lange, 1999; 
García, 2004; Morgan, 2007; Pernerger, 1998); therefore, multiple comparisons were not 
accounted for in the interpretation of results. However, exact p-values are reported so that 
readers may adjust for multiple comparisons using the Bonferroni correction of p = .001 
for 69 comparisons conducted in this study.   
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2.9.1 Data cleaning and transformation. Prior to all analyses, data were 
subjected to data cleaning to locate out-of-range values, univariate outliers and missing 
data. The distributions of each variable of interest were examined for normality, 
skewness and kurtosis. Data were also inspected for multivariate outliers. Lastly, 
variables were also evaluated for multicollinearity and singularity. Diagnostic 
information for all variables of interest is presented in Appendix F. 
2.9.2 Weighting. Since equal numbers of participants were selected from each of 
the six regions in Ontario, weights are required to restore population representation. The 
final annualized weight (FWGHT) used in the current study is a function of the selection 
weight and a post stratification adjustment. 
The quarterly aggregated sampling weight variable (RHHWGTC1‐4) consisted 
of four components: the relative household weight (HHWGTC1‐4), which is equal to the 
proportion of household residents age 18 and older; the relative region weight 
(RWGTC1‐4), which is directly proportional to the percentage of all Ontario households 
located in the region; survey quarter (the quarterly sampling interval) and post-strata 
adjustments. Cycles are weighted so that each quarterly wave makes an equal 
contribution to the weighted N. Quarterly relative household and relative region variables 
were summed into cumulative relative household (HHWGTALL) and relative region 
(RWGTALL) variables. Finally these variables were aggregated into the cumulative 
region-household variable (RHHWGTALL).  
In order to reduce bias and adjust for non-response and non-coverage of 
households without telephones, probability surveys usually apply post-strata population 
adjustments to the base weight according to census information (Casady & Lepkowski, 
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1999). The post stratification adjustment was based on eight post-strata representing four 
age groups (18-24; 25-44; 45-64; 65+) by sex (male; female) configuration from the 2006 
Census (Ialomiteanu & Adlaf, 2011). These adjustments were applied in calculating the 
final annualized weight (FWGHT) (Ialomiteanu & Adlaf, 2011). Therefore, the 
cumulative regional and household weight (RHHWGTALL) and the post-strata 
population adjustment weight (postwtsa) comprise the final annualized weight 
(FWGHT) variable used in this study. The final annualized weight (FWGHT) was 
applied to all analyses in the current study.  
2.10 Descriptive and Bivariate Analyses 
2.10.1 Demographic information. Preliminary analyses consisted of calculating 
the frequencies and 95% confidence intervals (C.I.s) of all demographic variables for the 
entire panel B sample. Demographic variables included in these analyses were: age, sex, 
marital status, education, employment, average annual household income and household 
location. 
2.10.2 Internal consistency of measures. Next, the internal consistency of all 
measures used in the study was assessed. The Cronbach’s alpha coefficients and inter-
item correlations for the ASRS-v1.1 Screener, the GHQ-12, the AUDIT, the cannabis-
specific version of the ASSIST and the MINI-APD were calculated.  
2.10.3 Mental health in Ontario. The prevalence of psychiatric distress was 
estimated by calculating the frequency, proportion and 95% C.I.s of those who scored 4 
or more on the GHQ-12. Also, the prevalence of past 12 month anti-anxiety and 
antidepressant medication use in Ontario was determined by calculating the frequencies, 
proportions and 95% C.I.s for these two variables. The prevalence of ASPD screening 
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status in Ontario was established by calculating the frequency, proportion and 95% C.I. 
of the ASPD screening status based on a cut-off score of 3 on the MINI-APD. 
2.10.4 Substance use in Ontario. Hazardous drinking was defined by a score of 
8 or more on the AUDIT. The frequency, proportion and 95% C.I. was calculated. The 
frequencies and 95% C.I.s for lifetime, past 12 month and past 3 month cannabis, 
marijuana or hash use were calculated along with the frequency, proportion and 95% of 
cannabis abuse.. The frequency, proportion and 95% C.I. of lifetime cocaine use were 
also calculated.  
2.10.5 Adult ADHD screening status prevalence. The prevalence of a positive 
screen for adult ADHD in Ontario was estimated by calculating the frequency, proportion 
and 95% C.I. of the sample that scored 14 and above on the ASRS-v1.1 Screener 
(recommended by Kessler et. al., 2007).  
2.10.6 ADHD screening status and demographic variables. Frequencies, 
proportions, odds ratios (ORs) for ADHD screening status and all demographic variables 
(age, sex, marital status, education, employment, average annual household income and 
household location) were calculated along with their 95% C.I.s. Chi-square tests of 
independence were also performed when possible to determine whether significant 
differences in sex, age, marital status, education, employment, annual household income 
or household location existed between those who screened positive and those who 
screened negative for ADHD.       
2.10.7 Previous ADHD diagnosis and ADHD medication use. Frequencies, 
proportions, chi-square tests, ORs and 95% C.I.s were calculated for ADHD screening 
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status and previous ADHD diagnosis, as well as previous ADHD medication use, and 
ADHD medication use prior to 18 years of age. 
2.10.8 Adult ADHD screening status and mental health. Frequencies, 
proportions and ORs along with 95% C.I.s were calculated for past 12 month anti-anxiety 
medication use, and past 12 month antidepressant use. Chi-square tests of independence 
were also performed to examine if any significant differences in psychotropic medication 
use existed between those who screened positive and those who screened negative for 
ADHD. 
ORs and 95% C.I.s were calculated for psychiatric distress and a chi-square test 
of independence was executed to determine if any significant differences in psychiatric 
distress existed between those who screened positive for ADHD and those who screened 
negative for ADHD.  
The ORs and 95% C.I.s of the proportion of those who scored three or more on the 
ASPD module of the MINI were calculated and a chi-square test of independence was 
performed to investigate whether a significant difference existed in ASPD screening 
status rates between the ADHD and non-ADHD screened groups. The OR was also 
calculated along with its 95% C.I. 
2. 10.9 ADHD screening status and substance use. The frequency, proportion , 
OR and 95% C.I. for hazardous alcohol use in both the ADHD positive and the ADHD 
negative screening groups were calculated and a chi-square test of independence was 
carried out to test for any differences in hazardous alcohol use between the two groups.  
Frequencies and proportions of those who screened positive for ADHD and those 
who screened negative for ADHD along with the ORs and 95% C.I.s for lifetime, past 12 
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month, and past 3 month cannabis use as well as cannabis abuse were calculated. Chi-
square tests were performed to test for significant differences between the ADHD 
positive and ADHD negative screening groups. The frequencies, proportions, ORs and 
95% C.I.s for lifetime cocaine use were also calculated and chi-square tests were 
performed to test for significant differences between those in the ADHD positive and 
ADHD negative screener groups. 
Only crude ORs could be calculated because our sample did not meet the 
guidelines for multinomial logistic regression that indicate a minimum of 10 cases per 
independent variable (Schwab, 2002). Thus the sample size was too small for the conduct 
of adjusted ORs. All the aforementioned analyses were also conducted stratified by sex. 
Moreover, differences between males and females who screened positive for ADHD, 
between males who screened positive and males who screened negative for ADHD, 
between females who screened positive and females who screened negative for ADHD as 
well as males and females who screened negative for ADHD were also examined.     
2.11 Multivariate Analyses 
Research evidence demonstrates that ADHD is a possible risk factor for 
psychiatric distress. As indicated in the literature review, a notably large percentage of 
individuals with ADHD also have at least one additional mental disorder, most 
commonly, depression or anxiety and this association has been observed across a 
numerous studies involving different populations.  
In the current study ADHD was assumed to precede psychiatric distress (anxiety 
and depression). The theory that guided the multivariate model is that proposed by 
Biederman & Faraone (2005). These authors state that ADHD may lay the foundation in 
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childhood for subsequent adversity- both developmental and environmental, such as 
deficits in attention and cognition, learning disabilities, academic failure, deficits in 
emotion, fear and aggression regulation, as well as difficulties in parental attachment, 
interpersonal relationships, peer rejection and increases in impulsivity and risk-taking 
behaviours, all factors which may lead to the development of further psychiatric 
impairments in adolescence and adulthood (Biederman & Faraone, 2005). According to 
the DSM-IV-TR ADHD is a disorder of early developmental origin, while depression and 
anxiety have a later onset (APA, 2000). The onset of depression typically occurs during 
adolescence (Hankin, 2005) and increases in prevalence with age (Kessler, 2002). 
Ostrander and Herman (2006) found that parent management and locus of control 
mediated the relationship between ADHD and subsequent depression in children and 
adolescents, thus also modelling ADHD as a precursor to later depression. Also, 
depression and anxiety in ADHD may result from sequential mental health issues as for 
example; anxiety in ADHD may reflect concerns about competency and performance 
(Hankin 2006; Ostrander & Herman, 2006; Schatz & Rostain, 2006).  
In the present study, we used hierarchical binary logistic regression to examine 
ADHD screening status as a predictor variable for psychiatric distress while controlling 
for age, sex, antisocial behaviour screening status and substance use. Table 1.1 displays 
all variables of interest in the present study. 
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Table 1.1 
 Study Variables 
Variable and Type    Measurement 
Exposure Variable 
ADHD Screening Status   Scores of 13 or more on the ASRS-v1.1 
Dichotomous    1 = Yes 
     0 = No 
Outcome Variable 
Psychiatric Distress Scores of 4 or more on the GHQ-12 using the 
Dichotomous    binary scoring method 
1 = Yes 
0 = No 
Demographic Variables 
Age     1 = 18-24 years old 
Categorical     2 = 25-44 years old 
3 = 45-64 years old 
4 = 65 + years old 
 
Sex     1 = Male 
Nominal     0 = Female 
 
Marital Status    1 = Married/Living with a partner 
Nominal     2 = Widowed, divorced, separated 
3 = Never married 
 
 
 
Education     1 = Less than high school 
Ordinal    2 = Completed high school 
3 = Some post-secondary education 
4 = University degree 
 
Employment Status   1 = Employed 
Nominal     2 = Unemployed 
3 = Other   
Annual Household Income  1 = Less than 30,000 
55 
 
 
Ordinal    2 = 30, 000 - 49,000 
3 = 50, 000 -79, 000 
4 = 80,000 + 
 
Household Location   1 = Urban 
Dichotomous    0 = Rural 
     
Past 12 Month Anti-anxiety  1 = Yes 
Medication Use    0 = No 
Dichotomous     
Past 12 Month Antidepressant Use  1 = Yes 
Continuous    0 = No 
Antisocial Personality Disorder  
screening status   Scores of 6 or more on the MINI-APD 
Dichotomous    1 = Yes 
0 = No 
Substance Use Variables 
Hazardous Alcohol Use Scores of 8 or more on the AUDIT 
Dichotomous 1 = Yes 
0 = No 
Lifetime Cannabis, Marijuana  
or Hash Use    1 = Yes 
Dichotomous    0 = No 
 
Past 12 Month Cannabis, Marijuana  
or Hash Use    1 = Yes 
Dichotomous     0 = No 
    
Past 3 Month Cannabis, Marijuana  
or Hash Use    1 = Yes 
Dichotomous    0 = No 
 
Cannabis Abuse   Scores of 1.5 or more on the ASSIST 
Dichotomous    1 = Yes 
0 = No 
Lifetime Cocaine Use   1 = Yes 
Dichotomous    0 = No 
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Chapter 3: Results 
 
3.1 Description of the Study Sample 
 
A sample of 3039 Ontarians met eligibility criteria for this study (Panel A = 1040 
and Panel B = 1999). However, only Panel B of the CAMH Monitor was selected for 
analyses as it comprised the items of interest in the current study. Therefore, all analyses 
were conducted on a weighted sample of 1999 individuals from the general population of 
Ontario. Only weighted results are reported herein. 
The mean age of participants was 47 years old (SD = 17). When age was divided 
into four categories, the largest group based on numeric size was those between the ages 
of 25 to 44 years old while those 18 to 24 years old comprised the smallest age group. 
Slightly more than half (53%) of the sample was female. The majority of the sample 
(68%) were married or living with a partner. Over two thirds of the sample reported 
having some post-secondary education (35%) or a university degree (35%). The large 
majority of respondents (85%) lived in an urban area. Descriptive statistics for the full 
sample (Panel B) are presented below in Table 3.1.   
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Table 3.1  
Descriptive Statistics for Demographic Variables (Panel B) 
Variable                    Freq.       Proportion (%)    [95% C.I] 
Age (4 categories) 
18-24              210     10.56    [9.27, 12.03] 
25-44                         747              37.58 [35.48, 39.79] 
45-64                          646              32.53 [30.48, 34.65] 
65 +                        324              16.29  [14.73, 18.03] 
Sex 
Male              942     47.55   [45.22, 49.65] 
Female                     1044              52.56  [50.35, 54.78] 
Marital Status 
Married/ Living with a partner        1353              68.12   [66.02, 70.17] 
Previously married                       210              10.57     [9.27, 12.03] 
Never married            404              20.36  [18.60, 22.19] 
Education 
< High school             193               9.71    [8.47, 11.13] 
Completed high school            398             20.02  [18.31, 21.88] 
Some post-secondary                        688             34.61   [32.55, 36.79] 
University degree             693             34.86   [32.80, 37.04] 
Employment  
Employed             1281             64.80   [62.64, 66.90] 
Unemployed                              85                4.30        [3.47, 5.31]              
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Other               611               30.91   [28.89, 33.01] 
Annual Household Income  
< 30,000           169       8.51                [7.34, 9.85] 
30,000-49,000           223               11.23              [989, 12.72] 
50,000-79,000                      368               18.53           [16.86, 20.33] 
80,000 +                       764              38.47            [36.33, 40.66] 
Don’t know/Refused           462              23.26            [21.43, 25.19] 
Household Location 
Rural                   301             15.16            [13.63, 16.83] 
Urban           1686             84.89            [83.22, 86.42] 
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3.2 Internal Consistency Reliability of Measures: Cronbach’s Alphas 
The alpha coefficients for the ASRS-v1.1 Screener, the GHQ-12, the MINI-APD, 
the AUDIT and the ASSIST are presented in Table 3.2.1 below. 
Table 3.2.1  
Cronbach’s Alphas and Inter-Item Correlations of the ASRS-v1.1 Screener, the GHQ-12, 
the MINI APD, the AUDIT and the ASSIST                
Measure  Alpha     Mean      Min.    Max.     Range    Variance   N of Items 
ASRS-v1.1 Screener   .75     0.35       0.23     0.59        0.36         0.01              6 
GHQ-12      .82         0.27       0.04     0.57        0.53         0.02             12     
 
MINI-APD                .73         0.03       0.00     0.12        0.12         0.00             11 
AUDIT     .78         0.35       0.14     0.67        0.53         0.02             10 
ASSIST                         .72         0.27       0.09    0.54         0.45         0.02              7 
3.3 Descriptive Statistics and Population Proportions for Mental Health and 
Substance Use Variables (Full Panel B Sample)   
3.3.1 Psychiatric Distress. Using the GHQ-12 with a cut-off value of 4, the 
prevalence of psychiatric distress in the Ontario population was 9.93% [8.66, 11.34]. The 
overall mean GHQ-12 score was 1.05 (SD = 2.05).  
3.3.2 Past 12 month anti-anxiety medication use and past 12 month 
antidepressant use. The prevalence of past 12 month anti-anxiety medication use in the 
Ontario population was 7.06% [5.99, 8.30] and similarly, the prevalence of past 12 month 
antidepressant use in the Ontario population was 7.07% [6.00, 8.31]. 
3.3.3 Antisocial personality disorder screening status in Ontario. Using a cut-
off score of five or more, approximately 0.71% [0.40, 1.21] of the Ontario population 
screened positive for antisocial personality disorder on the MINI-APD.   
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3.3.4 Hazardous alcohol use in Ontario. The prevalence of hazardous alcohol 
use in Ontario, as defined by a score of eight or more on the AUDIT, was approximately 
13.06% [11.61, 14.66].  
3.3.5 Cannabis, marijuana and hash use and abuse in Ontario. As shown in 
Table 3.3.6 below, approximately 41% of the population had used cannabis, marijuana or 
hash at least once in their lifetime. In addition, roughly 14% had used cannabis, 
marijuana or hash over the past 12 months, and nearly 10% reported using cannabis, 
marijuana or hash over the past three months. In their validation study of the ASSIST, the 
WHO suggested that scores of 1.5 or more best delineated cannabis use versus cannabis 
abuse (Humeniuk & Ali, 2006). Using this cut-off value, approximately 9% of the 
Ontario population screened positive for cannabis abuse. 
Table 3.3.5  
 
 Cannabis Use in Ontario 
Time Period       Freq.    Proportion (%)  [95% C.I.] 
Lifetime        799             40.21             [38.31, 42.69] 
Past 12 months                  272                    13.81             [12.33, 15.43] 
Past three months       188                     9.47     [8.24, 10.86] 
Cannabis Abuse                
Yes         181                     9.15                     [7.93, 10.93] 
No        1797             90.85                           [89.47, 92.07] 
3.3.6 Lifetime cocaine use in Ontario.  Approximately 7.03% [5.96, 8.27] of the 
Ontario population have used cocaine at least once in their lifetime.  
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3.4 Description of the Study Population According to ADHD Screener Status 
3.4.1 Prevalence of adult ADHD screener status. As previously mentioned, the 
ASRS v1.1 Screener is comprised of six questions reflecting the impairments common in 
adult ADHD. Response options are rated on a five-point Likert scale as follows: 0 
‘never’, 1 ‘rarely’, 2 ‘sometimes’,  3 ‘often’, and 4 ‘very often’. Summary scores have a 
possible range from 0-24. Kessler et al. (2007), the developers of the measure, proposed 
an optimal case finding threshold of 13/14, meaning that scores less than or equal to 13 
are considered ADHD negative and scores of 14 or more are considered ADHD positive. 
Using this cut point, 3.47% [2.73, 4.40] of Ontario adults screened positive for ADHD on 
the ASRS v1.1Screener.  
3.4.2 The association of age and ADHD screener status. The average age of 
those who screened positive for adult ADHD was 35.59 years (SD = 14.64) and 46.84 
years (SD = 17.03) for those who screened negative for ADHD. Positive ADHD Screener 
status was highest among those 18-24 years of age and lowest among those in the 65+ 
category. The relationship between ADHD Screener status and age was significant, χ2 (df 
= 3, N = 1926) = 11.48, p = .009.  
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Table 3.4.2  
Frequencies and Proportions for Age According to ADHD Screener Status  
               
ADHD Positive (N = 69)    ADHD Negative (N =1857) 
       Freq.   Proportion (%)   [95% C.I.]            Freq.   Proportion (%)   [95% C.I.] 
Age     
18-24          13            18.84         [10.79, 30.42]          197           10.61          [9.26, 12.12] 
25-44           31            44.92         [33.10, 57.32]          716           38.56        [36.35, 40.82] 
45-64           22            31.88         [21.47, 44.33]    624         33.60        [31.46, 35.81] 
65 +          3               4.35           [1.13, 13.01]           320         17.23        [15.55, 19.04]          
    
3.4.3 Sex and ADHD screener status. As shown in Table 3.4.3, the proportion of 
men and women in both the ADHD positive and ADHD negative groups were 
approximately equal. No significant relationship between sex and ADHD Screener status 
was found, χ2 (df =1, N = 1988) = 0.29, p = .591. 
Table 3.4.3  
 Frequencies and Proportions for Sex According to ADHD Screener Status  
 
              ADHD Positive (N = 70)                     ADHD Negative (N =1918) 
       Freq.   Proportion (%)   [95% C.I.] Freq.   Proportion (%)   [95% C.I.] 
   
Male          31          44.29           [32.60, 56.61]          912      47.55        [45.30, 48.81] 
Female        39          55.71           [43.39, 67.40]        1006      52.45        [50.19, 54.70] 
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3.4.4 Marital status and ADHD screener status. The relationship between 
marital status and ADHD Screener status was significant, χ2 (df = 2, N = 1967) = 12.34, p 
= .002. Based on examination of the standardized residuals, individuals with ADHD 
positive screen were more likely to have never been married (see Table 3.4.4 below).    
Table 3.4.4  
 
 Frequencies and Proportions for Marital Status and ADHD Screener Status  
                  ADHD Positive (N = 69)                       ADHD Negative (N =1898) 
                Freq.  Proportion (%)  [95% C.I.]         Freq.  Proportion (%)  [95% C.I.] 
 
Marital Status 
 
Married/       35       50.72         [38.51, 62.85]        1318         69.44       [67.33, 71.47] 
Partner 
 
Widowed/        
Separated/      9       13.04           [6.50, 23.82]          201         10.59         [9.26, 12.08] 
Divorced 
 
Never                 25       36.23         [25.25, 48.75]          379         19.97       [18.21, 21.86] 
Married  
 
 
3.4.5 Education and ADHD screener status. The majority of individuals in both 
ADHD screening status groups reported having some post-secondary education or a 
university degree (see Table 3.4.5). Also, roughly 10% of both groups had not completed 
high school. No relationship between education and ADHD screener status was found, χ2 
(3, N = 1971) = 2.91, p = .406.  
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Table 3.4.5  
 
 Frequencies and Proportions for Education According to ADHD Screener Status  
                  ADHD Positive (N = 67)                  ADHD Negative (N = 1904) 
      Freq.   Proportion (%)   [95% C.I.]      Freq.   Proportion (%)   [95% C.I.]  
Education 
 
< High school       9          13.43         [6.70, 24.47]       184           9.66           [8.39, 11.10]              
 
Completed  
high school         13         19.40       [11.12, 31.24]       385           20.22        [18.45, 22.11]            
 
Some  
post-secondary   27         40.30       [28.72, 53.00]       660           34.66        [32.53, 36.85] 
University       
degree         18         26.87       [17.11, 39.31]       675           35.45        [33.31, 37.65] 
 
3.4.6 Employment and ADHD screener status. Table 3.4.6 shows the 
proportions for each category of employment according to ADHD Screener status. No 
significant difference in employment status between those who screened positive for 
ADHD and those who screened negative for ADHD was found, χ2 (2, N = 1977) = 2.55, p 
= .279. 
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Table 3.4.6  
 Frequencies and Proportions for Employment Status According to ADHD Screener 
Status  
                   ADHD Positive (N = 68)                 ADHD Negative (N =1908) 
      Freq.   Proportion (%)   [95% C.I.]     Freq.   Proportion (%)   [95% C.I.] 
    
Employment 
Status 
 
Employed          48         68.57        [56.23, 78.85]      1233         64.66          [62.46, 66.80]  
Unemployed        5          7.14          [2.66, 16.56]           80           4.20              [3.36, 5.22]             
Other                  17     24.29        [15.17, 36.27]        594       31.15          [29.09, 33.29] 
Total     70  100.00        -   1907       100.00                     -  
 
3.4.7 Annual Household Income and ADHD screener status. As Table 3.4.7 
indicates, similar proportions of individuals in both the ADHD positive (35%) and 
ADHD negative (39%) screen groups had an average household income of more than 
80,000 dollars a year. No significant difference in average annual household income was 
found between the two groups, χ2 (df = 4, N = 1986) = 4.67, p = .323. 
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Table 3.4.7  
 Frequencies and Proportions for Annual Household Income According to ADHD 
Screener Status  
      ADHD Positive (N = 69)        ADHD Negative (N =1917) 
             Freq.   Proportion (%)   [95% C.I.]      Freq.   Proportion (%)   [95% C.I.] 
Annual Household  
Income Range 
< 30,000     9         13.04            [6.50, 23.82]      160          8.35             [7.17, 9.70]  
30,000-49,000     9         13.04            [6.50, 23.82]      214        11.16           [9.80, 12.68]       
50,000-79,000    16        23.19          [14.22, 35.18]    352        18.36         [16.67, 20.18] 
80,000 +      24       34.78          [23.98, 47.28]    740      38.60         [36.42, 40.83] 
Don’t know/     11       15.94            [8.60, 27.16]       451        23.53        [21.66, 25.51]  
Refused                
    
3.4.8 Household location and ADHD screener status. The majority of both the 
ADHD positive (87%) and ADHD negative (85%) groups lived in an urban area. No 
significant relationship between household location and ADHD Screener status was 
found, χ2 (1, N = 1986) = 0.237, p = .626. Household location according to ADHD 
Screener status is presented in Table 3.4.8 below. 
Table 3.4.8  
 Frequencies and Proportions for Household Location According to ADHD Status     
         ADHD Positive (N = 69)           ADHD Negative (N =1917) 
Freq.   Proportion (%)   [95% C.I.]    Freq.   Proportion (%)   [95% C.I.] 
Location 
Urban    60          86.96        [76.18, 93.50]       1626        84.82        [83.12, 86.38]            
 
Rural       9          13.04          [6.50, 23.82]         291         15.18        [13.62, 16.88] 
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3.5 Descriptive Statistics and Population Proportions for Mental Health and 
Substance Use Variables by ADHD Screener Status 
3.5.1 Previous ADHD diagnosis by ADHD screener status. Among those who 
screened positive for ADHD on the ASRS v1.1 Screener, 10.14% [4.52, 20.37] had 
previously been diagnosed with ADHD by a healthcare professional. In addition, 2.40% 
[1.78, 3.22] of those who screened negative for ADHD had previously been diagnosed 
with ADHD by a healthcare professional. 
A separate cross-tabulation was conducted to disaggregate previous ADHD 
diagnosis according to age. Results showed that the vast majority of those previously 
diagnosed with ADHD were under the age of 44 with 49.02% [34.95, 63.23] belonging to 
the 25 to 44 year old age group, followed by 37.25% [24.47, 51.94] in the 18 to 24 year 
old age group, and 11.76% [4.87, 24.55] in the 45 to 64 year old age group. Only 1.96% 
[0.10, 11.79] of those who had previously been diagnosed with ADHD belonged to the 
65 and over age group. Furthermore, previous ADHD diagnoses were most prevalent 
among those aged 18-24 years of age (9.05%) [5.68, 13.98], followed by those aged 25 to 
44 years old (3.36%) [2.23, 4.99], those 45 to 64 years old (0.93) [0.38, 2.12], and those 
aged 65 and over (0.31) [0.02, 1.99].   
3.5.2 Previous ADHD medication use and ADHD screener status. Of those 
previously diagnosed with ADHD, 83.33% [36.48, 99.12] were treated with prescription 
medication for the disorder. In addition, of those previously diagnosed and treated with 
prescription medication for ADHD, 66.67% [24.11, 94.00] had been treated with ADHD 
medication before the age of 18. Furthermore, none of these individuals had been treated 
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with ADHD medication in the past 12 months nor was anyone in the sample currently 
taking/prescribed ADHD medication. 
3.5.3 Anti-anxiety and antidepressant medication use and ADHD screener 
status. As shown in Table 3.5.4, about 40% of the ADHD positive group and 
approximately 6% of the ADHD negative group had taken prescription medication to 
reduce anxiety and panic attacks in the past 12 months. Of those who had taken anti-
anxiety medication in the past year, 20.00% [13.91, 27.78] had an ADHD positive screen. 
There was a significant association between anti-anxiety medication use over the past 12 
months and ADHD screening status, χ2 (1, N = 1984) = 120.07, p = .000. Individuals who 
screened positive had higher odds of past 12 month anti-anxiety medication use than 
those who screened negative for ADHD (OR = 10.73; 95% CI = 6.41, 17.95).  
Antidepressant medication use in the last year according to ADHD screener status 
is also presented in Table 3.5.4. Approximately 36% of those who screened positive for 
ADHD reported taking prescription medication to treat depression in the past 12 months, 
whereas about 6% of those who screened negative for ADHD reported taking such 
medication in the past 12 months. Of those who had taken antidepressants in the last year, 
17.86% [12.10, 25.43] screened positive for ADHD. Antidepressant medication use in the 
past 12 months differed significantly by ADHD status, χ2 (1, N = 1980) = 92.52, p = .000, 
with the ADHD positive group having higher odds of antidepressant medication in the 
past year (OR = 8.87; 95% CI = 5.25, 15.01).  
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Table 3.5.3  
Psychotropic Medication Use by ADHD Screener Status 
                  ADHD Positive                              ADHD Negative    
                     Freq.    (%)     [95% C.I.]         Freq.     (%)    [95% C.I.]    χ2    df     p-value 
Anti-anxiety             
Yes                  28     40.00   [28.69, 52.41]      112      5.85       [4.86, 7.02]             
 
No             42     60.00   [47.59, 71.31]    1802     94.15   [92.98, 95.14] 
 
Total             70   100.00         -             1914   100.00             -   
                           
                             120.07   1   < .000 
Antidepressants       
Yes  25     36.23    [25.25, 48.75]       115     6.00        [5.02, 7.21] 
No                   44     63.77    [51.25, 74.75]     1796    93.08   [92.79, 94.98] 
Total             69   100.00         -              1911   100.00              - 
                                         92.52   1   < .000 
3.5.4 Psychiatric distress according to ADHD screener status. Psychiatric 
distress differed significantly by ADHD Screener status, (χ2 (1, N = 1986) = 90.10, p = 
.000), with those in the ADHD positive group being more likely to have psychiatric 
distress than those in the ADHD negative group (43.48% [31.77, 55.92] versus 8.71% 
[7.50, 10.08] respectively). Moreover, those in the ADHD positive group had higher odds 
of psychiatric distress (OR = 8.06; 95% CI = 4.88, 13.31) compared to the non-ADHD 
group. Those who screened positive for ADHD represented 15.23% [10.67, 21.19] of all 
those who screened positive for psychiatric distress.  
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3.5.5 Antisocial Personality Disorder screener status and ADHD screener 
status. Of those who screened positive for ADHD, 8.82% [3.64, 18.85] screened positive 
for ASPD, whereas 0.42% [0.19, 0.86] of those who screened negative for ADHD 
screened positive for ASPD. Of all those who screened positive for ASPD, 42.86% 
[18.82, 70.35] also had ADHD. ASPD screening status differed significantly by ADHD 
screening status, χ2 (1, N = 1951) = 64.98, p = .000. Those who screened positive for 
ADHD had higher odds of screening positive for ASPD (OR = 22.68; 95% CI = 7.64, 
67.35).  
3.5.6 Hazardous alcohol use and ADHD screener status. As seen in Table 
3.5.6, a significant association between ADHD screening status and hazardous alcohol 
use as measured by the AUDIT was found, χ2 (1, N = 1938) = 10.25, p = .001. The 
ADHD positive group had higher odds of hazardous alcohol use than the ADHD negative 
group (OR = 2.41; 95% CI = 1.38, 4.18). Of those in the ADHD positive group, 
approximately 26% screened positive for hazardous alcohol use on the AUDIT, whereas 
half that amount (about 13%) of the ADHD negative group screened positive for 
hazardous alcohol use on the AUDIT.  
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Table 3.5.6  
 
Hazardous Alcohol Use (AUDIT 8+) and ADHD Screener Status   
                                           ADHD Positive     ADHD Negative                                       
                     Freq.   (%)    [95% C.I.]          Freq.   (%)    [95% C.I.]       χ2    df    p-value 
     
Hazardous  
Alcohol Use                                                               
Yes      18     25.71    [16.74, 37.78]     235   12.58   [11.13, 14.19]       
No            52     74.29    [62.22, 83.66]   1633   87.42   [85.81, 88.87]   
                                                                                                                10.25    1     .001 
 
3.5.7 Cannabis, marijuana and hash use and abuse according to ADHD 
screener status. As shown in Table 3.5.7 below, roughly 73% of those who screened 
positive for ADHD and approximately 39% of those who screened negative for ADHD 
reported using cannabis, marijuana or hash in their lifetime. Lifetime cannabis, marijuana 
or hash use differed significantly by ADHD status, χ2 (1, N = 1974) = 31.58, p = .000. 
Those in the ADHD positive had higher odds of lifetime cannabis, marijuana or hash use 
compared to the ADHD negative group (OR = 4.15; 95% CI = 2.43, 7.08).  
Cannabis use over the past 12 months is also presented in Table 3.5.7. 
Approximately 26% of those in the ADHD positive group compared to 13% of the 
ADHD negative group have used cannabis, marijuana or hash in the past 12 months. Past 
12 month cannabis, marijuana or hash use differed significantly by ADHD screener 
status, χ2 (1, N = 1970) = 9.06, p = .003, with those in the ADHD positive group having 
higher odds of past 12 month cannabis, marijuana or hash use compared to the ADHD 
negative group (OR = 2.29; 95% CI = 1.32, 3.98).   
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 However, the association between cannabis, marijuana or hash use over the past 
three months and ADHD screener status was not significant, χ2 (1, N = 1985) = 3.49, p = 
.062, with about 16% of the ADHD positive group and 9% of the ADHD negative group 
reported using cannabis, marijuana or hash in the past three months. About 15% of those 
who screened positive for ADHD and roughly 9% of those who screened negative for 
ADHD screened positive for cannabis abuse. Those who screened positive for ADHD 
were no more likely than those in those who screened negative for ADHD to screen 
positive for cannabis abuse, χ2 (1, N = 1978) = 2.61, p = .106. Frequencies, proportions, 
and 95% confidence intervals for lifetime, past 12 month, and past three month cannabis, 
marijuana and hash use, and cannabis abuse stratified by ADHD screener status are 
presented in Table 3.5.7 below.  
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Table 3.5.7  
Cannabis Use and  ADHD Screener Status   
        
                                  ADHD Positive   ADHD Negative                                
 Freq.   Prop. (%)   [95% C.I.]     Freq.   Prop. (%)   [95% C.I.]       χ2   df   p-value 
     
Lifetime                                                              
Yes    51       72.86     [62.22, 83.66]      748     39.29     [37.09, 41.53]      
 
No         19       27.14     [17.52, 39.30]    1156     60.71     [58.47, 62.91]   
 
       31.58   1    .000      
 
Past 12 months     
Yes   18      26.09     [16.59, 38.28]       254     13.36     [11.88, 14.99]    
 
No   51      73.91     [61.72, 83.31]     1647     86.64     [85.01, 88.12] 
       
         9.06   1   .003 
Past 3 months 
 
Yes    11     15.94      [8.60, 27.16]        177       9.24      [8.00, 10.65] 
 
No         58     84.06     [72.84. 91.40]       173     90.76     [89.35, 92.00]         
 
        3.49   1   .062 
Cannabis  
Abuse 
Yes          10        14.71     [7.66, 25.85]     171       8.95     [7.73, 10.34] 
No          58        85.29    [74.15, 92.34]   1739     91.05   [89.66, 92.27] 
        2.61   1   .106 
 
 
3.5.8 Lifetime cocaine use according to ADHD screener status. Approximately 
twenty-three percent (23.19%) [14.22, 35.18] of those who screened positive for ADHD 
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and 6.36% [5.33, 7.57] of those who screened negative for ADHD reported using cocaine 
in their lifetime. Also, 11.59% [6.98, 18.42] of those who used cocaine in their lifetime 
screened positive for ADHD. A significant relationship between lifetime cocaine use and 
ADHD screener status was found, χ2 (3, N = 1986) = 29.40, p = .000, with the ADHD 
positive group having higher odds of lifetime cocaine use than the ADHD negative group 
(OR = 4.42; 95% CI = 2.45, 7.96).  
3.6 Summary of Key Findings   
The prevalence of positive adult ADHD screen was found to be approximately 
3.47% using the ASRS v1.1 Screener. Descriptive analyses of demographic variables 
comparing those who screened positive for ADHD on the ASRS v1.1 Screener to those 
who did not revealed that men and women are equally likely to screen positive for 
ADHD and that the rates of a positive adult ADHD screen appear to be highest among 
those 18-24 years old and lowest among those 65 and over. Those who screen positive for 
ADHD appear to be more likely to have never been married. The rates of full-time 
employment were similar between the two groups, however, a larger proportion of those 
who screened positive for ADHD reported being unemployed or endorsed ‘other’ (being 
on social assistance or having an alternative form of income) as their category of 
employment. Furthermore, no significant differences in education, annual household 
income or household location were found.   
Only about 10% of those who screened positive for ADHD reported being 
previously diagnosed with ADHD by a healthcare professional, the majority of who were 
under the age of 44. Most of those who had a previous diagnosis of ADHD reported 
being treated with prescription medication for the disorder, with treatment starting before 
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the age of 18 in a substantial proportion of cases. High rates of anti-anxiety and 
antidepressant medication use was found among those who screened positive for ADHD 
with correspondingly high rates of psychiatric distress being reported among the ADHD 
positive group as well. Significantly higher rates of ASPD positive screen were also 
reported in the ADHD positive group. Significantly elevated rates of hazardous alcohol 
use, lifetime and past 12 month cannabis use were also found among those who screened 
positive for ADHD. However, no significant differences in past three month cannabis use 
or cannabis abuse were found between the groups.   
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Chapter 4: Sex and ADHD Screener Status 
4.1 Sex, ADHD Screener Status and Previous ADHD Diagnosis  
No significant differences in previous ADHD diagnosis were found between men 
and women who screened positive for ADHD. Women who screened positive for ADHD 
however, were more likely to have a previous diagnosis of ADHD than women who 
screened negative for ADHD, χ2 (1, N = 1041) = 24.25, p = .000. Among those who 
screened negative for ADHD, men were more likely to have previously been diagnosed 
than women, χ2 (1, N = 1909) = 17.87, p = .000. No significant difference in previous 
ADHD diagnosis was found between men and women who screened positive for ADHD, 
χ2 (1, N = 70) = 0.01, p = .936.  
4.2 Sex and Previous ADHD Medication Use  
Of those previously diagnosed, 74.36% [57.57, 86.40] of males and 76.92% 
[45.98, 43.84] of females were treated with ADHD medication and no significant 
difference in ADHD medication use between sexes was found, χ2 (1, N = 52) = 0.34, p = 
.853. Of those previously diagnosed and treated with medication, none had been treated 
with medication in the past 12 months. Furthermore, of those previously diagnosed and 
treated with medication, 86.21% [67.43, 95.49] of men were treated with medication 
before the age of 18 and 54.55% [24.57, 81.87] of women were treated with ADHD 
medication before the age of 18. A significant difference in ADHD medication use prior 
to age 18 between men and women was found, χ2 (1, N = 4) = 4.59, p = .032. 
4.3. Sex, ADHD Screener Status and Anti-anxiety Medication Use  
4.3.1 ADHD screener status and anti-anxiety medication use among men. 
Past year anti-anxiety medication use was present among 30.00% [15.41, 49.56] of men 
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who screened positive for ADHD and 4.51% [3.29, 6.12] of men who screened negative 
for ADHD. Moreover, men who screened positive for ADHD represented 18.00% [9.05, 
31.92] of those who had reported taking anti-anxiety medication in the past year. Past 
year anti-anxiety medication use among men differed significantly by ADHD screener 
status, χ2 (1, N = 939) = 37.43, p = .000. Men who screened positive for ADHD had 
higher odds of past year anti-anxiety medication use than men who screened negative for 
ADHD (OR = 9.07; 95% CI = 3.91, 21.05).  
4.3.2 ADHD and anti-anxiety medication use among women. Among women 
in the positive ADHD screener group, 47.37% [31.31, 63.95] reported taking anti-anxiety 
medication in the past year compared to 52.63% [36.05, 68.69] who had not. Among 
women in the negative ADHD screener status group, 7.07% [5.60, 8.88] reported taking 
anti-anxiety medication in the past year compared to 92.93% [91.12, 94.40] that had not. 
Also, 20.22% [12.73, 30.33] of women who reported taking anti-anxiety medication in 
the past year screened positive for ADHD. A significant association was found between 
ADHD screener status and anti-anxiety medication use among women, χ2 (1, N = 1042) = 
76.11, p = .000, with women who screened positive for ADHD having higher odds of 
past 12 month anti-anxiety medication use compared to women who screened negative 
for ADHD (OR = 11.83; 95% CI = 5.99, 23.37).  
4.3.3 Anti-anxiety medication use among men and women who screened 
negative for ADHD. Of those who screened negative for ADHD and who reported 
taking anti-anxiety medication in the past year, 36.61% [27.86, 46.29] were men and 
63.39% [53.71, 72.14] were women. A significant relationship was found between sex 
and past year anti-anxiety medication use among those who screened negative for 
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ADHD, χ2 (1, N = 1913) = 5.68, p = .017. Women who screened negative for ADHD had 
higher odds of past 12 month anti-anxiety medication use compared to men who screened 
negative for ADHD (OR = 1.61; 95% CI = 1.09, 2.39). 
4.3.4 Anti-anxiety medication use among men and women who screened 
positive for ADHD. Thirty percent [15.41, 49.56] of men and 47.40% [31.31, 63.95] of 
women who screened positive for ADHD reported taking anti-anxiety medication in the 
past year. No significant difference in anti-anxiety medication use between men and 
women who screened positive for ADHD was found, χ2 (1, N = 68) = 2.11, p = .146. 
4.4. Sex, ADHD Screener Status and Antidepressant Medication Use 
4.4.1 ADHD screener status and antidepressant medication use among men. 
Among men who screened positive for ADHD, 25.81% [12.54, 44.93] reported taking 
antidepressant medication in the past year and 4.29% [3.11, 5.87] of men who screened 
negative for ADHD reported taking antidepressant medication in the past year. Also, men 
who screened positive for ADHD represented 17.02% [8.14, 31.35] of all men who had 
reported taking antidepressants in the past year. There was a significant relationship 
between antidepressant medication use among men and ADHD screener status, χ2 (1, N = 
940) = 29.22, p = .000. Men who screened positive for ADHD had higher odds of taking 
antidepressants in the past 12 months compared to men who screened negative for 
ADHD (OR = 7.76; 95% CI = 3.26, 18.45). 
4.4.2 ADHD Screener status and antidepressant medication use among 
women. Antidepressant medication use over the past year was prevalent among 46.15% 
[30.43, 62.62] of women who screened positive for ADHD and 7.55% [6.03, 9.40] of 
women who screened negative for ADHD. In addition, women who screened positive for 
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ADHD represented 19.15% [12.04, 28.84] of all women who reported taking 
antidepressants in the past year. Past year antidepressant medication use among women 
differed significantly by ADHD screener status, χ2 (1, N = 1041) = 67.98, p = .000, with 
women who screened positive for ADHD having higher odds of past 12 month 
antidepressant use than women who screened negative for ADHD (OR = 10.44, 95% CI 
= 5.34, 24.44).  
4.4.3 Antidepressant use among men and women who screened negative for 
ADHD. Past year antidepressant medication use was prevalent among 4.29% [3.11, 5.87] 
of men and among 7.55% [6.03, 9.40] of women who screened negative for ADHD. Of 
all those who screened negative for ADHD and who reported taking antidepressants in 
the past year, 33.91% [25.51, 43.40] were men and 66.09% [56.60, 74.49] were women. 
There was a significant association between sex and past year antidepressant use among 
those screening negative for ADHD, χ2 (1, N = 1911) = 9.15, p = .002, with women 
having higher odds of past 12 month antidepressant use than men (OR = 1.83; 95% CI = 
1.23, 2.72). 
4.4.4 Antidepressant medication use among men and women who screened 
positive for ADHD. Past year antidepressant use was prevalent among 25.81% [12.54, 
44.93] of men and 46.15% [30.43, 62.62] of women who screened positive for ADHD. 
No significant difference in past year reported antidepressant use was found between men 
and women who screened positive for ADHD, χ2 (1, N = 70) = 3.06, p = .080. 
4.5 Sex, ADHD Screener status and Psychiatric Distress  
4.5.1 ADHD screener status and psychiatric distress among men. A larger 
proportion of men who screened positive for ADHD than men who screened negative for 
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ADHD screened positive for psychiatric  distress (35.48% [19.83, 54.62] versus 7.46% 
[5.88, 9.41] respectively). Moreover, of all men who screened positive for psychiatric 
distress, 13.92% [7.48, 23.97] also screened positive for ADHD. Psychiatric distress, as 
measured by the GHQ-12, among men differed significantly by ADHD screener status, χ2 
(1, N = 942) = 30.64, p = .000, with men who screened positive for ADHD having higher 
odds of psychiatric distress than men who screened negative for ADHD (OR = 6.82; 95% 
CI =3.14, 14.82).  
4.5.2. ADHD screener status and psychiatric distress among women. 
Psychiatric distress was present among 48.72% [32.71, 64.97] of women who screened 
positive for ADHD and in 9.84% [8.10, 11.89] of women who screened negative for 
ADHD. Of all women who screened positive for psychiatric distress, 16.10% [10.21, 
24.26] also screened positive for ADHD. A significant association between psychiatric 
distress and ADHD screener status was found among women, χ2 (1, N = 1045) = 56.65, p 
= .000, with women who screened positive for ADHD having higher odds of psychiatric 
distress than women who screened negative for ADHD (OR = 8.70; 95% CI = 4.49, 
16.86).  
4.5.3 Psychiatric distress among men and women who screened negative for 
ADHD. Approximately 9.84% [8.10, 11.89] of women who screened negative for ADHD 
and 7.46% [5.88, 9.41] of men who screened negative for ADHD had psychiatric distress. 
Among those who screened positive for psychiatric distress, 40.72% [33.27, 48.60] were 
men and 59.28% [51.40, 66.73] were women. No significant difference in psychiatric 
distress between men and women who screened negative for ADHD was found, χ2 (1, N 
= 7) = 3.40, p = .065. 
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4.5.4 Psychiatric distress among men and women who screened positive for 
ADHD. Among those who screened positive for ADHD, 35.48% [19.83, 54.62] of men 
and 48.72% [32.71, 64.97] of women screened positive for psychiatric distress. Among 
all those who screened positive for psychiatric distress, 63.33% [43.90, 79.45] of men 
also screened positive for ADHD and 36.67% [20.55, 56.10] of women also screened 
positive for ADHD. No significant difference in psychiatric distress between men and 
women who screened positive for ADHD was found, χ2 (1, N = 70) = 1.24, p = .266.  
4.6 Sex, ADHD Screener Status and Antisocial Personality Disorder (ASPD) 
Screener Status 
4.6.1 ADHD screener status and ASPD screener status among men. 
Approximately 20.00% [9.51, 37.31] of men who screened positive for ADHD also 
screened positive for ASPD, whereas 0.90% [0.42, 1.84] of men who screened negative 
for ADHD also screened positive for ASPD.  Of those who screened positive for ASPD, 
42.86% [18.82, 70.35] screened positive for ADHD and 57.14% [29.65, 81.18] did not. A 
significant association between ASPD screener status and ADHD screener status in men 
was found, χ2 (1, N = 915) = 70.23, p = .000, with men who screened positive for ADHD 
having higher odds screen of screening positive for ASPD than men who screened 
negative for ADHD (OR = 27.41; 95% CI = 8.82, 85.14). No women screened positive 
for ASPD in this sample. 
4.7 Sex, ADHD Screener Status and Hazardous Alcohol Use  
4.7.1 ADHD screener status and hazardous alcohol use among men. Similar 
proportions of men who screened positive for ADHD and men who screened negative for 
ADHD screened positive for hazardous alcohol use as measured by the AUDIT (25.81% 
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[12.54, 44.93] versus 18.72% [16.22, 21.50], respectively). ADHD was prevalent among 
4.65% [2.18, 9.26] of all men who screened positive for hazardous alcohol use. No 
significant difference in hazardous alcohol use between men who screened positive for 
ADHD and men who screened negative for ADHD was found, χ2 (1, N = 907) = 0.98, p = 
.323.  
4.7.2 ADHD screener status and hazardous alcohol use among women. 
Among women, 23.68% [12.02, 40.61] of those who screened positive for ADHD and 
7.16% [5.67, 8.99] of those who screened negative for ADHD screened positive for 
hazardous alcohol use. Of all women who screened positive for hazardous alcohol use, 
11.25% [5.59, 20.76] also screened positive for ADHD. Hazardous alcohol use among 
women differed significantly by ADHD screener status, χ2 (1, N = 1030) = 13.95, p = 
.000. Women who screened positive for ADHD had higher odds of hazardous alcohol use 
than women who screened negative for ADHD (OR = 4.03 95% CI = 1.84, 8.83).  
4.7.3 Hazardous alcohol use among men and women who screened negative 
for ADHD. A larger proportion of men who screened negative for ADHD than women 
who screened negative for ADHD screened positive for hazardous alcohol use (18.72% 
[16.22, 21.50] versus 7.16% [5.67, 8.99]). Also, of all those who screened positive for 
hazardous alcohol use, 67.98% [63.42, 75.50] were men. A significant relationship 
between sex and hazardous alcohol use among men and women who screened negative 
for ADHD was found, χ2 (1, N = 1868) = 56.57, p = .000, with men having higher odds of 
hazardous alcohol use compared to women (OR = 2.99; 95% CI = 2.22, 4.01).  
4.7.4 Hazardous alcohol use among men and women who screened positive 
for ADHD. A similar proportion of men who screened positive for ADHD (25.81%) 
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[12.54, 44.93] and women who screened positive for ADHD (23.68%)  [12.02, 40.61] 
also screened positive for hazardous alcohol use. Of all those who screened positive for 
ADHD and hazardous alcohol use, 47.06% [23.86, 71.47] were men and 52.94% [28.53, 
76.14] were women. No significant sex difference in hazardous alcohol use among those 
who screened positive for ADHD was found, χ2 (1, N = 69) = 0.04, p = .839.  
4.8 Sex, ADHD Screener Status and Cannabis Use and Abuse 
4.8.1 ADHD screener status and cannabis use and abuse among men. A larger 
proportion of men who screened positive for ADHD (83.33%) [64.55, 93.69] than men 
who screened negative for ADHD (43.27%) [40.02, 46.57] reported using cannabis, 
marijuana, or hash in their lifetime. Of all men who reported using cannabis in their 
lifetime, 6.00% [4.00, 8.85] also screened positive for ADHD. Lifetime cannabis, 
marijuana or hash use among men differed significantly by ADHD Screener status, χ2 (1, 
N = 936) = 18.87, p = .000. Men who screened positive for ADHD were more likely to 
report having used cannabis, marijuana or hash in their lifetime than men who screened 
negative for ADHD (OR= 6.56; 95% CI = 2.49, 17.28). However, no significant 
differences were found between men in both the positive and negative ADHD screener 
groups for cannabis, marijuana or hash use over the past 12 months, χ2 (1, N = 935) = 
2.15, p = .143, or over the past 3 months, χ2 (1, N = 940) = 2.21, p = .137. No significant 
difference in cannabis abuse between men who screened positive for ADHD and men 
who screened negative for ADHD was found, χ2 (1, N = 934) = 2.63, p  = .105.   
4.8.2 ADHD screener status and cannabis use among women. Of all women 
who screened positive for ADHD, 65.79% [48.58, 79.86] reported using cannabis in their 
lifetime compared to 35.67% [32.71, 38.74] of women who screened negative for 
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ADHD. Women who screened positive for ADHD represented 6.56% [4.37, 9.66] of all 
women who reported using cannabis, marijuana or hash in their lifetime. Lifetime 
cannabis, marijuana and hash use among women differed significantly by ADHD 
screener status, χ2 (1, N = 1036) = 14.28, p = .000, with women who screened positive for 
ADHD having higher odds of lifetime cannabis, marijuana or hash use than women who 
screened negative for ADHD (OR = 3.47; 95% CI = 1.75, 6.86). A larger proportion of 
women who screened positive for ADHD, 26.32% [13.98, 43.39], compared to women 
who screened negative for ADHD, 11.04% [9.20, 13.19], also reported using cannabis, 
marijuana or hash over the past 12 months. Women who screened positive for ADHD 
represented 8.33% [4.29, 15.16] of all women who reported using cannabis, marijuana or 
hash in the past 12 months. Past 12 month cannabis, marijuana or hash use among 
women differed significantly by ADHD screener status, χ2 (1, N = 1034) = 8.32, p = .004, 
with women who screened positive for ADHD having higher odds of past 12 month 
cannabis, marijuana or hash compared to women who screened negative for ADHD (OR 
= 2.88; 95% CI = 1.36, 6.08). Yet no significant difference in past three month cannabis, 
marijuana or hash use between women who screened positive for ADHD and women 
who screened negative for ADHD was found, χ2 (1, N = 1045) = 1.53, p = .216.  
4.8.3 Cannabis use among men and women who screened negative for 
ADHD. Lifetime cannabis marijuana or hash use was prevalent among 43.27% [40.02, 
46.57] of men and 35.67% [32.71, 38.74] of women who screened negative for ADHD. 
Of those who had used cannabis, marijuana or hash in their lifetime, 52.41% [48.76, 
56.03] were men and 47.59 [43.97, 51.24] were women. Past 12 month cannabis, 
marijuana or hash use was prevalent among 15.93% [13.64, 18.52] of men who screened 
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negative for ADHD and among 11.04% [9.20, 13.19] of women who screened negative 
for ADHD. Of those who had used cannabis, marijuana or hash in the past 12 months, 
56.69% [50.34, 62.83] were men and 43.31% [37.17, 49.66] were women. Past 3 month 
cannabis, marijuana or hash use was prevalent among 11.21% [9.32, 13.43] of men who 
screened negative for ADHD and 7.46% [5.95, 9.30] of women who screened negative 
for ADHD. Of those who had used cannabis, marijuana or hash in the past 3 months, 
57.63% [49.98, 64.94] were men and 42.37% [35.06, 50.02] were women. Men and 
women who screened negative for ADHD were found to differ on lifetime, past 12 month 
and past 3 month cannabis, marijuana or hash use, respectively (χ2 (1, N = 1904) = 11.49, 
p = .001; χ2 (1, N = 1900) = 9.77, p = .002; χ2 (1, N = 1916) = 8.03, p = .005), with men 
who screened negative for ADHD having higher odds of lifetime cannabis, marijuana or 
hash use (OR = 1.38; 95% CI = 1.14, 1.65), past 12 month use (OR = 1.53; 95% CI = 
1.17, 1.99) and past 3 month use (OR = 1.57; 95% CI = 1.15, 2.14) than women who 
screened negative for ADHD.  
Approximately 10.62% [8.73, 12.86] of men who screened negative for ADHD 
and 7.46% [5.95, 5.30] of women who screened negative for ADHD met the cut-off for 
cannabis abuse. Of those who abused cannabis, 56.14% [48.36, 63.64] were men and 
43.86% [36.36, 51.64] were women. A significant difference in cannabis abuse between 
men and women who screened negative for ADHD was found, χ2 (1, N = 1910) = 5.85, p 
= .016, with men having higher odds cannabis abuse compared to women (OR = 1.48; 
95% CI = 1.08, 2.02).  
4.8.4 Cannabis use among men and women who screened positive for ADHD. 
Among those who screened positive for ADHD, 83.33% [64.55, 93.69] of men and 
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65.79% [48.58, 79.86] of women reported using cannabis, marijuana or hash in their 
lifetime and no significant difference in lifetime cannabis, marijuana or hash use between 
men and women who screened positive for ADHD was found, χ2 (1, N = 68) = 2.65, p = 
.103. Regarding cannabis, marijuana or hash use over the past 12 months among those 
who screened positive for ADHD, 25.81% [12.54, 44.93] of men and 26.32% [13.98, 
43.39] of women endorsed using cannabis over the past 12 months and no significant 
difference in past 12 month cannabis, marijuana or hash use between men and women 
who screened positive for ADHD was found χ2 (1, N = 69) = 0.002, p = .962. Moreover, 
20.00% [8.40, 39.13] of men and 12.82% [4.82, 28.23] of women reported using 
cannabis, marijuana or hash over the past 3 months and again, no significant difference in 
past 3 month cannabis, marijuana or hash use between men and women who screened 
positive for ADHD was found,  χ2 (1, N = 69) = 0.65, p = .419. Moreover men and 
women who screened positive for ADHD did not differ in rates of cannabis abuse, χ2 (1, 
N = 68) = 1.20, p = .273. 
4.9 Sex, ADHD Screener Status and Lifetime Cocaine Use 
4.9.1 ADHD and lifetime cocaine use among men. About 22.58% [10.28, 
41.54] of men who screened positive for ADHD and 9.46% [7.67, 11.60] of men who 
screened negative for ADHD reported using cocaine in their lifetime. Men who screened 
positive for ADHD accounted for 7.53% [3.3.4, 15.40] of all men who had reported using 
cocaine in their lifetime. Lifetime cocaine use among men differed significantly by 
ADHD screener status, χ2 (1, N = 940) = 5.79, p = .016, with men who screened positive  
for ADHD having higher odds lifetime cocaine use than men who screened negative for 
ADHD (OR = 2.79; 95% CI = 1.17, 6.67). 
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4.9.2 ADHD screener status and lifetime cocaine use among women. Among 
women, 23.68% [12.02, 40.61] of those who screened positive for ADHD and 3.71% 
[2.66, 5.13] of those who screened negative for ADHD had reported using cocaine in 
their lifetime. Also, women who screened positive for ADHD accounted for 19.57% 
[9.87, 34.38] of all women who had reported using cocaine in their lifetime. A significant 
association between lifetime cocaine use among women and ADHD screener status was 
found, χ2 (1, N = 1036) = 34.43, p = .000, with women who screened positive for ADHD 
having higher odds of lifetime cocaine use than women who screened negative for 
ADHD (OR = 8.06; 95% CI =3.56, 18.24). 
4.9.3 Lifetime cocaine use among men and women who screened negative for 
ADHD. In those who screened negative for ADHD, 9.46% [7.67, 11.50] of men and 
3.71% [2.66, 5.13] of women reported using cocaine in their lifetime. Of all those who 
reported using cocaine in their lifetime, 69.92% [60.89, 77.68] were men and 30.08% 
[22.32, 39.11] were women. A significant association between sex and lifetime cocaine 
use among those who screened positive for ADHD was found, χ2 (1, N = 1907) = 26.10, p 
= .000, with men having higher odds of lifetime cocaine use than women (OR = 2.71; 
95% CI = 1.83, 4.03). 
4.9.4 Lifetime cocaine use among men and women who screened positive for 
ADHD. Regarding lifetime cocaine use, 22.58% [10.28, 41.54] of men and 23.68% 
[12.02, 40.61] of women who screened positive for ADHD had reported using cocaine in 
their lifetime. Of those who had reported using cocaine in their lifetime, 43.75% [20.75, 
69.45] were men and 56.25% [30.55, 79.25] were women. No significant difference in 
lifetime cocaine use between men and women who screened positive for ADHD was 
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found, χ2 (1, N = 69) = 0.01, p = .914. Results from all analyses stratified by sex and 
ADHD screener status are presented in Table 4.1 below. 
Table 4.1  
Proportions and 95% Confidence Intervals for Variables Stratified by Sex 
 
Variable 
 
ADHD
Men (%) 
 
Positive 
Women (%) 
 
ADHD 
  Men (%) 
 
Negative 
Women (%) 
      
Previous 
ADHD 
Diagnosis 
 9.68  
[2.53, 26.90] 
10.26  
[3.34, 25.16] 
3.97 
[2.83,5.51] 
1.00  
[0.51, 1.89] 
      
Anti-anxiety  
Med Use 
 30.00  
[15.41, 49.56]
47.37  
[31.31, 63.95] 
4.51  
[3.29, 6.12] 
7.07  
[5.60, 8.88] 
      
Antidepressant 
Med Use 
 25.81  
[12.54, 44.93]
46.15 
[30.43, 62.62] 
4.29  
[3.11, 5.87] 
7.55 
[6.03, 9.40] 
      
Psychiatric 
Distress 
 35.48  
[19.83, 54.62]
48.72  
[32.71, 64.97] 
7.46  
[5.88, 9.41] 
9.84  
[8.10, 11.89] 
      
ASPD Screener
Status 
 20.00  
[9.51, 37.31] 
0 0.90  
[0.42, 1.84] 
0 
      
Hazardous 
Alcohol Use 
 25.81  
[12.54, 44.93]
23.68  
[12.02, 40.61] 
18.72  
[16.22, 21.50] 
7.16 
[5.67,8.99] 
      
Cannabis 
Lifetime 
 83.33  
[64.55, 93.69]
65.79 
[48.58, 79.86] 
43.27  
[40.02, 46.57] 
35.67  
[32.71, 38.74] 
      
Cannabis Past 
12 Months 
 25.81  
[12.54, 44.93]
26.32  
[13.98, 43.39] 
15.93 
[8.40,39.13] 
11.04  
[9.20, 13.19] 
      
Cannabis Past 3 
Months 
 5.56  
[2.28, 12.19] 
12.82 
[4.82,28.23] 
11.21 
 [9.32, 13.43] 
7.46  
[5.95, 9.30] 
      
Cannabis 
Abuse 
 20.00  
[8.40, 39.13] 
10.53  
[3.43, 25.75] 
10.62  
[8.73, 12.86] 
7.46 
[5.95,5.30] 
      
Cocaine 
Lifetime 
 22.58 
[10.28, 41.54]
23.68 
 [12.02, 40.61]
9.46  
[7.67, 11.60] 
3.71  
[2.66, 5.13] 
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Chapter 5: Hierarchical Logistic Regression Model 
A logistic regression analysis was conducted to predict psychiatric distress in 
1871 participants using age, sex, ASPD screener status, ADHD screener status, and 
substance use as predictors. Psychiatric distress was used as a screener for anxiety and 
depression. Lewis and Wessely (1990) found that the convergent validity between the 
GHQ-12 (psychiatric distress) and the Hospital Anxiety and Depression Scale was 0.74. 
In hierarchical logistic regression, variables are entered in steps (blocks) following 
theoretical or pragmatic reasoning about the sequential order of the variables that may 
predict a given outcome. Covariates were entered in three blocks as follows: 
demographic variables (block 1), psychiatric variables (block 2), and substance use 
variables (block 3).  
Block 1 consisted of the demographic variables age and sex. These have been 
found to be associated to depression and anxiety; studies have shown that anxiety and 
depressive disorders are most prevalent at middle age and among women (Kroenke, 
Strine, Spitzer, Williams, Berry & Mokdad, 2009; Bland, 1997; Lehtinen & Joukamaa, 
1997; Kessler, McGonagle, Swartz, Blazer & Nelson, 1993). Antisocial personality 
disorder (ASPD) screener status and ADHD screener status were entered in block 2. 
ASPD was included in the model due to its frequent co-occurrence with ADHD (Barkley, 
Fischer, Smallish, & Fletcher, 2004; Mannuzza, Klein, Bessler, Malloy, & LaPadula, 
1998; Satterfield & Schell, 1997; Weiss, Hechtman, Milroy & Perlman, 1985). As such, 
antisocial traits needed to be controlled for in order to isolate the effects of ADHD on 
psychiatric distress. Here, ADHD was the main predictor variable of interest hence its 
inclusion in the model was imperative. Additionally, according to DSM-IV-TR, ADHD is 
considered a disorder of early developmental origins, while depression is considered a 
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disorder of later age onset (Ostrander & Herman, 2006). Finally, hazardous alcohol use 
and cannabis use were entered into the model in block 3. Frequent alcohol and cannabis 
use has been shown to increase the risk of depression and anxiety and has also been 
found to be associated with ADHD (Horwood et al., 2012; Boden & Ferguson, 2011; 
Biederman et al., 1995; Biederman et al., 1997).  As such, the nature and magnitude of 
the contribution of these variables to the overall outcome was of interest.  
Table 5.1 displays the results from the hierarchical logistic regression analysis for 
psychiatric distress. Results from block 1 showed that the addition of the variables age 
and sex added to the model (Model χ2 = 12.20, p = .002). Age accounted for about 7% of 
the variance in psychiatric distress (Wald χ2 = 6.51, p = .001). Younger individuals had 
higher odds of psychiatric distress than older individuals (OR = 0.99; 95% CI = 0.98, 
1.00), with a 1.2% decrease in the odds of psychiatric distress with each one year increase 
in age. Sex was also a significant predictor of psychiatric distress (OR = 0.68; 95% CI = 
0.48, 0.92), accounting for approximately 6% of the variance between those who were 
above threshold for psychiatric distress and those who were not (Wald χ2 = 5.71, p = 
.017). Furthermore, females were more likely to have psychiatric distress and being 
female was associated with a 31.60% increase in odds of psychiatric distress.  
Psychiatric predictors were added following demographic predictors in block 2. 
The addition of psychiatric predictors was significant, Block χ2 = 50.49, p = .000. ASPD 
screener status did not significantly predict psychiatric distress. ADHD screener status 
however was found to significantly predict psychiatric distress and accounted for about 
50% of the variability in psychiatric distress in the sample (Wald χ2 = 49.84, p = .000). 
Moreover, those who screened positive for ADHD had approximately 7 times the odds of 
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psychiatric distress (OR= 6.85; 95% CI = 4.00, 11.72). Furthermore, with the addition of 
the ADHD variable, age was no longer a significant predictor of psychiatric distress.  
Two substance abuse variables, hazardous alcohol use and cannabis use were 
subsequently added in block 3. This block was non-significant; hazardous alcohol use 
and cannabis abuse did not significantly predict psychiatric distress, Block χ2 = 0.06, p = 
.969.   
A test of the full model against a constant only model was statistically significant, 
indicating that the predictors as a set reliably distinguished between those who screened 
positive for psychiatric distress and those who did not (Model χ2 = 62.75, p = .000, df = 
6). The full model resulted in the correct classification of 89.94% of the data. The 
Hosmer-Lemeshow goodness-of-fit test was greater than .05; therefore we failed to reject 
the null hypothesis that there is no difference between observed and model-predicted 
values, implying that the model’s estimates fit the data at an acceptable level and is well-
calibrated to predict cases from non-cases (c = 0.81). Sex and ADHD were the only two 
independent predictors of psychiatric distress, as the percentage of variance accounted for 
by each variable remained relatively unchanged in block 3. Sex was associated with 
increased odds of psychiatric distress and ADHD was associated with roughly a 
sevenfold increase in the risk of psychiatric distress.  
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Table 5.1 
Hierarchical Binary Logistic Regression Analysis for Psychiatric Distress (N = 1871) 
Variable 
  
β 
 
S.E. 
 
Wald 
 
df 
 
Sig. 
 
Exp. 
(β) 
 
95% C.I. 
         
Block 0         
 (Constant) -2.19 .08 801.27 1 .000 0.11  
         
Block 1         
 Age -.01 .01 6.51 1 .011 0.99 0.98, 1.00 
 Sex -.38 .16 5.71 1 .017 0.68 0.50, 0.93 
 (Constant) -1.49 .23 41.52 1 .000 0.23  
         
Block 2         
 Age -.01 .01 3.23 1 .072 0.99 0.98, 1.00 
 Sex -.40 .16 5.97 1 .015 0.67 0.49, 0.92 
 ASPD 
screen 
 .90 .79 1.30 1 .255 2.47 0.52, 1.64 
 ADHD 
screen 
1.92 .27 49.84 1 .000 6.88 4.03, 1.75 
 (Constant) -1.77 .24 53.35 1 .000 0.17  
         
Block 3         
 Age -.01 .01 2.99 1 .084 0.99 0.98, 1.00 
 Sex -.41 .17 5.94 1 .015 0.67 0.48, 0.92 
 ASPD 
screen 
 .90 .79 1.29 1 .255 2.46 0.52, 1.56 
 ADHD 
screen 
1.92 .27 49.30 1 .000 6.85 4.00,11.72 
 Cannabis 
Abuse 
-.05 .28 0.04 1 .851 0.95 0.54, 1.66 
 AUDIT 
8+ 
 .05 .25 0.46 1 .830 1.05 0.65, 1.71 
 (Constant) -1.98 .26 46.32 1 .000 0.17  
 
Note: Block 1 χ2 (2) = 12.20, p = .002, -2 Log likelihood = 1190.68; Block 2 χ2 (4) = 62.69, p = .000, -2 
Log likelihood = 1140.19; Block 3 χ2 (6) = 62.75, p = .000, -2 Log likelihood = 1140.12. 
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Chapter 6: Discussion 
 
6.1 Findings of Interest 
The purpose of this study was to estimate the prevalence and correlates of adult 
ADHD in Ontario using population-based data, although it is important to point out that 
the results of this study are based on self-report screening tools and not psychiatric 
diagnosis. Thus, readers should be mindful that the results of this study may not reflect 
actual prevalence and correlates of diagnosed ADHD in the community. That said, the 
overall prevalence of adult ADHD in Ontario, using the ASRS Screener v1.1,was found 
to be approximately 3.5%. This estimate is in accordance with the WHO World Mental 
Health epidemiological studies that estimated the prevalence of adult ADHD to be 
approximately 3.4% in the total sample using the same screening measure (Fayaad et al., 
2007; Kessler et al., 2006; Medina-Mora et al., 2005), however it is slightly lower than 
population-based estimates from the U.S. also using the same measure (Kessler et al., 
2006). Approximately equal proportions of men and women screened positive for 
ADHD, which is in line with earlier evidence of an equalization of the disorder between 
the sexes in adulthood (Faraone & Biederman, 2005; Kessler et al., 2005; McGough et 
al., 2005). 
Significant age differences were found in this study. Specifically, estimates of 
ADHD positive screen were highest among those 18-34 years old and declined with 
increasing age. These results are in keeping with earlier studies that reported a decline of 
ADHD symptoms with increasing age (Biederman et al., 2000; Faraone, Bierderman, 
Spencer, Wilens, Seidman, Mick & Doyle, 2000).  
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Only 10% of adults who screened positive for ADHD had previously been 
diagnosed with ADHD. Another recent epidemiological ADHD study found similarly 
low rates of previous ADHD diagnoses (de Zwaan, 2012). Furthermore, the vast majority 
(86.25%) of those who reported previous diagnosis with ADHD was under the age of 44 
and reported ADHD diagnoses were most prevalent among those aged 18-34 year old, 
suggesting a cohort effect resulting from the lack of a consistent conceptualization of the 
disorder throughout history. In fact, it was not until relatively recently (the early 1980s) 
that objective diagnostic criteria for ADHD (then termed ADD) appeared in DSM III. 
Thus, those who were school-aged prior to the 1980s were much less likely to have been 
sent to a medical practitioner and even less likely to have received a diagnosis. Indeed it 
is much more probable that prior to the 1980s, children who we would now consider as 
having ADHD were simply labeled ‘hyperactive’, ‘defiant’ or their behaviour was 
excused on the premise that ‘boys will be boys’ and that was the end of it.  The low 
diagnostic rate could also indicate that the ASRS Screener v1.1 is missing persons with 
diagnosed ADHD. 
The prevalence of adult ADHD screener status was not found to differ between 
urban and rural areas as it has in previous studies that reported higher estimates of 
psychopathology in urban compared to rural areas (Peen, Shoevers, Beekman & Dekker, 
2010). Variations in the definitions of what constitutes “rural” and “urban” areas between 
studies have been cited as a possible explanation for discrepant results in the literature (de 
Zwaan, 2012). Furthermore, divergent findings regarding ADHD and urbanization 
indicate that this association requires further investigation among adults. 
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A lower rate of ADHD positive screen was found among those who were married, 
while a higher rate of ADHD positive screen was found among those who had never been 
married. Results from the current study are consistent with those from previous 
population studies (Kessler et al., 2006; de Zwaan, 2012) that have also examined the 
relationship between ADHD and marital status. These studies found that not only were 
those with ADHD more likely to have never been married, but they were also more likely 
to be separated or divorced- a finding that was not corroborated in the current study. 
Nonetheless, taken together, the tendency for those with ADHD to be less likely to be 
married and more likely to be previously or never married may reflect the interpersonal 
difficulties often reported in this population.  
However, the effect of age must also be considered as a plausible explanation for 
our finding that those with ADHD were less likely to be married, as a large proportion of 
those who screened positive for ADHD were between the ages of 18 to 34 and hence are 
less likely to be married due to their younger age. This cohort effect may also explain 
why our study failed to support earlier work that found that those with ADHD were more 
likely to be previously married. Subsequent analyses should control for the effect of age 
on marital status in ADHD.  
Our study did not find any differences in employment according to ADHD 
screener status. These results therefore do not support the association between ADHD 
and occupational challenges in adulthood found in the literature (Barkley, 2002). 
Previous studies have found that those with ADHD were more likely to experience a 
number of negative employment outcomes including being more likely to be terminated 
from a job, frequent job changes, and lower job performance ratings (Manuzza, Klein, 
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Bessler, Malloy & Hynes, 1997). However, the aforementioned studies were based on 
clinical samples that may display higher levels of impairment than individuals who 
screened positively with ADHD in the general population. 
Moreover, the current study found that those who screened positive for ADHD 
did not differ from their non-ADHD counterparts in educational attainment or annual 
household income. The majority of both groups reported having some post-secondary 
education or a university degree, a finding that stands in stark contrast to the general 
consensus that ADHD is associated with low educational performance (Weiss et al. 1985; 
Manuzza et al. 1993; Murphy, Barkley & Bush, 2002). In fact, education is generally 
thought to be the area in which ADHD has the greatest impact (Barkley, 2002). Poor 
educational outcomes have been corroborated by numerous studies citing that 32-38% of 
those with ADHD do not complete high school, few people with ADHD enter college, 
and of those who do, only about 5% graduate (Fischer, Barley, Smallish & Fletcher, 
2002).  
Again, the discrepancy in findings between our study and the particularly poorer 
educational outcomes reported in previous studies could be due to important differences 
in methodology. Mainly, these studies were follow-up reports of clinically-referred 
samples and these samples, may be biased in that their impairments may be more severe 
than those found in the general population. Children who are referred to clinics by their 
parents and adults who are distressed to the point of seeking treatment represent only a 
subset of ADHD and this subset may in all likelihood, display greater functional 
impairment. On the other hand, the results of this study were based on a screening tool 
and not a clinical diagnosis and thus may not be accurate in its assessment of ADHD. 
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The current study used the GHQ-12 to ascertain current prevalence estimates of 
psychiatric distress. A large proportion (43.48%) of those who screened positive for 
ADHD also screened positive for psychiatric distress compared with 8.71% of those who 
screened negative for ADHD. Furthermore, those who screened positive for ADHD had 
higher odds of psychiatric distress than those who screened negative for ADHD (OR = 
8.06).  Men and women who screened positive for ADHD also had significantly higher 
odds of psychiatric distress compared to their same sex counterparts (OR = 6.82 and 8.70 
respectively) with rates being highest among women who screened positive for ADHD.  
These results are consistent with previous work with referred and non-referred 
groups of children, adolescents, and adults demonstrating additional mental health issues 
in ADHD, particularly where mood and anxiety disorders are concerned (Biederman et 
al., 1993; Kooij, Buitelaar, van den Oord, Furer, Rijnders & Hodiamont, 2004). 
Furthermore, epidemiological studies have reported prevalence rates of psychiatric 
distress in the general population to be around 15%, whereas the rates of psychiatric 
distress are above 30% in ADHD (Shekim, Asarnow, Hess, Zaucha & Wheeler, 1990; 
Biederman et al., 1991; Jensen, Shervette, Xenakis & Richters, 1993; Sobanski, 2006). 
Additionally, the equalization of depression and anxiety among men and women who 
screened positive for ADHD is indicative of increased psychological vulnerability 
associated with the disorder and also demonstrates similarities rather than differences in 
the expression of adult ADHD between sexes.  
Results from our regression analysis demonstrate that ADHD contributes to a 
significant proportion of the variance in psychiatric distress. Some investigators have 
hypothesized that depression in ADHD is analogous to an adjustment disorder reflecting 
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demoralization resulting from chronic social and academic failure (Sobanski, 2006). 
Based on this theory, we speculate that ADHD and depression may be a function of the 
demoralizing effects of the disorder, possibly resulting from an absence of treatment in 
this population. These results are also consistent with the hypothesis that ADHD poses a 
biological predisposition toward adverse environmental and social factors as well as 
further mental health issues, although it is important to point out that the results of the 
regression were based on a cross-sectional database; thus directionality of prediction 
among variables cannot be determined.  
The rates of anti-anxiety and antidepressant medication use were also notably 
elevated in those who screened positive for ADHD and did not differ significantly 
between sexes. A higher rate of anti-anxiety and antidepressant medication use in general 
is not surprising given the correlation between ADHD and other mental health issues. 
However, differential diagnosis is a prominent issue due to shared symptoms between 
ADHD and many other psychiatric disorders (Milberger, Biederman, Faraone, Murphy & 
Tsuang, 1995). For example, anxiety and depression often consist of symptoms of 
inattention and restlessness which are hallmarks of ADHD. However, this study cannot 
disaggregate ADHD from other psychiatric disorders. 
The prevalence of an ASPD positive screen was significantly higher among men 
who screened positive for ADHD (8.82%) than among men who screened negative for 
ADHD (0.42%), however the sample size was notably small (n = 6).  This finding is 
supported by the results of previous longitudinal studies with children and retrospective 
studies with adults that consistently report high rates of ASPD in adult ADHD and among 
men in general (Weiss et al., 1985, Manuzza et al., 1993; Barkley, Fischer, Smallish, & 
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Fletcher, 2004; Mannuzza, Klein, Bessler, Malloy, & LaPadula, 1998; Satterfield & 
Schell, 1997; Weiss, Hechtman, Milroy & Perlman, 1985). The literature indicates that 
hyperactivity and impulsivity in ADHD can lead to early conduct problems resulting in 
ASPD and does predict greater delinquency and criminality in males but not in females 
(Babinski, 1999). However, other authors underscore the oversimplification of the 
widespread claims of poor outcomes in ADHD and of shared etiology for ADHD and 
ASPD and hypothesize that the association between ADHD and ASPD is a product of the 
overlap between ADHD and CD (Lilienfeld & Waldman, 1990). Hence, the association 
may simply reflect the persistence of antisocial behaviour (CD) from childhood into 
adulthood and not ADHD as such.     
The current study also found significantly higher rates of harmful alcohol use 
among those with ADHD positive screen, which is supported by previous studies that 
reported a markedly higher incidence of alcohol abuse and dependence in ADHD 
compared to controls (Downey et al., 1997; Biederman, Wilens, Mick, Faraone & 
Spencer, 1998; Ohlmeier et al., 2008). Yet higher rates of alcohol consumption have also 
been found to be associated with younger age in general (Johnson, 1998; Caetano & 
Kaskutas, 1995; Fillmore, 1991) and those in the ADHD positive group were primarily of 
younger age than those in the ADHD negative group. Therefore, the higher rates of 
hazardous alcohol use found in this study could also be a consequence of age.  
 Various researchers have consistently reported an association between ADHD 
and substance use disorder (SUD), with up to 50% of adults with ADHD suffering from a 
concurrent SUD (Biederman et al., 1995, 1998; Wilens, Biederman, Mick, Faraone & 
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Spencer, 1997). ADHD is also assumed to be associated with a twofold risk of SUD 
compared to the general population.  
Our results showed that individuals who screened positive for ADHD had 
significantly elevated rates of lifetime and past 12 month cannabis use; however their use 
over the past 3 months did not differ from those who screened negative for ADHD. These 
results may suggest a propensity toward greater risk-taking behaviour in this population, 
as individuals with ADHD have shown a tendency to experiment more liberally with 
substance use than those without ADHD (Carroll & Rounsaville, 1993; Levin & Kleber, 
1995; Wilens et al., 1997; Biederman et al., 1998). However our findings do not indicate 
elevated rates of recent cannabis use, or chronic cannabis use among those who screened 
positively for ADHD. 
Sex-specific comparisons revealed no significant differences in hazardous alcohol 
use, cannabis use, or abuse between men who screened positive for ADHD and men who 
screened negative for ADHD. Women who screened positive for ADHD however had 
significantly higher rates of hazardous alcohol use, as well as lifetime and past 12 month 
cannabis use than women who screened negative for ADHD. Although cannabis use, 
abuse, and lifetime cocaine use were more likely among men in the general population, 
they did not differ significantly between men and women who screened positive for 
ADHD.  These results stand in contrast to earlier findings that men with ADHD have a 
higher frequency of substance use than women with ADHD (Millstein, Wilens, 
Biederman & Spencer, 1997; Biederman et al. 2004; McGough et al. 2005), yet they 
corroborate earlier work by Biederman and colleagues (1994) indicating that ADHD 
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females may share a similarly increased risk for substance use with their male 
counterparts.  
Although our findings showed higher odds for substance use in those who 
screened positive for ADHD, the vast majority of those who screened positive for ADHD 
did not engage in hazardous alcohol use (74.29%), had not used cannabis in the last year 
(73.91%) or in the past 3 months (84.06%), and most were likewise not cannabis abusers 
(85.29%). Many studies and reviews present a behavioural determinism perspective 
whereby ADHD is presented “firmly as a biological disorder” that “has such a profound 
effect on brain function that every aspect of the life of an affected individual may be 
permanently compromised” (Comings et al., 2005). Yet this is not the whole story. This 
perspective may be attributable to the synthesis of the findings derived principally from 
highly impaired clinical samples. It would be important to examine what proportion of 
those who screen positively for ADHD in the CAMH Monitor would also receive a 
clinical diagnosis of ADHD, as our results show that those who screened positively for 
ADHD show a propensity for psychiatric distress and greater odds of substance use yet 
seem to be functioning reasonably well in areas such as education, employment, and 
annual household income.  
6.2 Limitations 
 
These results however must be considered in light of the limitations inherent in 
this study. Because this was a preliminary analysis of only one year of data, sample sizes 
were too small for more sophisticated analyses. Importantly, age was not controlled for 
because our sample did not meet the guidelines for multinomial logistic regression that 
indicate a minimum of 10 cases per independent variable (Schwab, 2002). Adjusted ORs 
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were not calculated in the current study and thus age may have undue influence on the 
results of bivariate relationships. Therefore findings must be interpreted with caution. For 
example, individuals with positive screen for ADHD had a lower likelihood of being 
married and higher rates of hazardous alcohol use; yet these findings may be an artifact 
resulting from the uncontrolled effect of age. Future studies using the adult ADHD 
screener of the CAMH Monitor dataset should examine multiple years of data and 
examine odds ratios that have been adjusted for age and sex in comparison to the crude 
odds ratios presented here. 
The key limitation, as previously mentioned, is that this study examined 
prevalence and correlates of a number of screening tools. Subsequent research should 
sample and conduct a psychiatric assessment of a cohort of participants who screened 
positive and negative on the ASRS-v1.1 Screener in order to assess the sensitivity, 
specificity and other important measures of degree of overlap between the screening tools 
and actual psychiatric diagnoses. A related key limitation in this study was the overlap 
between the items on the ASRS-v1.1 Screener and the GHQ-12 screening instruments. 
The similarities between items in these screening measures make it difficult to ascertain 
whether the ASRS is actually assessing ADHD symptomatology and not some 
ambiguous conglomerate of psychological symptoms applicable to a wide range of 
psychiatric disorders. Therefore, one cannot label those who screened positive for ADHD 
with ADHDs and this fact must be taken into consideration when interpreting our 
findings. Thus, the use of screening measures such as the ASRS-v1.1 Screener, the GHQ-
12, the AUDIT, the ASSIST and the MINI-APD as opposed to full-length assessments 
and clinical diagnoses is an important methodological limitation of this study.  
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Another important limitation of this work involves the generalizability of the 
study results. The CAMH Monitor is only representative of non-institutionalized 
Ontarians age 18 and older (n = 9,118,084 from 2001 Ontario Census) (Ialomiteanu & 
Adlaf, 2007).  The data collection method used in this study has several limitations, 
chiefly that 1) the survey is based on households with telephones 2) the survey is based 
on self-report and 3) the presence of interview barriers. 
Excluded by design are Ontario households that are phoneless, which represent 
1% of Ontario residents (Statistics Canada, 2011). Also excluded are those too ill or aged 
to be interviewed and those unable to communicate on the telephone or in English.  In 
addition, household surveys are limited to those residing in conventional households and 
are not intended as a sample of all possible adults. As such, those in prisons, hospitals, 
military establishments, and transient populations such as the homeless are excluded. 
Importantly, these excluded groups often contain an especially large number of drug and 
alcohol users (Rossi, 1989). However, the coverage error depends firstly upon the 
difference in drug use and mental health status between those surveyed and those not 
surveyed, and secondly, the size of the group missed (Ialomiteanu & Adlaf, 2011). 
Impairments may be substantially higher in the excluded group than are those in the 
sampled group, yet if the size of the excluded group is small relative to the total 
population, the bias is usually minimal (Kandel, 1991; Trinkoff, Ritter, & Anthony, 
1990). One common deficit of telephone surveys is that they often over-represent those 
with higher education and under-represent those with lower education (Trewin & Lee, 
1988). 
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Furthermore, survey estimates are susceptible to self- report errors that are 
influenced by the conditions under which the survey is conducted. One limitation of the 
CAMH Monitor in this regard is its reliance on self-reports. Reviews of self-report 
methods for alcohol and drug use suggest that although surveys tend to underestimate 
true usage, they are still deemed the best available method to estimate such behaviours 
(Harrison, Haaga, & Richards, 1993; Turner, Lessler, & Gfroefer, 1992). One of the most 
important sources of bias to consider is social desirability bias, which is the tendency of 
respondents to answer questions in a manner that will be viewed favorably by others 
(Krosnick, 1999).   
Given that this was a preliminary assessment of adult ADHD screening status 
using the first year of data collection in a multi-year study, the sample size was relatively 
small. Specifically, cell counts were too low for more refined disaggregated effects and 
analyses may have had insufficient power to detect statistical significance. Additionally, 
missing data on the annual household income variable (> 5%) was also a limitation in this 
study as imputation methods were not used to correct for this. Furthermore, the design 
effect created by the 2 stage probability sampling was not accounted for in this study. 
Therefore for the aforementioned reasons it is most important that caution be taken when 
generalizing the results of this study to the entire population of Ontario.  
6.3 Directions for Future Research 
 
Directions for future research would include using combined data from multiple 
waves of the CAMH Monitor in order to further investigate disaggregated results. Many 
analyses were not possible in the current study due to the low sample size; hence 
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amassing several years of data would not only improve sample size and statistical power, 
but would also allow for more extensive analysis of the data. 
Future research could stratify results by age group in view of providing further 
insight into the similarities and differences in descriptive information, mental health 
correlates and substance use across all stages of adulthood. Also, preferential drug use in 
ADHD could be examined using a Canadian sample, as this was not possible due to low 
cell counts for non-prescribed ADHD medication use, prescription analgesic use, opiate 
use, and past year cocaine use. Furthermore, since such a small portion of the sample of 
those who screened positive for ADHD had been previously diagnosed, potential studies 
examining predictive factors for ADHD diagnoses are needed. Prospective follow-up 
studies of young adults who screened positive for ADHD may also lend to the ASRS-
v1.1 as a valid predictor of ADHD, as well as ADHD as a risk factor for later outcomes.  
ADHD is characterized by three symptom domains: inattention, hyperactivity and 
impulsivity. The current theory of adult ADHD describes an attenuation of hyperactivity 
and a persistence of inattention in adulthood. As such, the ASRS-v1.1 Screener primarily 
emphasizes symptoms of inattention, with four out of the six ASRS-v1.1 Screener items 
representing inattention and the remaining two items pertaining to hyperactivity. 
Importantly the Screener does not contain a single item related to impulsivity. Therefore, 
future studies using items representing all symptom domains are recommended. Also, 
examining symptom domains in relation to demographic, psychiatric and substance use 
variables may also reveal important differences between these groups. Since ADHD and 
additional mental health issues display unique profiles and trajectories, comparing 
outcomes between profiles would be an important priority for future research. Also, 
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further studies of not only risk but resiliency factors in ADHD are also warranted. 
Finally, as previously mentioned, it would be very important to conduct clinical 
assessments of a cohort of respondents who screened positively and negatively on the 
ASRS-v1.1 Screener, in order to determine the performance of the screener against 
clinical diagnoses. 
 
6.4 Summary and Conclusions 
ADHD positive screen was significantly associated with greater rates of 
psychiatric distress and antidepressant and anti-anxiety medication use. ADHD positive 
screen was also found to be associated with higher rates of lifetime and past 12 month 
cannabis use, however the greater majority of those who screened positively with ADHD 
had not used cannabis in the past 3 months. Moreover, despite higher odds of cannabis 
use disorders in ADHD, the vast majority did not screen positive for cannabis abuse. 
Inconsistent with the results of previous studies, individuals who screened positively for 
ADHD did not differ from those who screened negatively for ADHD in educational 
attainment, employment status or annual household income. These findings are intriguing 
and require further investigation.  
 
107 
 
 
 
REFERENCES 
 
Alberts-Corush, J., Firestone, P., & Goodman, J.T. (1986). Attention and impulsivity 
characteristics of the biological and adoptive parents of hyperactive and normal 
control children. American Journal of Orthopsychiatry, 56, 413 - 423. 
Alexander, G.E., DeLong, M. R. & Strick, P. L. (1986). Parallel organization of 
functionally segregated circuits linking basal ganglis and cortes. Annual Review of 
Neuroscience, 9, 357-381. 
Almeida Montes, L.G., Hernandez Garcia, A.O. & Ricardo-Garcell, J. (2007). ADHD 
prevalence in adult outpatients with nonpsychotic psychiatric illnesses. Journal of 
Attention Disorders, 11, 150–156. 
Althoff, R., Rettew, D., & Hudziak, J. (2003) Attention deficit/hyperacivity disorder, 
oppositional defiant disorder, and conduct disorder. Psychological Annals, 334, 
245–252. 
Amelia, A. M., Garnier-Dykstra, L. M., Caldeira, K. M., Vincent, K., O’Grady, K. & 
Wish, E. (2010). Persistent non-medical use of prescription stimulants among 
college students: possible association with ADHD symptoms. Journal of Attention 
disorders, 15, 347- 
 
Amen, D.G., Stubblefield, M., Carmicheal, B., Thisted, R. (1996). Brain SPECT findings 
and aggressiveness. Annals Clinical Psychiatry, 8, 129-137. 
 
American Academy of Pediatrics. (2000). Clinical practice guideline: Diagnosis and 
evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics, 105, 
1158–1170. 
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental 
disorders (4th ed., text rev.). Washington, DC: American Psychiatric Association. 
American Psychiatric Association. (1994). Diagnostic and statistical manual of mental 
disorders (4th ed.). Washington: D.C.: American Psychiatric Association. 
Anderson, J.C. (1996). Is childhood hyperactivity the product of western culture? Lancet, 
348, 73–74. 
Anderson, J.C.,Williams, S., McGee, R. & Silva, P.A.(1987). DSM-III disorders in 
preadolescent children: prevalence in a large sample from the general population. 
Archives of General Psychiatry, 44, 69-76. 
Angold, A. & Costello, E.J. (1993). Depressive comorbidity in children and adolescents: 
empirical, theoretical, and methodological issues. American Journal of Psychiatry, 
150, 1779-1791. 
108 
 
 
 
Angold, A., Costello, E.J., & Erkanli A. (1999). Comorbidity. Journal of Child 
Psychology and Psychiatry, 40, 57–87. 
 
Babinski, L. M., Hartsough, C. S. and Lambert, N. M. (1999), Childhood conduct 
problems, hyperactivity-impulsivity, and inattention as predictors of adult criminal 
activity. Journal of Child Psychology and Psychiatry, 40, 347–355. 
Babor, T.F., Biddle-Higgins, J.C., Saunders, J.B. & Monteiro, M.G. (2001). AUDIT: The 
Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Health 
Care. Geneva, Switzerland: World Health Organization. 
 
Banaschewski, T., Becker, K., Scherag, S., Franke, B. & Coghill, D. (2010). Molecular 
genetics of attention-deficit/hyperactivity disorder: an overview. European Child 
and Adolescent Psychiatry, 19, 237-257.  
Bannerjee, T.D., Middleton, F. & Faraone, S.V. (2007). Environmental risk factors for 
attention-deficit hyperactivity disorder. Acta Paediatrica, 96, 1269-74.   
Barbaresi, W., Katusic, S., Colligan, R., Weaver, A., Pankratz, V., Mrazek, D. & 
Jacobsen, S. (2004). How common is attention-deficit/hyperactivity disorder? 
towards resolution of the controversy: results from a population-based study. Acta 
Paediatrica Supplement 93, 55-59. 
Barkley, R. A., Murphy, K. R., & Fischer, M. (2008). ADHD in Adults: What the Science 
Says. New York: Guilford. 
Barkley, R. A., Fischer, M., Smallish, L. & Fletcher, K. (2004). Young adult follow-up of 
hyperactive children: antisocial activities and drug use. The Journal of Child 
Psychology and Psychiatry, 45, 195-211. 
Barkley, R. A. (2002). Major life activity and health outcomes associated with attention-
deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 63 (suppl.), 10-15. 
 
Barkley, R. A., Fischer, M., Smallish, L., & Fletcher, K. (2002). The persistence of 
attention-deficit/hyperactivity disorder into young adulthood as a function of 
reporting source and definition of disorder. Journal of Abnormal Psychology, 111, 
279 –289. 
 
Bauermeister, J.J., Shrout, P.E., Ramirez, R., Bravo, M., Alegria, M., Martinez-Taboas, 
A., Chavez, L., Rubio-Stipec, M., Garcia, P., Ribera, J.C. & Canino, G. (2007). 
ADHD correlates, comorbidity, and impairment in community and treated samples 
of children and adolescents. Journal of Abnormal Child Psychology, 35, 883-898. 
 
Bender, R. & Lange, S. (1999). Multiple test procedures other than  Bonferroni’s deserve 
wider use. British Medical Journal, 318, 600. 
109 
 
 
Bergman, H. & Kallmen, H. (2002). Alcohol use among Swedes and a psychometric 
evaluation of the Alcohol Use Disorders Identification Test. Alcohol and 
Alcoholism, 37, 245–251. 
Biederman, J., Monuteaux, M.C., Spencer, T., Wilens, T.E., MacPherson, H. & Faraone, 
S.V. (2008). Stimulant therapy and the risk for subsequent substance use disorders 
in male adults with ADHD: A naturalistic controlled 10-year follow-up study. 
Focus, 6, 358-365. 
Biederman, J. & Faraone, S.V. (2005). Attention-deficit hyperactivity disorder. Lancet, 
366, 237–48. 
Biederman, J., Mick, E. & Faraone, S. V. (2000). Age-dependent decline of symptoms of 
attention deficit hyperactivity disorder: Impact of remission definition and 
symptom type. American Journal of Psychiatry, 157, 816-818. 
Biederman, J. & Wilens, T. E. (1999). T. Attention-deficit/hyperactivity disorder and 
comorbidity. Pediatric Clinics of North America, 46, 915-927. 
Biederman, J., Faraone, S. V., Mick, E., Williamson, S., Wilens, T. E., Spencer, 
T. J., Weber, W., Jetton, J., Kraus, I., Pert, J., Zallen, B. (1999) Clinical correlates 
of ADHD in females: Findings from a large group of girls ascertained from 
pediatric and psychiatric referral sources. Journal of the American Academy of 
Child and Adolescent Psychiatry, 38, 966–975. 
Biederman, J. (1998). Attention-deficit/hyperactivity disorder: A lifespan perspective. 
Journal of Clinical Psychiatry, 59, 4-16. 
Biederman, J., Wilens, T.E., Mick, E., Faraone, S.V. & Spencer, T. (1998). Does 
attention-deficit hyperactivity disorder impact the developmental course of drug 
and alcohol abuse and dependence? Biological Psychiatry, 44, 269-273. 
Biederman, J., Wilens, T., Mick, E., Faraone, S., Weber, W., Curtis, S., Thornell, A., 
Pfister, K., Jetton, J., Soriano, J. (1997) Is ADHD a risk for psychoactive substance 
use disorder? Findings from a four year follow-up study. Journal of the American 
Academy of Child and Adolescent Psychiatry, 36, 21–29. 
 
Biederman, J., Faraone, S.V.,  Milberger, S., Guite, J., Mick, E., Chen, I. (1996). A 
prospective 4 year follow-up study of attention-deficit hyperactivity and related 
disorders. Archives of General Psychiatry, 53, 437-446. 
Biederman, J., Wilens, T., Mick, E. et al. (1995). Psychoactive substance use disorders in 
adults with attention-deficit/hyperactivity disorder (ADHD): effects of ADHD and 
psychiatric comorbidity. American Journal of Psychiatry, 152, 1652-1658. 
110 
 
 
Biederman, J., Faraone, S. V, Spencer, T., Wilens, T., Mick, E., Lapey, K. A. (1994). 
Gender differences in a sample of adults with attention deficit hyperactivity 
disorder. Psychiatry Research, 53, 13-29.  
 
 
Biederman, J., Faraone, S.V., Spencer, T.,Wilens, T., Norman, D. & Lapey, K.A. (1993). 
Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in 
adults with attention deficit hyperactivity disorder. American Journal of Psychiatry, 
150, 1792–1798. 
 
Biederman, J., Faraone, S.V., Keenan, K., Benjamin, J., et al. (1992). Further evidence 
for family-genetic risk factors in attention deficit hyperactivity disorder: Patterns of 
comorbidity in probands and relatives in psychiatrically and pediatrically referred 
samples. Archives of General Psychiatry, 49, 728-738. 
Biederman J., Faraone S.V., Keenan K., Steingard R., Tsuang M.T. (1991). Familial 
association between attention deficit disorder and anxiety disorders. American 
Journal of Psychiatry, 148, 251–256. 
 
Biederman, J.F., Faraone, S.V., Keenan, K., and Tsuang, M.T. (1991b). Evidence of 
familial association between attention deficit disorder and major affective 
disorders. Archives of General Psychiatry, 48, 633-642.  
Biederman, J., Newcom, J. & Sprich, S. (1991). Comorbidity of attention deficit 
hyperactivity disorder with conduct, depressive, anxiety, and other disorders. 
American Journal of Psychiatry, 148, 564-577.  
Biederman, J., Faraone, S.V., Keenan, K., Knee, D. & Tsuang, M.T. (1990). Family-
genetic and psychosocial risk factors in DSM-III attention deficit disorder. Journal 
of the American Academy of Child & Adolescent Psychiatry, 29, 526-533. 
 
Biederman, J., Munir, K., Knee, D., Armentano, M., Autor, S., Waternaux, C., and 
Tsaung, M. (1987). High rate of affective disorders in probands with attention 
deficit disorder and in their relatives: A controlled family study. American Journal 
of Psychiatry, 144, 330-333. 
 
Bird, H.R., Canino, G., Rubio-Stipec, M., Gould, M.S., Ribera, J., Sesman, M., et al. 
(1988). Estimates of the prevalence of childhood maladjustment in a community 
survey in Puerto Rico: the use of combined measures. Archives of General 
Psychiatry, 45, 1120-1126. 
 
Bird, H.R., Gould, M. S. & Staghezza, B. M. (1993). Patterns of diagnostic comorbidity 
in a community sample of children aged 9 through 16 years. Journal of the 
American Academy of Child and Adolescent Psychiatry, 32, 361-368. 
 
 
111 
 
 
Bitter, I., Simon, V., Balint, S., Meszaros, A. & Czobor, P. (2010). How do different 
diagnostic criteria, age and gender affect the prevalence of attention deficit 
hyperactivity disorder in adults? an epidemiological study in a Hungarian 
community sample. European Archives of Psychiatry and Clinical Neuroscience, 
260, 287–296. 
 
Blackman, G.L., Ostrander, R. & Herman, K.C. (2005). Children with ADHD and 
depression: a multisource, multimethod assessment of clinical, social, and academic 
functioning. Journal of Attention Disorders, 8, 195-207. 
 
Bland, R. C. (1997). Epidemiology of affective disorders: a review. Canadian Journal of 
Psychiatry, 42, 367-377. 
Blumberg, S.J., Luke, J.V. & Cynamon, M.L. (2006). Telephone coverage and health 
survey estimates: Evaluating the need for concern about wireless substitution. 
American Journal of Public Health, 96, 926-931. 
 
Boden, J. M. & Fergusson, D. M. (2011), Alcohol and depression. Addiction, 106, 906–
914. 
Breslau, N., Brown, G.G., DelDotto, J.E., Kumar, S., Exhuthachan, S., Andreski, P., & 
Hufnagle, K.G. (1996). Psychiatric sequelae of low birth weight at 6 years of age. 
Journal of Abnormal Child Psychology, 24, 385-400.  
 
Brown, R., Freeman, W., Perrin, J., Stein, M., Amler, R., Feldman, H., et al. (2001). 
Prevalence and assessment of attention-deficit/hyperactivity disorder in primary 
care settings. Pediatrics, 107, E46-E53.  
 
Butler, S. F., Arrendondo, D. E., & McCloskey, V. (1995). Affective comorbidity in 
children and adolescents with attention deficit hyperactivity disorder. Annals of 
Clinical Psychiatry, 7, 51-55. 
 
Caetano, R., & Kaskutas, L.A.(1995). Changes in drinking patterns among whites, 
blacks, and Hispanics, 1984–1992. Journal of Studies on Alcohol 56, 558–565. 
Campbell, A., Walker, J., & Farrell, G. (2003). Confirmatory factor analysis of the GHQ-
12: can I see that again? Australian New Zealand Journal of Psychiatry, 37, 475-
83.  
Cantwell, D.P. (1996). Attention deficit disorder: a review of the past 10 years. Journal 
of the Academy of Child and Adolescent Psychiatry, 35, 978-987.  
Carroll, K. & Rounsaville B. (1993). History and significance of childhood attention 
deficit disorder in treatment-seeking cocaine abusers. Comprehensive Psychiatry, 
34, 75-82. 
 
112 
 
 
Cattlin, G. & Ingram, S. (1988). The effects ofCATI on costs and quality of data: a 
comparison of CATI & paper methods in centralized interviewing, R. M. Groves, 
P.P. Biemer, L.E. Lyberg, J.T. Massey, W.L. Nicholls II & J. Waksberg (Eds). 
Telephone Survey Methodology (pp. 437-474). New York : Wiley. 
 
Cherpitel C. J. (1998) Differences in performance of screening instruments for problem 
drinking among blacks, whites, and Hispanics in an emergency room population. 
Journal of Studies on Alcohol, 59, 420-426.  
Cherpitel, C. J. (2001) Screening for alcohol problems: a comparison of instrument 
performance among black emergency department and primary care patients. 
Journal of Substance Use, 5, 290-297.  
Cherpitel, C. J.(1997) Comparison of screening instruments for alcohol problems 
between black and white emergency room patients from two regions of the country. 
Alcoholism Clinical and Experimental Research, 21, 1391-1397. 
 
Christakis, D.A., Zimmerman, F.J., DiGiuseppe, D.L. & McCarty, C.A. (2004). Early 
television exposure and subsequent attentional problems in children. Pediatrics, 
113, 708-713. 
 
Clements, R. (1998) A critical evaluation of several alcohol screening instruments using 
the CIDI-SAM as a criterion measure. Alcoholism Clinical and Experimental 
Research, 22, 985-993.  
Cook, R. L., Chung, T., Kelly, T. M. & Clark, D. B. (2005). Alcohol screening in young 
persons attending a sexually transmitted disease clinic. Journal of General Internal 
Medicine, 20, 1-6. 
 
Comings, D.E., Chen, T.J., Blum, K, et al. (2005). Neurogenetic interactions and aberrant 
behavioral comorbidity of attention deficit hyperactivity disorder (ADHD): 
dispelling myths. Theoretical Biology and Medical Modelling, 2, 50. 
 
Cumyn, L., French, L. & Hechtman, L. (2009). ADHD and comorbid depression. Current 
Attention Disorders Reports, 1, 53-59. 
 
Curtin, R., Presser, S. & Singer, E. (2005). Changes in telephone survey nonresponse 
over the past quarter century. Public Opinion Quarterly, 69, 87-98. 
 
Dawe, S., Seinen, A. & Kavanagh, D. (2000). An examination of the utility of the 
AUDIT as a screening tool for alcohol use in the police work-place. Drug and 
Alcohol Review, 19, 49-54.  
DeMilio, L. (1989). Psychiatric syndromes in adolescent substance abusers. American 
Journal of Psychiatry, 146, 1212-1214. 
 
De Zwaan M., Gruss, B., Muller, A., Graap, H., Martin, A., Glaesmer, H., Hilbert, A & 
Phillipsen, A. (2012). The estimated prevalence and correlates of adult ADHD in a 
German community sample. European Archives of Psychiatry and Clinical 
Neuroscience, 262, 79-86.  
113 
 
 
 
Disney, E. R., Elkins, I. J., McGue, M. & Iacono, W. G. (1999) Effects of ADHD, 
conduct disorder, and gender on substance use and abuse in adolescence. American 
Journal of Psychiatry, 156, 1515-1521. 
Dougherty, D. D., Bonab, A. A., Spencer, T. J.,  Rauch, S. L., Madras, B. K. & 
Fischman, A. J. (1999). Dopmaine transporter density is elevated in patients with 
ADHD. Lancet, 354, 2132-2133. 
 
Douglas, V.I. (1972). Stop, look, and listen: The problem of sustained attention and 
impulse control in hyperactive and normal children. Canadian Journal of 
Behavioural Science, 4, 259-282. 
 
Downey, K. K., Stelson, F. W., Pomerleau, O. F. & Girodani, B. (1997). Adult attention-
deficit hyperactivity disorder: Psychological test profiles in a clinical population. 
Journal of Nervous and Mental Disease, 185, 32-38. 
 
DuPaul, G.J., Schaughency, E.A., Weyandt, L.L., Tripp, G., Kiesner, J., Ota, K., Stanish, 
H. (2001) Self-report of ADHD symptoms in university students: cross-gender and 
cross-national prevalence. Journal of Learning Disabilities, 34, 370–379. 
Dybek, G., Bischof, J., Grothues, S., Reinhardt, C., Meyer, U., Hapke, et al. (2006). The 
reliability and validity of the Alcohol Use Disorders Identification Test (AUDIT) in 
a German general practice population sample. Journal of Studies on Alcohol, 67, 
473-481. 
Elia, J., Ambrosini, P. J., Rapoport,  J. L. (1999). Treatment of attention-deficit-
hyperactivity disorder. New England Journal of Medicine, 340, 780-788. 
Famularo, R., Kinscherff, R. & Fenton, T. (1992). Psychiatric diagnoses of maltreated 
children: preliminary findings. Journal of the American Academy of Child and 
Adolescent Psychiatry, 31, 863-7. 
 
Faraone, S.V. & Biederman, J. (1997). Do attention deficit hyperactivity disorder and 
major depression share familial risk factors? Journal of Nervous and Mental 
Disease, 185, 533-541. 
 
Faraone, S.V., Biederman, J., & Friedman, D. (2000). Validity of DSM-IV subtypes of 
attention-deficit/hyperactivity disorder: A family study perspective. Journal of the 
American Academy of Child and Adolescent Psychiatry, 39, 300-307. 
 
Faraone, S.V., Bierderman, J., Spencer, T., Wilens, T., Seidman, L. J., Mick, E. & Doyle, 
A. E. (2000). Attention-deficit/hyperactivity disorder in adults: An overview. 
Biological Psychiatry, 48, 9-20. 
 
Faraone, S.V. (2004). Genetics of adult attention-deficit/hyperactivity disorder. 
Psychiatric Clinics of North America, 27, 303-21. 
114 
 
 
 
Faraone, S. V. & Biederman, J. (2005). What is the prevalence of adult ADHD? Results 
of a population screen of 966 adults. Journal of Attention Disorders, 9, 384-391. 
Faraone SV, Biederman J. (2002): Pathophysiology of Attention Deficit Hyperactivity 
Disorder. In: Davis K, Charney D, Coyle JT, Nemeroff C (eds), ACNP's Fifth 
Generation of Progress—Version 2. New York, Lipponcott, Williams, and Wilkens  
Faraone, S.V., Biederman, J., Mick, E. (2006). The age-dependent decline of attention 
deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychological 
Medicine, 36, 159-65. 
Faraone, S.V., Doyle, A.E., Lasky-Su, J., Sklar, P.B., D'Angelo, E., Gonzalez-Heydrich, 
J., Kratochvil, C., Mick, E., Klein, K., Rezac, A.J. & Biederman, J. (2008). Linkage 
analysis of attention deficit hyperactivity disorder. American Journal of Medical 
Genetics, 147, 1387-1391. 
 
Faraone, S.V. & Glatt, S. J. (2010). A comparison of the efficacy of medications for adult 
attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. Journal 
of Clinical Psychiatry, 71, 754-763. 
 
Fayyad, J., De Graaf, R., Kessler, R.C., Alonso, J., Angermeyer, M., Demyttenaere, K., 
DeGirolamo, G., Haro, J.M., Karam, E.G., Lara, C., Frick, P. & Marsee, M. 
(2006). Psychopathy and developmental pathways to antisocial behavior in youth. 
In C. Patrick (Ed.), Handbook of psychopathy (pp. 355−374). NewYork: Guilford 
Press. 
 
Fillmore, K. M., Hartka, E., Johnstone, B. M., Leino, E. V., Motoyoshi, M., & Temple, 
M. T. (1991). A meta‐analysis of life course variation in drinking*. British journal 
of addiction, 86, 1221-1268. 
 
Frick, P., & Morris, A. (2004). Temperament and developmental pathways to conduct 
problems. Journal of Clinical Child and Adolescent Psychology, 33, 54−68. 
 
Feingold, B. F. (1976). Hyperkinesis and learning disabilities linked to the ingestion of 
artificial food colors and flavors. Journal of Learning Disabilities, 9, 551-559.  
Fischer, M., Barkley, R. A., Smallish, L. & Fletcher, K. (2002). Young adult follow-up of 
hyperactive children: Self-reported psychiatric disorders, comorbidity, and the role 
of childhood conduct problems and teen CD. Journal of Abnormal Child 
Psychology, 30, 463-475.  
Frick, P.J., & Marsee, M.A. (2006). Psychopathy and developmental pathways to 
antisocial behavior in youth. In C.J. Patrick (Ed.), Handbook of psychopathy (pp. 
353-374). New York: Guilford. 
115 
 
 
Furman, L. (2005). What is attention-deficit hyperactivity disorder (ADHD)? Journal of 
Child Neurology, 20, 994-1002. 
 
Gadow, K.D., Sprafkin, J., Schneider, J., Nolan, E.E., Schwartz, J. & Weiss, M.D. 
(2007). ODD, ADHD, versus ODD + ADHD in clinic and community adults. 
Journal of Attention Disorders. 11, 374-83. 
 
Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. (1999): Role of 
serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. 
Science, 83, 397–401. 
 
Garcia, L.V. (2004). Escaping the Bonferroni iron claw in ecological studies. Oikos, 105, 
657-663. 
 
Gaub, M., & Carlson, C. L. (1997). Gender differences in ADHD: A meta-analysis and 
critical review. Journal of the American Academy of Child and Adolescent 
Psychiatry, 36, 1036-1045. 
Gershon, J. (2002). A meta-analytic review of gender differences in ADHD. Journal of 
Attention Disorders, 5, 143-154. 
Giedd, J. N., Blumenthal, J., Molloy, E., & Castellanos, F.X. (2006). Brain imaging of 
attention deficit/hyperactivity disorder. Annals of the New York Academy of 
Sciences, 931, 33-49. 
Giros B, Jaber M, Jones S, Wightman RM, Caron M. (1996): Hyperlocomotion and 
indifference to cocaine and amphetamine in mice lacking the dopamine transporter. 
Nature, 379, 606–612. 
 
Gittelman, R., Mannuzza, S., Shenker, R. & Bonagura, N. (1985). Hyperactive boys 
almost grown up: I. Psychiatric status. Archives of General Psychiatry, 42, 937–
947. 
 
Goldberg, D. & Huxley, P. (1980) Mental Illness in the community: The pathway to 
psychiatric care. London: Tavistock Publications. 
Goldberg, D. (1985) Identifying psychiatric illnesses among general medical patients. 
British Medical Journal, 291, 161-162. 
 
Goldberg, D., Gater, R., Sartorius, N., Ustun, T. B., Piccinelli, M, Gureje, O. & Rutter, C. 
(1997). The validity of two versions of the GHQ in the WHO study of mental 
illness in general health care. Psychological Medicine, 27, 191-197. 
 
Goldman, L. S., Genel, M., Bezman, R. J., Slanetz, P. J. (1998). Diagnosis and treatment 
of attention-deficit/hyperactivity disorder in children and adolescents. Journal of 
the American Medical Association, 279, 1100-1107.  
 
116 
 
 
Gomez, R., Harvey, J., Quick, C., Sharer, I. & Harris, G. (1999). DSM-IV AD/HD: 
Confirmatory factor models, prevalence, and gender and age differences based on 
parent and teacher ratings of Australian primary school children. Journal of Child 
Psychology and Psychiatry, 40, 265-274. 
 
Goyer, P.F., Andreason, P.J., Semple, W.E., Clayton, A.H., King, A.C., Compton-Totm, 
B.A., Schulz, S.C. & Cohen, R.M. (1994). Positron-emission tomography and 
personality disorders. Neuropsychopharmacology, 10, 21-28. 
 
Hankin, B.L. (2006). Adolescent depression: Description, causes, and interventions. 
Epilepsy & Behavior, 8, 102-114. 
 
Health Canada. Canadian alcohol and drug use monitoring survey: Summary of results 
for 2010. Available online from: http://www.hc-sc.gc.ca/hc-ps/drugs-
drogues/stat/_2010/summary-sommaire-eng.php. 
 
Hearne, R., Connolly, A. & Sheehan, J. (2002) Alcohol abuse: prevalence and detection 
in a general hospital. Journal of the Royal Society of Medicine, 95, 84-87. 
 
Heeringa, Steven, Brady T. West, and Patricia A. Berglund. (2010). Applied survey data 
analysis. Boca Raton : Taylor & Francis. 
 
Heiligenstein, E., Conyers, L.M., Berns, A.R. & Miller, M.A. (1998). Preliminary 
normative data on DSM-IV attention deficit hyperactivity disorder in college students. 
Journal of the American College of Health, 46, 185–188. 
Henry, G,T. (1990). Practical sampling, applied social research methods series, volume 
21. Sage Publications. 
 
Herskovits, E.H., Megalooikomonou, V., Davatzikos, C., Chen, A., Bryan, R.N. & 
Gerring, J. P. (1999). Is the spatial distribution of brain lesions associated with 
closed-head injury predictive of subsequent development of attention 
deficit/hyperactivity disorder? Analysis with brain imaging database. Radiology, 
213, 389-94. 
Hill, J. (2003). Early identification of individuals at risk for antisocial personality 
disorder. British Journal of Psychiatry, 182, s11-s14. 
Hines, J.L., King, T.S. & Curry, W.J. (2012). The adult ADHD Self-Report Scalre for 
screening for adult attention deficit-hyperactivity disorder (ADHD). Journal of the 
American Board of Family Medicine, 25, 847-853. 
 
Horner, B. & Scheibe, K. (1997). Prevalance and implications of ADHD among 
adolescents in treatment for substance abuse. Journal of the American Academy of 
Child and Adolescent Psychiatry, 36, 30–36. 
 
117 
 
 
Horwood, L. J., Fergusson, D.M., Coffey, C., Patton, G. C., Tait, R., Smart, D., Letcher, 
P., Silins, E., Hutchinson, D. M. (2012). Cannabis and depression: An integrative 
data analysis of four Australasian cohorts. Drug and Alcohol Dependence, in press. 
 
 
Humeniuk, R., Ali, R., Babor, T. F., Farrell, M., Formigoni, M.L., Jittiwutikarn, J., de 
Lacerda, R.B., Ling, W., Marsden, J., Monteiro, M., Nhiwatiwa, S., Pal, H., 
Poznyak, V. & Simon, S. (2008). Validation of the alcohol, smoking and substance 
involvement screening test (ASSIST). Addiction, 103, 1039-1047. 
 
Humeniuk, R. & Ali, R. (2006). Validation of the Alcohol Smoking and Substance 
Involvement Screening Test (ASSIST and pilot brief intervention [electronic 
resource]: A technical report of phase II findings of the WHO ASSIST project. 
Avaiable from 
http://www.who.int/substance_abuse/activities/assist_technicalreport_phase2_final.
pdf 
 
Ialomiteanu, A & Adlaf, E.M. (2012). CAMH Monitor 2011: Metadata User’s Guide. 
Toronto, ON, Centre for Addiction and Mental Health. Available from: 
http://www.camh.net/Research/camh_monitor.html 
 
Ialomiteanu, A & Adlaf, E.M. (2011) CAMH Monitor 2010: Technical Guide. Toronto, 
ON, Centre for Addiction and Mental Health. Available from: 
http://www.camh.net/Research/camh_monitor.html 
 
Ingram, S., Hetchman, L., & Morgenstern, G. (1999). Outcome issues in ADHD: 
Adolescent and adult long-term outcome. Mental Retardation and Developmental 
Disabilities Research Reviews, 5, 243-250. 
Jaber M, Dumartin B, Sagne C, Haycock JW, Roubert C, Giros B, Bloch B, Caron MG. 
(1999): Differential regulation of tyrosine hydroxylase in the basal ganglia of mice 
lacking the dopamine transporter. European Journal of Neuroscience, 11, 3499–
3511.  
Jensen, P.S., Martin, D. & Cantwell, D.P (1997). Comorbidity in ADHD: Implication for 
research practice and DSM-V. Journal of the American Academy of Child and 
Adolescent Psychiatry, 36, 1065-1079.  
Jensen, P.S.,  Shervette, R.E., Xenakis, S. N. & Richters, J. (1993) Anxiety and 
depressive disorders in attention deficit disorder with hyperactivity: new findings. 
The American Journal of Psychiatry, 150, 1203-1209. 
Jensen, P.S., Shervette, R.E., Xenakis, S.N. & Bain, M.W. (1988).  Psychosocial and 
medical histories of stimulant-treated children. Journal of the American Academy of 
Child and Adolescent Psychiatry, 27, 798-801. 
 
118 
 
 
Kalbag, A.S. & Levin, L.R. (2005). Adult ADHD and substance abuse: Diagnostic and 
treatment issues. Substance Use & Misuse, 40, 1955–1981. 
 
Karch S., Thalmeier T., Lutz J., Cerovecki A., Opgen-Rhein M., Hock B., Leicht G., 
Hennig-Fast K., Meindl T., Riedel M., Mulert C. & Pogarell O. (2010). Neural 
correlates (ERP/fMRI) of voluntary selection in adult ADHD patients. European 
Archives of Psychiatry and Clinical Neuroscience, 260, 427–440. 
Karustis, J.L., Power, T.J., Rescorla, L.A., Eiraldi, R.B. & Gallagher, P.R. (2000). 
Anxiety and depression in children with ADHD: Unique associations with 
academic and social functioning. Journal of Attention Disorders, 4, 133-149. 
Kavale, K. A., & Forness, S. R. (1983). Hyperactivity and diet treatment: A meta-
analysis of the Feingold hypothesis. Journal of Learning Disabilities, 16, 324-330. 
 
Kelly, T.M., Donovan, J. E., Chung, T., Cook, R. L. & Delbridge, T.R. (2004) Alcohol 
use disorders among emergency department treated older adolescents: a new brief 
screen (RUFT-Cut) using the AUDIT, CAGE, RAFFT, and RAPS-QF. Alcoholism 
Clinical and Experimental Research, 28, 746-753. 
Kessler, R.C., Adler, L.A., Gruber, M. J., Sarawate, C. A., Spencer, T. & Van Brunt, D. 
(2007). Validity of the World Health Organization Adult ADHD Self-Report Scale 
(ASRS) Screener in a representative sample of health plan members. International. 
Journal of Methods in Psychiatric Research, 16, 52–65. 
Kessler, R.C., Adler, L., Barkley, R., Biederman, J., Conners, C.K., Demler, O., Faraone, 
S.V., Greenhill, L.L., Howes, M.J., Secnik, K., Spencer, T., Ustun, T.B., Walters, 
E.E. & Zaslavsky, A.M. (2006). The prevalence and correlates of adult ADHD in 
the United States: results from the National Comorbidity Survey Replication. 
American Journal of Psychiatry, 163, 716-723. 
Kessler, R.C., Berglund, P., Demler, O., Jin, R., Merikangas, K. & Walters, E. E. (2005). 
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the 
National Comorbidity Survey Replication. Archives of General Psychiatry, 62, 
593-602.  
 
Kessler, R.C., Adler, L.A., Barkley, R., Biederman, J., Conners, C.K., Faraone, S.V., 
Greenhill, L.L., Jaeger, S., Secnik, K., Spencer, T., Ustun, T.B. & Zaslavsky, A.M. 
(2005).  Patterns and predictors of attention-deficit/hyperactivity disorder 
persistence into adulthood: Results from the National Comorbidity Survey 
Replication. Biological Psychiatry, 57, 1442-1451. 
 
Kessler, R.C., McGonagle, K. A., Swartz, M., Blazer, D. G., Nelson, C. B. (1993). Sex 
and depression in the National Comorbidity Survey I: Lifetime prevalence, 
chronicity and recurrence. Journal of Affective Disorders, 29, 85–96. 
Khantzian, E.J. (1985). The self-medication hypothesis of addictive disorders: focus on 
heroin and cocaine dependence. American Journal of Psychiatry, 142, 1259-1264. 
119 
 
 
Kilic C, Rezaki M, Rezaki B, Kaplan I, Ozgen G, Sagduyu A, Oztürk MO. (1997). 
General Health Questionnaire (GHQ12 & GHQ28): psychometric properties and 
factor structure of the scales in a Turkish primary care sample. Social Psychiatry 
and Psychiatric Epidemiology, 32, 327-331. 
Knouse, L. E., Bagwell, C. L., Barkley, R. A., & Murphy, K. R. (2005). Accuracy of self-
evaluation in adults with attention-deficit hyperactivity disorder. Journal of 
Attention Disorders, 8, 221–234. 
 
Kooij J.J., Buitelaar J.K., van den Oord E.J., Furer J.W., Rijnders C.A. & Hodiamont P.P. 
(2005) Internal and external validity of attention deficit hyperactivity disorder in a 
population-based sample of adults. Psychological Medicine, 35, 817–827. 
 
Kratzer, L. & Hodgins, S. (1997). Adult outcomes of child conduct problems: a cohort 
study. Journal of Abnormal Child Psychology, 25, 65-81.  
 
Krause KL, Dresel SH, Krause J, Kung HF, Tatsch K. (2000): Increased striatal 
dopamine transporter in adult patients with attention deficit hyperactivity disorder: 
effects of methylphenidate as measured by single photon emission computed 
tomography. Neuroscience Letters, 285, 107–110.  
Kroenke, K., Strine, T. W., Spitzer, R. L., Williams, J. B.W. (2009). The PHQ-8 as a 
measure of current depression in the general population. Journal of Affective 
Disorders, 114, 163-173. 
Kuruoglu, A.C., Arikan Z., Vural, G, Karatas, M., Arac, M. & Isik, E. (1996). Single 
photon emission computerised tomography in chronic alcoholism: antisocial 
personality disorder may be associated with decreased frontal perfusion. British 
Journal of Psychiatry, 169, 348-354. 
 
LeBlanc, N. & Morin, D. (2004). Depressive symptoms and associated factors in children 
with attention deficit hyperactivity disorder. Journal of Child and Adolescent 
Psychiatric Nursing, 17, 49-55. 
Lecrubier, Y., Sheehan, D.V., Weiller, E., Amorin, P., Bonora, I., Sheehan, K.H., et al. 
(1997). The MINI International Neuropsychiatric Interview (MINI). A short 
diagnostic structured interview: Reliability and validity according to the CIDI. 
European Psychiatry, 12, 224-231. 
 
Lee, S.S., Humphreys, K.L., Flory, K., Lui, R. & Glass, K. (2011). Prospective 
association of childhood attention-deficit/hyperactivity disorder (ADHD) and 
substance use and abuse/dependence: A meta-analytic review. Clinical Psychology 
Review, 3, 328–341. 
 
Lehtinen V & Joukamaa M. (1994). Epidemiology of depression: Prevalence, risk factors 
and treatment situation. Acta Psychiatrica Scandinavica, Suppl 377, 7-10. 
 
120 
 
 
Levin, F. R. & Evans, S. M. (2001). Diagnostic and treatment issues in comorbid 
substance abuse and adult attention-deficit hyperacity disorder. Psychiatry Annals, 
3, 303–312. 
 
Levin, F. R., Evans, S. & Kleber, H. D. (1998). Prevalence of adult 
attentiondeficit/hyperactivity disorder among cocaine abusers seeking treatment. 
Drug and Alcohol Dependency, 52, 15–25. 
 
Levin, F.R. & Kelber, H.D. (1995). Attention-deficit hyperactivity disorder and substance 
abuse: relationships and implications for treatment. Harvard Review of Psychiatry, 
2, 246-258. 
 
Levy, F., Hay, D.A., McStephen, M., Wood, C., & Waldman, I. (1997). Attention-deficit 
hyperactivity disorder: a category or a continuum? Genetic analysis of a large-scale 
twin study. Journal of the American Academy of Child and Adolescent Psychiatry, 
36, 737-744. 
 
Levy, F., McStephen, M., & Hay, D.A. (2001). The diagnostic genetics of ADHD 
symptoms and subtypes. In F. Levy and D. Hay (eds.) Attention, Genes, and ADHD 
(pp. 35 - 57). Philadelphia: Taylor & Francis. 
 
Lewis, G. & Wessely, S. (1990). Comparison of the General Health Questionnaire and 
the Hospital Anxiety and Depression Scale. British Journal of Psychiatry, 157, 
860-864. 
Lewinsohn, P. M., Rohde, P. & Seeley, J.R. (1994). Psychosocial risk factors for future 
adolescent suicide attempts. Journal of Consulting and Clinical Psychology, 62, 
297-305.  
 
Lilienfeld, S. O. & Waldman, I .D. The relation between childhood attention-deficit 
hyperactivity disorder and adult antisocial behavior re-examined: the problem of 
heterogeneity. Clinical Psychology Review, 10, 699-725. 
 
Loeber, R., Green, S., & Lahey, B. (2003). Risk factors for adult antisocial personality. In 
D. Farrington & J. Coid (Eds.), Early prevention of adult antisocial behavior 
Cambridge: Cambridge University Press. 
 
Loeber, R., Burke, J.D., Lahey, B.B., Winters, A., & Zera, M. (2000). Oppositional 
defiant and conduct disorder: A review of the past 10 years, part I. Journal of the 
American Academy of Child and Adolescent Psychiatry, 39, 1468-1484.Lou, H. 
(1996). Etiology and pathogenesis of attention-deficit/hyperactivity disorder 
(ADHD); significance of prematurity and perinatal hypoxic-haemodynamic 
encephalopathy. Acta Paediatrica, 85, 1266-1271. 
Maisto, S. A., Carey, M. P., Carey, K. B., Bordon, C.M. & Gleason, J. R. (2000) Use of 
the AUDIT and the DAST-10 to identify alcohol and drug use disorders among 
adults with a severe and persistent mental illness. Psychological Assessment, 12, 
121 
 
 
346-353. Mann, R.E., Cheung, J. T.-W., Ialomiteanu, A., Stoduto, G., Chan, V., 
Wickens, C.M.,  Ala-leppilampi, K., Goldbloom, D. and Rehm, J. (2011). 
Estimating prevalence of anxiety and mood disorder in survey data using the 
GHQ12:  Exploration of threshold values.  European Journal of Psychiatry, 25, 81-
91.   
Mannuzza, S., Klein, R.G., & Moulton, J.L. (2003). Persistence of attention 
deficit/hyperactivity disorder into adulthood: what have we learnt from the 
prospective follow-up studies? Journal of Attention Disorders, 7, 93-100. 
Mannuzza, S., Klein, R. G., Bessler, A., Malloy, P., & LaPadula, M. (1998). Adult 
psychiatric status of hyperactive boys grown up. American Journal of Psychiatry, 
155, 493-498. 
 
Manuzza, S., Klein, R.G., Bessler A., Malloy, P. & Hynes, M.E. (1997). Educational and 
occupational outcome of hyperactive boys grown up. Journal of the American 
Academy of Child and Adolescent Psychiatry, 36, 122-1227. 
 
Mannuzza, S., Klein, R.G., Bessler, A., Malloy, P. & LaPadula, M. (1993), Adult 
outcome of hyperactive boys: educational achievement, occupational rank and 
psychiatric status. Archives of General Psychiatry, 50, 565–576. 
 
Mannuzza, S., Klein, R.G., Bonagura, N., Malloy, P., Giampino, T.L. & Addalli, K.A. 
(1991). Hyperactive boys almost grown up, V: replication of psychiatric status. 
Archives of General Psychiatry, 48, 77–83. 
 
Mannuzza, S., Gittelman-Klein, R., Konig, P. H. & Giampino, T. L. (1989) Hyperactive 
boys almost grown up: IV. Criminality and its relationship to psychiatric status. 
Archives of General Psychiatry, 46: 1073–1079. 
Max, J., Fox, P., Lancaster, J., Kochunov, P., Mathews, K., Manes, F., Robertson, B., 
Arndt, S., Robin, D. & Lansing, R. (2002). Putamen Lesions and the Development 
of Attention-Deficit/Hyperactivity Symptomatology. Journal of the American 
Academy of Child & Adolescent Psychiatry, 41, 563-571. 
McCann, B. S., Simpson, T. L., Ries, R. & Roy-Byrne, P. (2000) Reliability and validity 
of screening instruments for drug and alcohol abuse in adults seeking evaluation for 
attention-deficit/hyperactivity disorder. American Journal of Addiction, 9, 1-
9.McGough, J. J., Smalley, S.L., McCracken, J.T., Yang, M., Del'Homme, M., 
Lynn, D.E. & Loo, S. (2005). Psychiatric comorbidity in adult attention deficit 
hyperactivity disorder: findings from multiplex families. American Journal of 
Psychiatry, 163, 1621-1627. 
McGough, J. J. & Barkley, R. A. (2004). Diagnostic controversies in adult attention-
deficit hyperactivity disorder. American Journal of Psychiatry, 161, 1948-1956. 
 
122 
 
 
Medina-Mora M. E., Borges G., Lara C., Benjet C., Blanco J., Fleiz C., Villatoro J., 
Rojas E. & Zambrano J. (2005) Prevalence, service use, and demographic 
correlates of 12-month DSM-IV psychiatric disorders in Mexico: results from the 
Mexican National Comorbidity Survey. Psychological Medicine, 35, 1773–1783. 
 
Mick, E., Biederman, J., Faraone, S.V., Sayer, J., & Kleinman, S. (2002). Case-control 
study of attention-deficit hyperactivity disorder and maternal smoking, alcohol use, 
and drug use during pregnancy. Journal of the American Academy of Child and 
Adolescent Psychiatry, 41, 378-385. 
 
Middleton, F. A. & Strick, P. L. (2001). Cerebellar projections to the prefrontal cortex of 
the primate. Journal of Neuroscience, 21, 700-712. 
 
Milberger, S., Biederman, J.,  Faraone, S.V., Murphy, J. & Tsuang, M.T.. (1995). 
Attention deficit hyperactivity disorder and comorbid disorders: Issues of 
overlapping symptoms. The American Journal of Psychiatry, 152, 1793-9 
 
Milberger, S., Biederman, J., Faraone, S.V., Guite, J., & Tsuang, M.T. (1997). 
Pregnancy, delivery, and infancy complications and attention deficit hyperactivity 
disorder: Issues of gene-environment interaction. Biological Psychiatry, 41, 65-75. 
 
Miller, T. & Leger, M. C. (2003). A very childish moral panic: Ritalin. Journal of 
Medical Humanities, 24, 9-33. 
 
Millstein RB, Wilens TE, Biederman J, Spencer TJ (1997) Presenting ADHD symptoms 
and subtypes in clinically referred adults with ADHD. Journal of Attention 
Disorders, 2, 159-166. 
 
Molina, B. & Pelham, W. (2003). Childhood predictors of adolescent substance use in a 
longitudinal study of children with ADHD. Journal of Abnormal Psychology, 112, 
497-507. 
 
Morgan, J. F. (2007). P value fetishism and use of the Bonferroni adjustment. Evidence 
Based Mental Health, 10, 34-35. 
 
MTA Cooperative Group (1999a) Moderators and mediators of treatment response for 
children with attention-deficit/hyperactivity disorder. Archives of General 
Psychiatry, 56, 1088-1096. 
 
MTA Cooperative Group (1999b) A 14-month randomized clinical trial of treatment 
strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. 
Multimodal treatment study of children with ADHD. Archives of General 
Psychiatry, 56, 1073-1086. 
 
123 
 
 
Murphy K. & Barkley R. A. (1996) Prevalence of DSM-IV symptoms of ADHD in adult 
licensed drivers: implication for clinical diagnosis. Journal of Attention Disorders, 
1, 147-161. 
 
Murphy K.R, Barkley R.A., Bush, T. (2002) Young adults with attention deficit 
hyperactivity disorder: subtype differences in comorbidity, educational, and clinical 
history. Journal of Nervous & Mental Disease, 190, 147-157. 
National Center for Chronic Disease Prevention and Health Promotion Centers for 
Disease Control and Prevention, Behavioral Risk Factor Surveillance System: 
technical information and data. Available from: 
http://www.cdc.gov/brfss/technical_infodata/index.htm. 
National Institute of Mental Health's Genetics Workgroup. 1998. Genetics and mental 
disorders. Report. (NIMH publication No. 98-4268). Washington, DC: U.S. 
Government.  
 
Nigg, J. (2006). Temperament and developmental psychopathology. Journal of Child 
Psychology and Psychiatry, 47, 395−422. 
 
Nolan, E.E., Volpe, R. J., Gadow, K.D., Sprafkin, J. (1999). Developmental, gender, 
comorbidity differences in clinically referred children with ADHD. Journal of 
Emotional and Behavioral Disorders, 7, 11-20. 
 
Northrop, D. (1993). Policy surveys: A survey of Ontario residents for the Addiction 
Research Foundation: Technical documentation. Toronto: Institute for Social 
Research, York University. 
 
Obel, C., Henriksen, T. B., Dalsgaard, S., Linnet, K., Skajaa, E., & Thomsen, P. H. 
(2004). Does children’s watching of television cause attention problems? Retesting 
the hypothesis in a Danish cohort. Pediatrics, 113, 1372-1374. 
Offord, D., Boyle, M. & Szatmari, P. (1987). Ontario child health study, six-month 
prevalence of disorder and rates of service utilization. Archives of General 
Psychiatry, 44, 832-836. 
 
Ohlmeier, M.D., Peters, K., Te Wildt, B.T., Zedler, M., Ziegenbein, M., Wiese, B., 
Emrich, H.M. & Schneider, U. (2008). Comorbidity of alcohol and substance 
dependence with attention-deficit/hyperactivity disorder (ADHD). Alcohol and 
Alcoholism, 43, 300-304. 
Ollendick, T. H., & King, N. J. (1994) Diagnosis, assessment, and treatment of 
internalizing problems in children:  The role of longitudinal data. Journal of 
Consulting and Clinical Psychology, 6, 918-927. 
124 
 
 
Ostrander, R. & Herman, K.C. (2006). Potential cognitive, parenting, and developmental 
mediators of the relationship between ADHD and depression. Journal of 
Consulting and Clinical Psychology, 74, 89-98.  
 
Owens, J. S., Goldfine, M. E., Evangelista, N. M., Hoza, B., & Kaiser, N. M. (2007). A 
critical review of self-perceptions and the positive illusory bias in children with 
ADHD. Clinical Child and Family Psychology Review, 10, 335-351. 
 
Paglia-Boak, A., Mann, R.E., Adlaf, E.M. Hamilton, H.A., Beitchman, J.H., Wolfe, D. 
and Rehm, J.(2012). Detailed OSDUHS Findings.  The Mental Health and Well-
Being of Ontario Students 1991-2011 (CAMH Research Document Series No. 33). 
Centre for Addiction and Mental Health, Toronto. 
 
Paloyelis, Y. (2007). Functional MRI in ADHD: a systematic literature review. Expert 
Review of Neurotherapeutics, 7, 1337-1356. 
 
Peen, J., Schoevers, R.A., Beekman, A.T. & Dekker, J. (2010). The current status of 
urban-rural differences in psychiatric disorders. Acta Psychiatrica Scandinavica, 
121, 84-93. 
 
Perneger, T.V. (1998). What’s wrong with Bonferroni adjustments. British Medical 
Journal, 316, 1236-1238. 
 
Pinninti, N.R., Madison, H., Musser, E. & Rissmiller, D. (2003). MINI International 
Neuropsychiatric Schedule: Clinical utility and patient acceptance. European 
Psychiatry 18, 361-364. 
 
Pliszka, S.R.,Carlson, C.L. & Swanson, J.M. (1999). ADHD with comorbid disorders: 
Clinical assessment and management. New York: The Guilford Press. 
 
Pliszka, S.R. (1998). Comorbidity of attention-deficit/hyperactivity disorder with 
psychiatric disorder: an overview. Journal of Clinical Psychiatry, 59, 50-58. 
 
Polanczyk, G. & Rhode, L. A. (2007). Epidemiology of attention-deficit/hyperactivity 
disorder across the lifespan. Current Opinion in Psychiatry, 20, 386-392. 
Polanczyk, G., de Lima, M.S., Horta, B.L., Biederman, J. & Rohde, L.A. (2007) The 
worldwide prevalence of ADHD: a systematic review and metaregression analysis. 
American Journal of Psychiatry, 164, 942–948. 
Politi, P.L., Piccinelli, M. & Wilkinson, G.(1994). Reliability, validity and factor 
structure of the 12-item General Health Questionnaire among young males in Italy. 
Acta Psychiatrica Scandinavia, 90, 432-7. 
125 
 
 
Poulin, C. (2007). From attention-deficit/hyperactivity disorder to medical stimulant use 
to the diversion of prescribed stimulants to non-medical stimulant use: connecting 
the dots. Addiction, 102, 740-751. 
 
Raine, A., Lencz, T., Bihrle, S., LaCasse, L. & Colletti, P. (2000). Reduced prefrontal 
gray matter volume and reduced autonomic activity in antisocial personality 
disorder. Archives of General Psychiatry, 57, 119-127.   
 
Raine, A., Meloy, J.R., Bihrle, S., Stoddard, J., Lacasse, L., Buchsbaum, M.S. (1998). 
Reduced prefrontal and increased subcortical brain functioning assessed using 
positron emission tomography in predatory and affective murderers. Behavioral 
Science and the Law, 16, 319-332. 
 
Reinert, D.F. & Allan, J.P. (2007). The alcohol use disorders identification test: an update 
of research findings. Alcoholism Clinical and Experimental Research, 31, 185-199. 
Robins, L.N.(1978). Sturdy childhood predictors of adult antisocial behaviour: 
replications from longitudinal studies. Psychological Bulletin, 8, 611-22. 
Robins, L.N. & Price, R.K. (1991). Adult disorders predicted by childhood conduct 
problems: results from the NIMH Epidemiological Catchment Area Project. 
Psychiatry, 54, 116-132. 
 
Romano, E., Baillargeon, R.H., Fortier, I., Wu, H.X., Robaey, P., Zoccolillo, M. & 
Tremblay, R.E. (2005). Individual change in methylphenidate use in a national 
sample of children aged 2 to 11 years. Canadian Journal of Psychiatry/Revue 
Canadienne de Psychiatrie, 50, 144-152. 
 
Rounsaville B, Anton S, Carroll K, Budde D, Prusoff B, Gawin F. (1991). Psychiatric 
diagnoses of treatment-seeking cocaine abusers. Archives of General Psychiatry, 
48, 43-51. 
 
Rubin A., Migneault, J. P., Marks, L., Goldstein, E., Ludena, K. & Friedman, R. H. 
(2006). Automated telephone screening for problem drinking. Journal of Studies on 
Alcohol, 67, 454-457. 
Rush B., Urbanoski K., Bassani D., Castel S., Wild T.C., Strike C., et al. (2008). 
Prevalence of co-occurring substance use and other mental disorders in the 
Canadian population. Canadian Journal of Psychiatry, 53, 800-809. 
 
Satterfield, J.H., & Schell, A. (1997). A prospective study of hyperactive boys with 
conduct problems and normal boys: Adolescent and adult criminality. Journal of 
the American Academy of Child and Adolescent Psychiatry, 36, 1726–1735. 
Saunders, J.B., Aasland, O.G., Babor, T.F., de la Fuente, J.R. & Grant, M. (1993). 
Development of the Alcohol Use Disorders Screening Test (AUDIT). WHO 
126 
 
 
collaborative project on early detection of persons with harmful alcohol 
consumption. II. Addiction, 88, 791-804. 
Schatz, D. B., Rostain, A.L. (2006). ADHD with comorbid anxiety: A review of the 
current literature. Journal of Attention Disorders, 10, 141-149. 
 
Schubiner, H., Tzelepis, A., Milberger, S., Lockhart, N., Kruger, M., Kelley, B. J. & 
Schoener, E. P. (2000). Prevalence of attention-deficit/hyperactivity disorder and 
conduct disorder among substance abusers. Journal of Clinical Psychiatry, 61, 244-
251. 
 
Schwab, J. A. (2002). Multinomial logistic regression: Basic relationships and complete 
problems. http://www.utexas.edu/courses/schwab/sw388r7/SolvingProblems/ 
Secnik, Swensen & Lage. (2005). Comorbidities and costs of adult patients diagnosed 
with attention-deficit hyperactivity disorder. Pharmacoeconomics, 23, 93-102. 
Seidman, L. J., Valera, E. & Makris, N. (2005). Structural brain imaging of attention-
deficit/ hyperactivity disorder. Biological Psychiatry, 57, 1263-1272. 
 
Selin, K.H. (2003). Test–retest reliability of the Alcohol Use Disorder Identification Test 
in a general population sample. Alcoholism Clinical and Experimental Research, 
27, 1428-1435. 
 
Shedler, J. & Block, J. (1990). Adolescent drug use and psychiatric  health: A 
longitudinal inquiry. American Psychology, 45, 612–630. 
 
Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Janavs, J., Weiller, E., Keskiner, A., et al. 
(1997). The validity of the Mini International Neuropsychiatric Interview (MINI) 
according to the SCID-P and its reliability. European Psychiatry, 12, 232-241. 
 
Sheehan, D.V., Lecrubier, Y., Sheehan, H., Amorin, P., Janavs, J., Weiller, E., et al. 
(1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): The 
development and validation of a structured diagnostic psychiatric interview for 
DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59, 22-33. 
Shekin, W.O., Asarnow, R. F., Hess, E., Zaucha, K. & Wheeler, N. (1990). A clinical and 
demographic profile of a sample of adults with attention deficit hyperactivity 
disorder, residual state. Comprehensive Psychiatry, 31, 416-25. 
Sherman, D., Iacono, W., & McGue, M. (1997). Attention-deficit/hyperactivity disorder 
dimensions: A twin study of inattention and impulsivity/hyperactivity. Journal of 
the American Academy of Child and Adolescent Psychiatry, 36, 745-753.  
 
Sherman, D. K., McGue, M. K., & Iacono, W. G. (1997). Twin concordance for attention 
deficit hyperactivity disorder: a comparison of teachers’ and mothers’ reports. 
American Journal of Psychiatry, 154, 532-535. 
127 
 
 
 
Shields, A. L., & Caruso, J. C. (2003). Reliability generalization of the Alcohol Use 
Disorders Identification Test. Educational and Psychological Measurement, 63, 404-413. 
 
Shields, A.L., Guttmannova, K. & Caruso, J.C. (2004). An examination of the factor 
structure of the Alcohol Use Disorders Identification Test in two high-risk samples. 
Substance Use and Misuse, 39, 1161–1182. 
 
Silberstein, R.B., Farrow, M., Levy, F., Pipingas, A., Hay, D.A. & Jarman, F.C. (1998). 
Functional brain electrical activity mapping in boys with Attention-
Deficit/Hyperactivity Disorder. Archives of General Psychiatry, 55, 1105-1112. 
 
Sobanski, E., Bruggemann, D., Alm, B., Kern, S., Deschner, M., Schubert, T., Philipsen, 
A. & Rietschel, M. (2007). Psychiatric comorbidity and functional impairment in a 
clinically referred sample of adults with attention-deficit/hyperactivity disorder 
(ADHD). European Archives of Psychiatry and Clinical Neuroscience, 257, 371–
377. 
 
Sobanski, E. (2006). Psychiatric comorbidity in adults with attention-deficit/hyperactivity 
disorder (ADHD). European Archives of Psychiatry and Clinical Neuroscience, 
256, 26-31. 
 
Sorensen, H. T., Sabroe, S. & Olsen, J. (1996). A franeworl for evaluation of secondary 
data sources for epidemiological research. International Journal of Epidemiology, 
25, 435-442. 
 
Souza, I., Pinheiro, M.A., Denardin, D., Mattos, P. & Rohde, L. A. (2004). Attention-
deficit/hyperactivity disorder and comorbidity in Brazil comparisons between two 
referred samples. European Child and Adolescent Psychiatry, 13, 243-248. 
Sprich, S., Biederman, J., Harding Crawford, M., Mundy, E., & Faraone, S.V. (2000). 
Adoptive and biological families of children and adolescents with ADHD. Journal 
of the American Academy of Child and Adolescent Psychiatry, 39, 1432-1437. 
Sprich-Buckminster, S., Biederman, J., Milberger, S., Faraone, S. & Krifcher Lehman, B. 
(1993). Are perinatal complicationsrelevant to the manifestation of ADD? Issues of 
comorbidity and familliality. Journal of the American Academy of Child and 
Adolescent Psychiatry, 32, 1032-1037.  
Statistics Canada. (2011). Residential Telephone Service Survey 2010 (RTSS). 
[Electronic Version], from: 
 http://www.statcan.gc.ca/dailyquotidien/110607/dq110607d-eng.htm. 
 
Steele, M., Jensen, P. S. & Quinn, D. M. (2006). Remission versus response as the goal 
of therapy in ADHD: a new standard for the field? Clinical Therapeutics, 28, 1892-
1908. 
128 
 
 
 
Stevens, T. & Mulsow, M. (2006). There is no meaningful relationship between 
television exposure and symptoms of attention deficit/hyperactivity disorder. 
Pediatrics, 117, 665-672. 
 
Still, G. (11902). The Coulstonian lectures on some abnormal physical conditions in 
children. Lecture 1. Lancet, 1008-1012, 1077-1082, 1163-1168. 
 
Swanson, J. M., Kinsbourne, M., Nigg, J., Lanphear, B., Stefanatos, G. A., Volkow, N. et 
al. (2007). Etiologic subtypes of attention-deficit/hyperactivity disorder: brain 
imaging, molecular genetic and environmental factors and the dopamine 
hypothesis. Neuropsychology Reviews, 17, 39-59. 
 
Toplak, M. E., Connors, L., Shuster, J., Knezevic, B., & Parks, S. (2008). Review of 
cognitive-behavioural, and neural-based interventions for Attention-
Deficit/Hyperactivity Disorder. Clinical Psychology Review, 28, 801-823. 
 
Valera, E.M., Faraone, S.V., Murray, K.E. & Seidman, I. J. (2007). Meta-analysis of 
structural imaging findings in attention deficit/hyperactivity disorder. Biological 
Psychiatry, 61, 1361-1369.  
van der Valk, J.C., Verhulst, F.C., Neale, M.C., & Boomsma, D.I. (1998). Longitudinal 
genetic analysis of problem behaviors in biologically related and unrelated 
adoptees. Behavior Genetics, 28, 365-380.  
Vieweg, B. W., Hedlund, J. L. (1983). The General Health Questionnaire: a 
comprehensive review. Journal of Operational Psychiatry, 14, 74-85. 
Volkow, N. D., Fowler, J. S.,  Wang, G. J, Swanson, J. M. & Telang, F. (2007). 
Dopamine in drug abuse and addiction: results of imaging studies and treatment 
implications. Archives of Neurology, 64, 1575-9. 
Volkow, N. D., Fowler, J. S.,  Wang, G. J.,  Ding, Y. S. & Gatley,S. J. (2002). Role of 
dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: 
Results from imaging studies. European Neuropsychopharmacology, 12, 557-566.  
 
Volkow, N.D., Tancredi, L.R., Grant, C., Gillespie, H., Valentine, A., Mullani, N., Wang, 
G.J. & Hollister, L. (1995). Brain glucose metabolism in violent psychiatric 
patients: a preliminary study. Psychiatry Research, 61, 243-253. 
Walters, G. D. & Knight, R. A. (2010). Antisocial personality disorder with and without 
antecedent childhood conduct disorder: does it make a difference? Journal of 
Personality Disorders, 24, 258-71.  
Waschbusch, D. (2002). A meta-analytic examination of comorbid hyperactive 
impulsive-attention problems and conduct problems. Psychological Bulletin, 128, 
118-150. 
129 
 
 
 
Weiss, M. D., Worling, D.E. & Wasdell, M.B. (2003). A chart review of the inattentive 
and combined types of ADHD. Journal of Attention Disorders, 7, 1-9. 
 
Weiss, G., Hechtman, L., Milroy, T. & Perlman, T. (1985). Psychiatric status of 
hyperactives as adults. Journal of the American Academy of Child and Adolescent 
Psychiatry, 24, 211-220 
 
Weiss. G. (1985). Follow-up studies on outcome of hyperactive children. 
Psychopharmacology Bulletin, 2, 169-177. 
 
Weiss, G., Hechtman, L., Milroy, T. & Perlman, T. (1985). Psychiatric status of 
hyperactives as adults: a controlled prospective 15-year follow-up of 63 
hyperactive children. Journal of the American Academy of Child and Adolescent 
Psychiatry, 24, 211-220. 
 
Weiss, G. & Hechtman, L. (1993). Hyperactive children grown up (2nd ed.). New York: 
Guilford Press. 
 
Wells-Parker, E., Dill, P., Williams, M., & Stoduto, G. (2006). Are depressed 
drinking/driving offenders more receptive to brief intervention? Addictive. 
Behavior. 31, 339-350. 
 
Wender, P. H., Reimherr, F. W. and Wood, D. R. (1981). Attention deficit disorder 
(‘minimal brain dysfunction’) in adults. a replication study of diagnosis and drug 
treatment. Archives of General Psychiatry, 38, 449-456. 
Werneke, U., Goldberg, D. P., Yalcin, I., Ustun, B. T. (2000).  The stability of the factor 
structure of the General Health Questionnaire. Psychological Medicine, 30, 823-
829. 
Weyandt L. L., Linterman I. & Rice J. A. (1995) Reported prevalence of attentional 
difficulties in a general sample of college students. Journal of Psychopathy and 
Behavior Assessment, 17, 293–304. 
 
WHO ASSIST Working Group. (2002).The Alcohol, Smoking and Substance 
Involvement Screening Test (ASSIST): development, reliability and feasibility. 
Addiction, 97, 1183-1194. 
 
Wilens, T. E. & Morrison, N. R. (2011). The intersection of attention-
deficit/hyperactivity disorder and substance abuse. Current Opinion in Psychiatry, 
24, 280-285. 
 
Wilens, T.E. & Biederman, J. (2006). Alcohol, drugs, and attention-deficit/hyperactivity 
disorder: a model for the study of addictions in youth. Journal of 
Psychopharmacology, 20, 580–588. 
 
130 
 
 
Wilens, T. (2004a). Attention-deficit/Hyperactivity Disorder and the substance use 
disorders: The nature of the relationship, subtypes at risk and treatment issues. 
Psychiatric Clinics of North America, 27, 283–302. 
 
Wilens, T. (2004b). Subtypes of ADHD at risk for substance abuse. ADHD subtypes and 
subgroups at risk for substance use disorders (NIDA). Symposium at the Annual 
Meetings of the American Psychiatric Association. APA, New York, NY. 
Wilens, T., Faraone, S., Biederman, J., Gunawardene, S. (2003). Does stimulant therapy 
of ADHD beget later substance abuse: A metanalytic review of the literature. 
Pediatrics, 11, 179-185. 
 
Wilens, T., Biederman, J., Brown, S., Tanguay, S., Monuteaux, M., Blake, C. & Spencer 
T. (2002). Psychiatric comorbidity and functioning in clinically referred 
preschoolers and school aged youth with ADHD. Journal of the American Academy 
of Child and Adolescent Psychiatry, 41, 262-268. 
Wilens, T., Biederman, J., Mick, E., Faraone, S.V. & Spencer, T. (1997). Attention 
deficit hyperactivity disorder (ADHD) is associated with early onset substance use 
disorders. Journal of Nervous and Mental Disease, 185, 475-482. 
Willcutt, E. (2005). The etiology of ADHD: behavioural and molecular genetic 
approaches. In Cognitive and Affective Neuroscience of Psychopathology (ed. D. 
Barch). Oxford: Oxford University Press. 
Willcutt, E.G., Pennington, B.F., & DeFries, J.C. (2000). Etiology of inattention and 
hyperactivity/impulsivity in a community sample of twins with learning difficulties. 
Journal of Abnormal Child Psychology, 28, 149-159. 
 
Williams, N. M., Zaharieva, I., Martin, A., Langley, K., Mantripragada, K., Fossdal, R.,  
Stefansson, H., Stefansson, K., Magnusson, P.,  Gudmundsson, O.O., Gustafsson, 
O. & Thapar, A. (2010). Rare chromosomal deletions and duplications in attention-
deficit hyperactivity disorder: a genome-wide analysis. The Lancet, 376, 1401-
1408. 
 
Willis, T. J. & Lovaas, I. (1977).  A behavioral approach to treating hyperactive children: 
The parent’s role.  In J. G. Millichap (Ed.), Learning disabilities and related 
disorders (pp. 119-140).  Chicago: Year Book Medical Publications. 
 
Wolraich, M.L., Wilson, D.B. & White, J. W.(1995). The effect of sugar on behavior or 
cognition in children. The Journal of the American Medical Association, 274, 1617- 
1621. 
 
Woolston, J. L., Rosenthal, S. L., Riddle, M.A., Sparrow, S.S., Cicchetti, D. & 
Zimmerman, L.D. (1989). Childhood comorbidity of anxiety/affective disorders 
and behavior disorders. Journal of the American Academy of Child and Adolescent 
Psychiatry, 28, 707-713. 
131 
 
 
Appendix A Adult ADHD Self-Report Scale version 1.1 
 
 
Questions Never
0 
   Rarely 
        1 
Sometimes 
2 
Often 
3 
Very Often 
4 
1. In the past 6 months, 
have you had trouble 
finishing a project? 
 
        
    
2. In the past 6 months, 
have you had difficulty 
getting things in order? 
 
 
    
3. In the past 6 months, 
have you had difficulty 
remembering 
appointments? 
     
4. In the past 6 months, 
have you delayed projects 
that required a lot of 
thought? 
     
5. In the past 6 months, 
how often have you 
fidgeted when sitting for a 
long time? 
 
     
6. In the past 6 months, 
have you felt overly active 
and compelled to do 
things? 
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Appendix B General Health Questionnaire 12 (GHQ-12)  
 
1. Over the past few weeks,  have 
You been able to concentrate on     
whatever you're doing?  
Better than 
usual 
No more 
than usual 
Rather more 
than usual 
Much 
more 
than 
usual 
2. Over the past few weeks, have 
you felt that you are playing a 
useful part in things? 
Not at all No more 
than usual 
Rather more 
than usual 
Much 
more 
than 
usual 
3. Over the past few weeks, have 
you felt capable of making 
decisions about things? 
More so 
than usual 
Same as 
usual 
Less than 
usual 
Much 
less 
4. Over the past few weeks, have 
you been able to enjoy your 
normal day-to-day activities? 
More so 
than usual 
Same as 
usual 
Less than 
usual 
Much 
less 
5. Over the past few weeks, have 
you been able to face up to your 
problems? 
Not at all No more 
than usual 
Rather more 
than usual 
Much 
more 
than 
usual 
6. Over the past few weeks, all 
things considered, have you been 
feeling reasonably happy? 
Not at all No more 
than usual 
Rather more 
than usual 
Much 
more 
than 
usual 
7. Over the past few weeks, have 
you lost much sleep because of 
worry? 
More so 
than usual 
Same as 
usual 
Less than 
usual 
Much 
less 
8. Over the past few weeks, have 
you felt constantly under strain? 
More so 
than usual 
Same as 
usual 
Less than 
usual 
Much 
less 
9. Over the past few weeks, have 
you felt you could not overcome 
your difficulties? 
Not at all No more 
than usual 
Rather more 
than usual 
Much 
more 
than 
usual 
10. Over the past few weeks, have 
you been feeling unhappy and 
depressed? 
Not at all No more 
than usual 
Rather more 
than usual 
Much 
more 
than 
usual 
11. Over the past few weeks, have 
you been losing confidence in 
yourself? 
Not at all No more 
than usual 
Rather more 
than usual 
Much 
more 
than 
usual 
12. Over the past few weeks, have 
you been thinking of yourself as a 
worthless person? 
More so 
than usual 
Same as 
usual 
Less than 
usual 
Much 
less 
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Appendix C Antisocial Personality Disorder Module from the MINI 
Neuropsychiatric Interview Version 5.0.0 
Before you were 15 years old, did you: 
1. Repeatedly skip school or run away from home overnight?  
 
 
Yes 
 
 
No 
2. Repeatedly lie, cheat, "con" others, or steal?  
 
Yes 
 
No 
3. Start fights or bully, threaten, or intimidate others?  
 
Yes 
 
No 
4. Deliberately destroy things or start fires?  
 
Yes 
 
No 
5. Deliberately hurt animals or people?  
 
Yes 
 
No 
Since you were 15 years old, have you: 
6. Repeatedly behaved in a way that others would consider 
irresponsible, like failing to pay for things you owed, deliberately 
being impulsive or deliberately not working to support yourself? 
 
 
 
 
Yes 
 
 
 
No 
7. Done things that are illegal even if you didn't get caught (for 
example, destroying property, shoplifting, stealing, selling drugs, or 
committing a felony)? 
 
 
Yes 
 
 
No 
8. Been in physical fights repeatedly (including physical fights with 
your spouse or children)? 
 
 
Yes 
 
No 
 
9. Often lied or "conned" other people to get money or pleasure, or 
lied just for fun? 
 
 
Yes 
 
No 
10. Exposed others to danger without caring? 
 
Yes 
 
No 
11. Felt no guilt after hurting, mistreating, lying to, or stealing from 
others, or after damaging property?  
 
Yes 
 
No 
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Appendix D Alcohol Use Disorders Identification Test (AUDIT) 
 
1. How often do you have a 
drink containing alcohol? 
 
Never 
 
Monthly 
or less 
2 – 4 
times a 
month 
 
2-3 times 
a week 
4 or more 
times a 
week 
2. How many drinks do you 
have on a typical day when 
you are drinking? 
 
1 or 2 
 
3 or 4 
 
5 or 6 
 
7 to 9 
 
10 or more 
3. How often do you have six 
or more drinks on one 
occasion? 
 
Never 
 
Less than 
monthly 
 
Monthly 
 
Weekly 
 
Daily or 
almost daily
4. How often during the last 
year have you found that you 
were unable to stop drinking 
once you had started? 
 
Never 
 
Less than 
monthly 
 
Monthly 
 
Weekly 
 
Daily or 
almost daily
5. How often during the past 
year have you failed to do 
what was normally expected of 
you because of drinking? 
Never  
Less than 
monthly 
 
Monthly 
 
Weekly 
 
Daily or 
almost daily
6. How often during the past 
year have you needed a drink 
in the morning after a night of 
drinking? 
 
Never 
 
Less than 
monthly 
 
Monthly 
 
Weekly 
 
Daily or 
almost daily
7. How often during the past 
year have you had a feeling of 
remorse of guilt after 
drinking? 
 
Never 
 
Less than 
monthly 
 
Monthly 
 
Weekly 
 
Daily or 
almost daily
8. How often during the past 
year have you been unable to 
remember what has happened 
the night before because of 
your drinking? 
 
Never 
 
Less than 
monthly 
 
Monthly 
 
Weekly 
 
Daily or 
almost daily
9. Have you or someone else 
been injured because of your 
drinking? 
 
No 
 
- 
Yes, but 
not in the 
last year 
 
- 
Yes, during 
the last year 
10. Has a relative, friend, 
doctor or other health worker 
been concerned about your 
drinking or suggested you cut 
down? 
 
 
 
No 
 
 
- 
 
 
Yes, but 
not in the 
last year 
 
 
- 
 
Yes, during 
the last year 
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Appendix E Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) 
for Cannabis Only 
 
 
1. How often have 
you used cannabis, 
marijuana or hash 
during the PAST 
THREE months? 
 
 
Never 
0 
 
Once or Twice 
2 
 
Monthly 
3 
 
Weekly 
4 
 
Daily or Almost 
Daily 
6 
 
2. During the PAST 
3 MONTHS, how 
often have you had a 
strong desire or urge 
to use cannabis, 
marijuana or hash? 
 
 
Never 
0 
 
Once or Twice 
3 
 
Monthly 
4 
 
Weekly 
5 
 
Daily or Almost 
Daily 
6 
 
3. During the PAST 
3 MONTHS, how 
often has your use of 
cannabis, marijuana 
or hash led to health, 
social, legal or 
financial problems? 
 
 
Never 
0 
 
Once or Twice 
4 
 
Monthly 
5 
 
Weekly 
6 
 
Daily or Almost 
Daily 
7 
 
4. During the PAST 
3 MONTHS, how 
often have you failed 
to do what was 
normally expected of 
you because of your 
use of cannabis, 
marijuana or hash? 
 
 
Never 
0 
 
Once or Twice 
5 
 
Monthly 
6 
 
Weekly 
7 
 
Daily or Almost 
Daily 
8 
 
5. Has a friend, 
relative, a doctor or 
anyone else ever 
expressed concern 
about your use of 
cannabis, 
marijuana or hash? 
 
 
Never 
0 
 
Yes, not past 3 
months 
3 
 
Yes, past 3 
months 
6 
 
 
- 
 
 
- 
 
6. Have you ever 
tried and failed to 
control, cut down or 
stop using cannabis, 
marijuana or hash? 
 
 
Never 
0 
 
Yes, not past 3 
months 
3 
 
Yes, past 3 
months 
6 
 
 
- 
 
 
- 
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Appendix F Diagnostic Statistics  
 
 
Variable 
 
N 
 
Range 
 
Min. 
 
Max. 
 
M 
 
SD 
 
Skewness 
 
Kurtosis 
         
Age 1926 3 1 4 2.563 0.895 0.059 -0.783
   
Sex 1986 1 0 1 0.474 0.499 0.103 -1.990
   
Marital Status 1968 2 1 3 1.518 0.813 0.109 -0.600
   
Education 1970 3 1 4 2.954 0.971 -.550 -0.731
   
Employment 
Status 
1977 7 1 8 3.250 3.203 0.784 -1.347
   
Annual 
Household 
Income 
1986 4 1 5 3.567 1.203 -0.685 -0.423
   
Household 
Location 
1986 1 0 1 0.849 .359 -1.946 1.789
   
ADHD 
Screening 
Status 
1986 1 0 1 0.035 .183 5.08 23.78
   
Previous 
ADHD 
Diagnosis 
 
1979 1 0 1 0.030 .161 5.878 32.589
Antidepressant 
Use 
1980 1 0 1 0.071 0.257 3.350 9.299
   
Psychiatric 
Distress 
1986 1 0 1 0.099 0.299 2.681 5.195
   
ASPD 
Screening 
Status 
1952 1 0 1 0.007 0.084 11.740 135.973
   
Hazardous 
Alcohol Use 
1937 1 0 1 0.130 0.337 2.197 2.828
   
137 
 
 
Cannabis 
Lifetime 
1974 1 0 1 0.405 0.491 0.389 -1.351
         
Cannabis Past 
12 Months 
1970 1 0 1 0.138 0.345 2.098 2.405 
         
Cannabis Past 3 
Months 
1985 1 0 1 0.094 0.293 2.770 5.681 
         
Cocaine 
Lifetime 
1976 1 0 1 0.070 0.255 3.370 9.365 
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